


# THE INTERNATIONAL LIVER CONGRESS<sup>™</sup>

Savour science  
together again

22-26  
JUNE  
2022  
LONDON



# List of accepted abstracts

## Contents

Acute liver failure and drug induced liver injury.....	2
Alcoholic liver disease.....	6
Cirrhosis and its complications: Portal Hypertension.....	13
Cirrhosis and its complications: ACLF and Critical illness.....	22
Cirrhosis and its complications: Other clinical complications except ACLF and critical illness.....	27
Cirrhosis and its complications: Experimental and pathophysiology.....	35
Fibrosis.....	40
Gut microbiota and liver disease.....	49
Immune-mediated and cholestatic disease: Clinical aspects.....	52
Immune-mediated and cholestatic: Experimental and pathophysiology.....	61
Immunology.....	64
Liver development, physiology and regeneration.....	70
Liver transplantation and hepatobiliary surgery: Clinical aspects.....	73
Liver transplantation and hepatobiliary surgery: Experimental and pathophysiology.....	84
Liver tumours: Clinical aspects except therapy.....	86
Liver tumours: Experimental and pathophysiology.....	93
Liver tumours: Therapy.....	102
Molecular and cellular biology.....	108
NAFLD: Clinical aspects except therapy.....	114
NAFLD: Diagnostics and non-invasive assessment.....	122
NAFLD: Experimental and pathophysiology.....	137
NAFLD: Therapy.....	151
Non-invasive assessment of liver disease except NAFLD.....	159
Nurses and Allied Health Professionals.....	163
Public Health.....	164
Rare liver diseases (including paediatric and genetic).....	177
Viral Hepatitis A, B, C, D, E: Virology.....	186
Viral hepatitis A/E: Clinical aspects.....	193
Viral hepatitis B/D: Clinical aspects except therapy.....	194
Viral hepatitis B/D: therapy.....	203
Viral hepatitis C: Clinical aspects except therapy.....	221
Viral Hepatitis C: Post SVR and long term follow up.....	226
Viral hepatitis C: Therapy and resistance.....	231
Late breaker.....	237

## Acute liver failure and drug induced liver injury

64

Obeticholic acid exacerbates the liver fibrosis of bile duct ligation model by inducing the liver expression of osteopontin

Poster Presentation

Presenter: Jie Wang

286

Prescription event monitoring of checkpoint inhibitor-induced liver injury and outcomes of rechallenge: a 10-year experience

Oral Presentation

Presenter: Edmond Atallah

350

The prognostic role of lysophosphatidylcholines and their immunomodulatory potential in acute liver failure

Oral Presentation

Presenter: Francesca Maria Trovato

356

A report on the Australian Drug Induced Liver Injury Network: AusDILIN

Poster Presentation

Presenter: Amanda Nicoll

575

Incidence, phenotype and prognostic relevance of COVID-19-related liver injury across different age strata

Poster Presentation

Presenter: Lukas Hartl

577

Two different types of COVID-19 vaccines and serial liver biochemistries

Poster Presentation

Presenter: Grace Lai-Hung Wong

685

Role of liver biopsy in management of immune checkpoint inhibitors hepatitis: a single-center retrospective study

Poster Presentation

Presenter: Lucia Parlati

1035

Immune checkpoint inhibitors induced liver injury: an observational study

Poster Presentation

Presenter: Lucy Meunier

1052

Liver toxicities of immune checkpoints inhibitors for cancer: a multicenter retrospective study

Poster Presentation

Presenter: Lucia Parlati

1096

Acute severe presentation of autoimmune hepatitis: a 20-year retrospective review of the United States

Poster Presentation

Presenter: Thomas Enke

1309

Single-cell metabolic profiling of primary human hepatocytes shows heterogenous responses to drug metabolism

Poster Presentation

Presenter: Eva Sofía Sánchez Quant

1590

Management of severe, steroid-resistant and steroid-refractory hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy

Poster Presentation

Presenter: Morven Cunningham

1706

Activation marker CD69 differentiates non-alcoholic steatohepatitis from drug-induced liver injury

Poster Presentation

Presenter: Alberto Garcia Garcia

1728

Natural antibodies are required for necrotic cell debris clearance and liver repair during necrotic liver injury

Poster Presentation

Presenter: Matheus Mattos

1771

Human paracetamol hepatotoxicity is mitigated by the gut-liver axis in vitro

Poster Presentation

Presenter: Martin Vandeputte

2011

A new score to predict mortality at baseline in patients not fulfilling KCH criteria for non acetaminophen induced liver failure-The "SAFE" score(Severity of ALF in emergency)

Poster Presentation

Presenter: Harshvardhan Tevethia

2337

Ten-year single center experience in hepatotoxicity due to mushroom poisoning

Poster Presentation

Presenter: Ozan Sarikaya

2347

CCl4-induced acute liver injury in C57/BL mice model showed elevated expressions of Na+ taurocholate cotransporting polypeptide on intestinal stellate cells

Poster Presentation

Presenter: Johnny Amer

2379

The association between chronic Colchicine use and incident decompensated cirrhosis

Poster Presentation

Presenter: Michal Carmiel

2455

Inhibition of C-C motif chemokine receptor 2 (CCR2) using a novel in silico designed peptide attenuates macrophage migration in vitro and intrahepatic monocyte recruitment in vivo

Poster Presentation

Presenter: Eline Geervliet

2548

Murine intrahepatic regulatory t cells modulate acute liver inflammation by promoting a protective and restorative microenvironment

Poster Presentation

Presenter: Ada Kurt

2596

Place of steroids and prognosis factors for grade =3 immune-checkpoint inhibitors induced hepatitis: a 6-year prospective study

Poster Presentation

Presenter: Eleonora De Martin

2923

FOXA2 prevents hyperbilirubinemia through maintaining apical MRP2 expression in acute liver failure

Poster Presentation

Presenter: Sai Wang

3000

Human liver biopsies from people with hemophilia A who received factor VIII gene transfer with valoctocogene roxaparvovec (AAV5-hFVIII-SQ) show unremarkable histopathology and reveal interindividual variability in transgene production

Poster Presentation

Presenter: Sylvia Fong

3065

Hepatobiliary disease after bone marrow transplant

Poster Presentation

Presenter: Maria Dezan

3200

Trends in liver transplantation for acute liver failure. A Spanish multicenter study

Poster Presentation

Presenter: Victoria Aguilera Sancho

3270

Liver toxicity associated to novel cyclin-dependent kinase inhibitor ribociclib in a cohort of advanced breast cancer patients

Poster Presentation

Presenter: Miki Scaravaglio

3280

Three COVID-19 medications - remdesivir, molnupiravir and ritonavir-boosted nirmatrelvir - and serial liver biochemistries in 22,456 subjects

Poster Presentation

Presenter: Grace Lai-Hung Wong

3356

The role of macrophage ETS Proto-oncogene 2 in acute-on-chronic liver failure

Poster Presentation

Presenter: Lulu He

3568

Novel strategies required to further improve outcomes in acute liver failure

Poster Presentation

Presenter: William Bernal

3615

Exogenous fibroblast growth factor 7 improved hepatocyte regeneration and ameliorated CCl<sub>4</sub>-induced acute liver injury in vivo

Poster Presentation

Presenter: Eline Geervliet

## Alcoholic liver disease

14

Heavy alcohol intake along with ALDH2 polymorphism increases the risk of hepatocellular carcinoma and mortality in hepatitis B virus-related cirrhosis

Poster Presentation

Presenter: Chih-Wen Lin

31

IL-1 $\beta$  Signal Inhibition in acute alcoholic hepatitis: a multicentre, randomised, double-blind, placebo-controlled phase 2 trial of canakinumab therapy (ISAIAH)

Oral Presentation

Presenter: Nikhil Vergis

127

Biomarkers for prediction of alcohol-related liver cirrhosis in the Swedish general population

Poster Presentation

Presenter: gustav jakobsson

152

A history of bariatric surgery is independently associated with a younger age at onset of severe alcoholic hepatitis

Poster Presentation

Presenter: Lukas Van Melkebeke

166

Cyclophilin inhibitor CRV431 as a potential therapy for alcohol-related liver disease

Poster Presentation

Presenter: Elena Palma

244

Anti-fibrotic effect of rifaximin in early alcohol-related liver disease: a double-blind, randomised, placebo-controlled trial

Oral Presentation

Presenter: Mads Israelsen

259

Survival and liver recompensation after declined for early liver transplantation for severe alcohol-associated hepatitis

Oral Presentation

Presenter: Christine Hsu

289

UK national service evaluation of transplant assessments for patients with alcohol related liver disease

Poster Presentation

Presenter: Christopher Oldroyd

316

Fibroblast growth factor 21 is the main alcohol responsive peptide hormone in humans and individuals with alcohol use disorder exhibit increased plasma concentrations after alcohol intake

Poster Presentation

Presenter: Amalie Lanng

341

Tight junction damage and increased gut permeability in alcohol-related liver disease may be mediated by gut proteases

Poster Presentation

Presenter: Charlotte Skinner

405

Incident acute kidney injury in severe alcohol-related hepatitis is strongly associated with mortality and can be predicted using micro-RNAs and markers of systemic inflammation

Poster Presentation

Presenter: Luke D. Tyson

446

The impact of addiction team integration into the management of patients transplanted for alcohol-related liver disease: results from a multicenter comparative study

Poster Presentation

Presenter: Jules Daniel

502

Probiotic LGG-derived exosome-like nanoparticles inhibit ALD through intestinal FXR activation in mice: role of miR194 and bile acids

Oral Presentation

Presenter: Wenke Feng



619

Risk of fractures and subsequent mortality in alcohol-related cirrhosis: a nationwide population-based cohort study

Poster Presentation

Presenter: Axel Wester

627

Use of statins among patients with cirrhosis due to alcohol-related liver disease - a danish nationwide cohort study

Poster Presentation

Presenter: Anna Marine Sølling Ramsing

707

Antibody response to gut microbiome bacteria in human alcoholic liver disease

Poster Presentation

Presenter: Antonella Putignano

798

Does screening for liver fibrosis change alcohol consumption, diet, and exercise? A prospective cohort study on the consequences of screening in 2,764 individuals

Oral Presentation

Presenter: Maria Kjærgaard

819

Socio-economic factors and healthcare setting are independently associated with medium and long-term outcomes from alcohol-related hepatitis

Poster Presentation

Presenter: Joshua Lambert

866

Sex-related differences in outcomes in alcohol-related cirrhosis following an episode of hepatic decompensation do not explain subsequent management inequalities

Poster Presentation

Presenter: Aaminah Mohammed

933

Influence of comorbidities and lifestyle factors on health-related quality of life in alcohol-related liver disease: a population-based survey

Poster Presentation

Presenter: Karen Dombestein Elde

1070

Patient and system-level factors underline offering and acceptance of alcohol use disorder therapy in veterans with cirrhosis

Poster Presentation

Presenter: Jasmohan S Bajaj

1071

24-Norursodeoxycholic acid ameliorates experimental alcoholic liver disease in both preventive and therapeutic settings

Poster Presentation

Presenter: Christoph Grander

1092

Impact of sex and recurrence in the prognosis of alcoholic hepatitis

Poster Presentation

Presenter: Jordi Gratacós-Gines

1260

Hepatocyte-derived biomarkers concentrations predict liver-related events within 2 years in patients with Child-Pugh class A alcohol-related cirrhosis

Poster Presentation

Presenter: Laure Elkrief

1264

Baseline plasma metabolic phenotype of patients with severe alcoholic hepatitis and its association with outcome

Oral Presentation

Presenter: Manisha Yadav

1274

Dynamic multiomics analysis characterizes circulating molecular determinants associated with poor outcome in patients with severe alcoholic hepatitis

Poster Presentation

Presenter: Jaswinder Maras

1310

Alcohol-induced changes of inflammatory markers in hepatic and systemic venous blood in early alcohol-related and non-alcoholic fatty liver disease

Poster Presentation

Presenter: Evelina Stankevic

1322

New treatment for alcohol-related liver disease: combinations of efficacy and treatment cost required for cost-effectiveness

Poster Presentation

Presenter: Davit Khlghatyan

1361

Active alcohol misuse is linked with lower short-chain fatty acid producing microbiota in a matched study of 450 patients with cirrhosis

Poster Presentation

Presenter: Jasmohan S Bajaj

1401

Role of macrophage-derived MLKL in alcohol-associated liver disease

Oral Presentation

Presenter: Laura Nagy

1470

Infections are common in patients with early alcohol-related liver disease and increases the risk of death

Poster Presentation

Presenter: Stine Johansen

1475

Abstinence is associated with better outcome in patients with hepatocellular carcinoma

Poster Presentation

Presenter: Astrid Marot

1488

In severe alcohol-related hepatitis, hepatocyte ballooning correlates with expression of p16 and components of a secretory phenotype that has been associated with cellular senescence

Poster Presentation

Presenter: Isabelle Hall

1501

Targeting cyclin M4 as a new therapeutical approach to treat alcoholic liver disease

Poster Presentation

Presenter: Irene González-Recio

1575

Hepatic transcriptional signature of alcohol on genes involved in canonical retinoid metabolism

Poster Presentation

Presenter: Steven Trasino

1585

COVID-19 pandemic impact on alcoholic hepatitis healthcare utilisation

Poster Presentation

Presenter: Leya Nedumannil

1776

The role of integrated alcohol liver care in the management of patients with alcohol related liver disease in an acute hospital setting

Poster Presentation

Presenter: Naina Shah

1794

Untargeted lipidomics unveils a specific plasma signature of severe alcoholic hepatitis

Poster Presentation

Presenter: Florent Artru

1867

Toll-like receptor 2 activation in monocytes of alcohol use disorder patients contributes to systemic inflammation and alcohol-associated liver disease

Poster Presentation

Presenter: Luca Maccioni

1902

Improving NIAAA criteria for the diagnosis of alcoholic hepatitis, role of systemic inflammation

Poster Presentation

Presenter: Emma Avitabile

2071

Alcohol associated hepatitis in Latin America: results from the AH-LATIN study

Poster Presentation

Presenter: Jorge Arnold

2264

Prophylaxis of withdrawal syndrome decreases mortality in patients with alcohol-associated hepatitis

Poster Presentation

Presenter: David Marti-Aguado

2277

The use of pharmacotherapy in the treatment of alcohol use disorder

Poster Presentation

Presenter: Kathryn Allen

2289

Application of machine learning algorithms to classify steatohepatitis on liver biopsy

Poster Presentation

Presenter: Resham Ramkissoon

2498

Calorie-protein deficit and body mass index are the independent predictors of mortality in severe alcoholic hepatitis

Poster Presentation

Presenter: Harshita Tripathi

2618

Alcoholic foamy degeneration: a unique variant of ALD that shows a characteristic pattern of gene expression with upregulation of lipid metabolism and mitochondrial genes and downregulation of fibrosis genes

Poster Presentation

Presenter: Jordi Gratacós-Gines

2820

Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study

Oral Presentation

Presenter: Stephan Buch

3139

Trends of alcohol-related liver disease hospitalisation during the COVID-19 pandemic

Poster Presentation

Presenter: Richard Goodheart

3143

Increased hospital admissions for alcohol-associated hepatitis during the COVID-19 pandemic in Alberta, Canada: a retrospective cohort study

Poster Presentation

Presenter: Alexandra Frolkis

3147

A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis

Poster Presentation

Presenter: Timothy MORGAN

3319

Loss of solute carrier family 38 member 4 (SLC38A4) as a driver for the pathogenesis of severe alcoholic hepatitis

Poster Presentation

Presenter: Nchimunya Nelisa Tebeka

3434

Refining the natural history of alcohol related liver disease: a competing risk analysis

Poster Presentation

Presenter: Richard Parker

3521

Ductular bilirubinostasis is a diagnostic biomarker for acute-on-chronic liver failure: results from a well-defined cohort of patients with alcoholic steatohepatitis

Poster Presentation

Presenter: Annelotte Broekhoven

3525

The lysosomal enzyme cathepsin D as a new marker for alcoholic liver disease

Poster Presentation

Presenter: Ronit Shiri-Sverdlov

3608

Potential biomarkers for differentiating alcoholic hepatitis from decompensated cirrhosis by serum metabolomic analysis

Poster Presentation

Presenter: Adelina Horhat

## Cirrhosis and its complications: Portal Hypertension

174

TIPS insertion leads to partial reversal of systemic inflammation in patients with decompensated liver cirrhosis

Poster Presentation

Presenter: Lena Stockhoff

199

RWE evaluating patients with cirrhosis and features of portal hypertension reveals significant comorbidities

Poster Presentation

Presenter: Peter Greasley

234

Durability of immune response to SARS-CoV-2 vaccination in patients with liver cirrhosis (LC) as compared to healthcare workers (HW)

Poster Presentation

Presenter: Alessandra Mangia

314

A simple model for predicting survival in cirrhotic patients undergoing portosystemic shunt embolization

Poster Presentation

Presenter: Won-Mook Choi

438

Blunted cardiovascular effects of beta-blockers in patients with cirrhosis: relation to severity?

Poster Presentation

Presenter: Puria Nabilou

564

Gender affects the association between serum creatinine levels and clinical response to terlipressin in patients with hepatorenal syndrome type of acute kidney injury

Poster Presentation

Presenter: Khurram Jamil

692

A novel cirrhotic ascites severity score predicts one-year mortality better than the classification into refractory or diuretic-responsive ascites

Poster Presentation

Presenter: Rasmus Hvidbjerg Gantzel

848

A network meta-analysis of numbers needed to treat to prevent an episode of overt hepatic encephalopathy in patients with cirrhosis treated for at least 6 months with lactulose alone, or lactulose plus rifaximin-alpha

Poster Presentation

Presenter: Eric Ngonga Kemadjou

943

Transjugular intrahepatic portosystemic shunt versus balloon-occluded transvenous obliteration for the management of ectopic varices

Poster Presentation

Presenter: Ranya Selim

975

Identification of potential new serum biomarkers for clinically significant portal hypertension by proteomic profiling of circulating extracellular vesicles

Poster Presentation

Presenter: Frane Pastrovic

1020

Factors influencing survival in cirrhotic patients with hepatic hydrothorax

Poster Presentation

Presenter: Sarah Romero

1051

Hepatic venous pressure gradient (HVPG) measured at events is lower in non-alcoholic fatty liver disease (NAFLD) associated cirrhosis as compared to alcoholic cirrhosis

Poster Presentation

Presenter: Lubomir Skladany

1087

Low subcutaneous adipose tissue is associated with mortality independently from portal hypertension in patients with cirrhosis

Poster Presentation

Presenter: Amine Benmassaoud

1088

The association between proton pump inhibitor exposure and key liver-related outcomes in patients with cirrhosis: a veterans affairs cohort study

Oral Presentation

Presenter: Nadim Mahmud

1142

Association of low mechano-energetic efficiency and prognosis in liver cirrhosis

Poster Presentation

Presenter: Sannia Sjöstedt

1161

Long term albumin administration is associated with reduced healthcare resource use in patients with uncomplicated cirrhotic ascites: results from a simulation model

Poster Presentation

Presenter: Elisabet Viayna

1219

Improved survival rates in hepatic encephalopathy after a decade of clinical practice with the addition of rifaximin-alpha to lactulose: a real-world data meta-analysis

Poster Presentation

Presenter: Juha Halonen

1224



Risk prediction of hepatic encephalopathy after molecular targeted therapy for hepatocellular carcinoma in patients with cirrhosis

Poster Presentation

Presenter: Kisako Fujiwara

1279

ABC: a novel algorithm to stratify decompensation risk in patients with cACLD (CHESS2102): an international, multicenter cohort study

Poster Presentation

Presenter: Chuan Liu

1301

Quantitative parameters of esophageal varices based on computed tomography may be used for predicting severe varices in patients with liver cirrhosis

Poster Presentation

Presenter: Shang Wan

1323

A cost-effectiveness evaluation of the GORE® VIATORR® TIPS Endoprosthesis versus large volume paracentesis in the management of portal hypertension complications in the Spanish healthcare system

Poster Presentation

Presenter: Mitesh Nakum

1458

Factor VIII/protein C ratio does not reflect coagulation but is linked to pathophysiological mechanisms driving disease progression in patients with advanced chronic liver disease

Poster Presentation

Presenter: Lorenz Balcar

1479

Prognostic impact of variants in TM6SF2 and MBOAT7 in patients who have progressed to advanced chronic liver disease

Poster Presentation

Presenter: Lorenz Balcar

1487

Clinical course of cirrhotic patients developing ascites as the single first decompensation

Oral Presentation

Presenter: Lorenz Balcar

1535

Hepatocellular carcinoma and number of elastic bands per session are strong predictors of bleeding after prophylactic endoscopic variceal bleeding

Poster Presentation

Presenter: Renato Medas

1563

Simultaneous large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: a randomized controlled trial

Poster Presentation

Presenter: Guohong Han

1576

TIPS with versus without variceal embolization for the prevention of variceal rebleeding: a randomized controlled trial

Oral Presentation

Presenter: Guohong Han

1589

Use of second-harmonic generation microscopy for automated detection of septa and nodules in needle liver biopsies of NASH cirrhosis

Poster Presentation

Presenter: Mazen Nouredin

1639

Hepcidin is higher in patients with more severe liver disease independent of portal hypertension

Poster Presentation

Presenter: Robin Greinert

1689

Effect of thrombocytopenia and platelet transfusion on outcomes of acute variceal bleeding: a real world experience

Poster Presentation

Presenter: Sagnik Biswas

1737

Personalized preemptive TIPS treatment for patients with Child-Pugh B cirrhosis and acute variceal bleeding by applying individualized prediction of treatment effect

Poster Presentation

Presenter: Guohong Han

1755

Real-world survival outcomes in patients with decompensated cirrhosis receiving long term human albumin infusions

Poster Presentation

Presenter: Nicholas Hannah

1831

Impact of non-selective beta-blockers on survival and liver-related complications after TIPS-Insertion

Poster Presentation

Presenter: Anja Tiede

1833

Real world validation of BAVENO-7 non-invasive diagnosis for clinically significant portal hypertension in compensated advanced chronic liver disease: international cohort study

Poster Presentation

Presenter: YU JUN WONG

1834

Derivation of machine learning histologic scores correlating with portal pressures and the development of varices in NASH patients with cirrhosis

Poster Presentation

Presenter: Mazen Nouredin

1883

Ruling out varices needing treatment with a non-invasive score in patients with compensated HBV cirrhosis

Poster Presentation

Presenter: Giacomo Emanuele Maria Rizzo

1908

Evaluation of clinically significant portal hypertension with a novel spleen-dedicated probe using transient elastography

Poster Presentation

Presenter: Aitor Odriozola Herrán

1914

Are psychometric tests helpful for the prediction of hepatic encephalopathy after TIPS insertion?

Poster Presentation

Presenter: Alena Friederike Ehrenbauer

1965

Stratified efficacy of first -line therapy to prevent first variceal bleeding according to previous decompensation of cirrhosis. A competing-risk meta-analyses of individual participant data

Poster Presentation

Presenter: Càndid Villanueva

2121

Baseline plasma renin activity(PRA) predicts risk of AKI in patients with cirrhosis: a prospective observational study

Poster Presentation

Presenter: srinivasa reddy golamari

2153

Carvedilol plus Simvastatin modulates systemic inflammation in cirrhosis with portal hypertension and non-response to B-blockers: randomised double-blind study

Oral Presentation

Presenter: Edilmar Alvarado-Tapias

2160

Performance of spleen stiffness measured by point-shear wave elastography in esophageal varices screening

Poster Presentation

Presenter: Mauro Giuffrè

2212

Non-invasive diagnosis of clinically significant portal hypertension and treatment with non-selective beta-blockers: a new paradigm

Oral Presentation

Presenter: Elton Dajti

2219

Portal pressure decreasing effect of beta blockers in cirrhosis with clinically significant portal hypertension, according to the components of metabolic syndrome

Poster Presentation

Presenter: Anna Brujats

2270

Non-invasive tests for clinically significant portal hypertension after HCV-cure - individual patient data meta-analysis and validation

Oral Presentation

Presenter: Georg Semmler

2286

Transjugular, intra-hepatic portosystemic shunt (TIPS) in elderly patients: preliminary analysis of a multi center retrospective cohort

Poster Presentation

Presenter: Davide Roccarina

2392

Endoscopic glue injection v/s endoscopic human thrombin injection for bleeding gastric varices - a randomized controlled trial

Poster Presentation

Presenter: Ashok Jhajharia

2484

Updating target PPG value to reduce clinical events in patients receiving covered-TIPS for the prevention of variceal rebleeding

Poster Presentation

Presenter: Guohong Han

2619

Impact of alcohol abstinence in patients with alcohol-related cirrhosis and portal hypertension

Poster Presentation

Presenter: Benedikt Hofer

2652

Substantial reduction of the diagnostic grey zone of the Baveno-VII CSPH criteria by sequential consideration of VITRO

Poster Presentation

Presenter: Mathias Jachs

2734

Causes and predictors of 30-day readmission in patients with gastric varices requiring Balloon-occluded retrograde transvenous obliteration (BRTO)

Poster Presentation

Presenter: Mohamed Ahmed

2809

Carvedilol is associated with superior hemodynamic response and rebleeding rates in comparison to propranolol in secondary prophylaxis of variceal bleeding

Poster Presentation

Presenter: Mathias Jachs

2819

Impact of early nasogastric tube feeding after endotherapy for acute variceal bleeding in patients with cirrhosis : a randomized controlled trial

Poster Presentation

Presenter: Jatin Yegurla

2952

Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in 3 phase III North American studies

Poster Presentation

Presenter: Michael Curry

3198

Expandable constrained 6mm transjugular intrahepatic portosystemic shunt: an alternative approach for high-risk patients?

Poster Presentation

Presenter: Hannah Schneider

3226

Covered TIPS reduces the risk of further decompensation: results from an individual patient data meta-analysis of 3924 patients with cirrhosis

Poster Presentation

Presenter: H el ene Larrue

3236

Non-invasive tools are suboptimal to predict the presence of varices needing treatment and risk of clinical decompensation in patients with autoimmune hepatitis related cirrhosis

Poster Presentation

Presenter: Randeep Rana

3465

Sarcopenia increases the risk of cirrhosis disease progression and death in patients with cirrhosis

Poster Presentation

Presenter: Sarah Wang

3626

A multi-compartmental model of the HepQuant SHUNT test can quantify anatomic shunting and stratify risk for varices: combined results from the HALT-C and SHUNT-V studies

Poster Presentation

Presenter: Michael McRae

3781

Hepatic recompensation according to Baveno VII criteria significantly reduces liver-related mortality in patients with decompensated alcohol-related cirrhosis

Poster Presentation

Presenter: Benedikt Hofer

3895

Sequential algorithm of spleen stiffness measured by a dedicated 100 Hz examination and Baveno VII criteria for clinically significant portal hypertension in compensated cirrhosis

Poster Presentation

Presenter: Ruiling He

3923

Improving of hepatic encephalopathy manifestations in cirrhotic patients with clinically significant portal hypertension treated with splenic artery embolization

Poster Presentation

Presenter: Sergii Kozlov

## Cirrhosis and its complications: ACLF and Critical illness

41

COVID-19 in patients with cirrhosis: insights from the multinational LEOSS registry

Poster Presentation

Presenter: Jonathan Frederik Brozat

216

Liver transplantation within 7-days of listing improves survival in ACLF-3

Oral Presentation

Presenter: Joseph Alukal

313

Serum metabolites on admission associate with the development of nosocomial infections in inpatients with cirrhosis

Poster Presentation

Presenter: Jasmohan S Bajaj

321

Association of impaired neutrophil migration with adverse outcomes in patients with liver cirrhosis

Poster Presentation

Presenter: Mona-May Langer

362

Renal and circulatory effects of terlipressin in patients with hepatorenal syndrome assessed by magnetic resonance imaging

Poster Presentation

Presenter: Puria Nabilou

434

SARS-CoV-2 infection in patients with underlying chronic liver disease is associated with significantly greater risks of inpatient hospitalization, intensive care unit admission, and overall mortality

Poster Presentation

Presenter: Robert Wong

593

Low FT3 levels are associated with acute decompensation and acute-on-chronic liver failure

Poster Presentation

Presenter: Mona-May Langer

640

Post hoc analyses of the ATTIRE trial suggest potential gender differences in response to albumin

Poster Presentation

Presenter: Alastair O'Brien

754

Can machines predict liver decompensation? Analysis of 1,415 patients with liver cirrhosis recruited at three German referral centers

Poster Presentation

Presenter: Sophie Elisabeth Müller

1123

LivR Well: a feasibility study for a home-based, multidisciplinary liver optimization program for the first 28 days after an admission for acute-on-chronic liver failure

Poster Presentation

Presenter: Natalie Ngu

1167

Neutrophil gelatinase-associated lipocalin predicts response to terlipressin and albumin in patients with hepatorenal syndrome

Oral Presentation

Presenter: Carmine Gabriele Gambino

1358

CLEARED Global consortium results highlight regional variation and need for equity in inpatient outcomes in hospitalized patients with Chronic Liver Disease

Oral Presentation

Presenter: Jasmohan S Bajaj

1417

Alcohol-associated hepatitis with acute-on-chronic liver failure in a diverse cohort: lung and circulatory organ failures along with MELD 35 are predictive of mortality

Poster Presentation

Presenter: Stephanie Rutledge

1561

Bilirubin and its dynamics are independently associated with mortality in patients with acute decompensation of cirrhosis

Poster Presentation

Presenter: Konstantin Kazankov



1610

Impact of predisposition and precipitants on the short-term prognosis among inpatients with chronic liver disease

Poster Presentation

Presenter: Yan Zhang

1663

A study evaluating outcomes of a virtual specialist liver cirrhosis clinic

Poster Presentation

Presenter: Claudia Moore-Gillon

1695

A novel metabolomics-based prognostic model shows superior diagnostic accuracy than MELD in chronic liver failure

Poster Presentation

Presenter: Rudolf E. Stauber

1724

Uncovering monocyte transcription, functional and metabolic signatures in recovery and non-recovery ACLF patients

Poster Presentation

Presenter: Rita Furtado Feio de Azevedo

1786

Predicting prognosis in large cohort of decompensated cirrhosis of liver (DCLD)- a machine learning (ML) approach

Oral Presentation

Presenter: Ashok Choudhury

1901

Early initiation of continuous renal replacement therapy improves renal outcomes and survival in patients with acute on chronic liver failure - a prospective cohort study

Poster Presentation

Presenter: Rakhi Maiwall

1927

Different clinical courses of acutely decompensated cirrhosis in hepatitis B virus high-endemic area: data from Chinese Acute-on-Chronic Liver Failure (CATCH-LIFE) study

Poster Presentation

Presenter: Tongyu Wang

1954

Characterization of energy and substrate metabolism in patients with spontaneously breathing and mechanically ventilated patients with liver cirrhosis: an indirect calorimeter based study

Poster Presentation

Presenter: Varsha Shasthry

1959

Extracorporeal membrane oxygenation, a valuable life-saving treatment in liver transplanted patients

Poster Presentation

Presenter: Benjamin Buchard

1974

Prevalence, profile and predictors of invasive fungal infections in acute on chronic liver failure (ACLF): analysis of APASL-ACLF research consortium database

Poster Presentation

Presenter: Pratibha Ramchandra Kale

2021

Maladaptive tubular repair is a harbinger of chronic kidney disease development in critically-ill cirrhosis patients admitted to intensive care unit - a prospective cohort study

Oral Presentation

Presenter: Rakhi Maiwall

2045

Outcomes in patients with cirrhosis and fungal infections: a systematic review and meta-analysis with machine learning

Poster Presentation

Presenter: Nipun Verma

2170

Impact of de presence of acute on chronic liver failure on morbi - mortality after liver transplantation

Poster Presentation

Presenter: Jorge Arnold

2176

Hyperammonaemia defines the risk of acute-on-chronic liver failure in clinically stable outpatients with cirrhosis

Oral Presentation

Presenter: María Pilar Ballester

2326

Comparative analysis of acute-on-chronic liver failure related to herbs and anti-tubercular drugs

Poster Presentation

Presenter: Ankur Jindal

2389

Untargeted lipidomics differentiate ACLF precipitated by severe alcoholic hepatitis

Poster Presentation

Presenter: Florent Artru

2396

Metabolomic analysis of organ failure marker compounds in blood samples of patients with decompensated liver cirrhosis after administration of the novel drug VS-01

Poster Presentation

Presenter: Wenyi Gu

2398

Metabolomic analysis of bacterial infection markers in blood samples of patients with decompensated liver cirrhosis infused with the novel drug VS-01

Poster Presentation

Presenter: Olaf Tyc

2414

Disturbances in sodium and chloride hemostasis predict outcome in stable and critically-ill patients with cirrhosis - not two sides of the same coin

Poster Presentation

Presenter: Georg Semmler

2790

Thrombospondin 1: an emerging key-role in the acute-on-chronic liver failure pathogenesis

Poster Presentation

Presenter: Hozeifa Mohamed Hassan

2810

Comprehensive immunophenotyping reveals profound alterations of T cell subsets in acute decompensation of liver cirrhosis

Poster Presentation

Presenter: Yasmina Chouik

2982

Sarcopenia assessed via computed tomography is associated with short-term outcomes and improves prognostic scores' performance in critically ill patients with acute on chronic liver failure

Poster Presentation

Presenter: Florent Artru

3291

Use of Tocilizumab in patients with stable chronic liver disease and severe COVID-19 for prevention of decompensated cirrhosis, a prospective, open-label, randomized controlled trial.

Poster Presentation

Presenter: Luis Alejandro Rosales Renteria

3536

Low hemoglobin level predicts early hospital readmission in patients with cirrhosis and acute decompensation

Poster Presentation

Presenter: Enrico Pompili

3718

Impact of increasing MELD 3.0 beyond 40 on liver transplant outcomes

Oral Presentation

Presenter: W. Ray Kim

3803

Beta-blockers can reduce mortality in patients with acute-on-chronic liver failure-a multi-center study

Poster Presentation

Presenter: Anand Kulkarni

## Cirrhosis and its complications: Other clinical complications except ACLF and critical illness

47

Evaluation of Interleukin-6 for stepwise diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis

Poster Presentation

Presenter: Simon Johannes Gairing

93

Evaluation of statins as a new therapy to alleviate chronotropic dysfunction in cirrhotic rats

Poster Presentation

Presenter: Qamar Niaz

103

The effect of sarcopenia on survival of patients with cirrhosis: a systematic review and meta-analysis

Poster Presentation

Presenter: Xinxing Tantai

184

Effectiveness of probiotics in the secondary prevention of hepatic encephalopathy among cirrhotic patients

Poster Presentation

Presenter: Muhammad Farooq Hanif

330

Sarcopenia as a predictor of mortality and complications in cirrhosis patients - A prospective cohort study

Poster Presentation

Presenter: NIDHIN DEVADAS

476

Diagnosis and pathophysiological analysis of sarcopenia using liver MR in chronic liver disease

Poster Presentation

Presenter: ATSUSHI NAKAMURA

500

Use of a cirrhosis database can positively impact patient care in United Kingdom practice

Poster Presentation

Presenter: Jessica Shearer

545

Psychomotor speed from minimal hepatic encephalopathy testing is associated with physical frailty in patients with end-stage liver disease

Poster Presentation

Presenter: Andres Duarte Rojo

618

A multistrain probiotic increases serum glutamine/glutamate ratio in patients with cirrhosis. A metabolomic analysis

Poster Presentation

Presenter: German Soriano

645

The composition of the bile acid pool is closely associated with fibrosis in the heart and liver of patients with cirrhosis

Poster Presentation

Presenter: Søren Møller

663

SBP vs. non-SBP bacterial infections at admission have comparable outcomes in a multi-center cohort of inpatients with cirrhosis

Poster Presentation

Presenter: Jacqueline O'Leary

693

Natural history of Hepatic Encephalopathy (HE) in a tertiary referral centre for hepatology

Poster Presentation

Presenter: Chiara Mangini

744

Public knowledge and attitudes toward liver diseases and liver cancer in the Brazilian population

Poster Presentation

Presenter: Paulo Bittencourt

863

The negative impact of the pandemic on hospital admissions, morbidity and 30-day mortality for acute cirrhosis decompensation: a tertiary care perspective

Poster Presentation

Presenter: Kohilan Gananandan

869

Comparison of recommended daily energy intakes in people with cirrhosis, based on current guidelines, and their directly measured energy requirements: an individual patient data analysis

Poster Presentation

Presenter: Marsha Morgan

870

Rifaximin for the prevention and treatment of hepatic encephalopathy: a systematic review and meta-analysis of randomized clinical trials

Poster Presentation

Presenter: Marsha Morgan

890

Impact of cirrhotic cardiomyopathy and severity of liver cirrhosis on the development of acute kidney injury

Oral Presentation

Presenter: Simona Bota

893

Influence of cirrhotic cardiomyopathy defined according to the new multidisciplinary diagnostic criteria on overall mortality among cirrhotic patients

Poster Presentation

Presenter: Simona Bota

942

Risk of herpes zoster infection in patients with cirrhosis: a nationwide population-based study in Korea

Poster Presentation

Presenter: Dongsu Jeon

984

Skeletal muscle pathological fat infiltration (myosteosis) associates with higher mortality in patients with cirrhosis

Poster Presentation

Presenter: Maryam Ebadi

1015

Application of CT-contrast media is not associated with a higher risk for acute kidney injury in patients with decompensated liver cirrhosis

Poster Presentation

Presenter: Tammo Lambert Tergast

1066

Etiological cure prevents further decompensation and mortality in cirrhotic patients with ascites as the single first decompensating event

Oral Presentation

Presenter: Marta Tonon

1151

Proton pump inhibitors are associated with higher mortality risk and higher risk of decompensation in patients with liver cirrhosis - A retrospective cohort study from the Amsterdam metropolitan area

Poster Presentation

Presenter: Koos de Wit

1211

Maintenance of sarcopenia and myosteosis after liver transplantation

Poster Presentation

Presenter: Franziska Recklies

1256

Clinical and prognostic characterization of the patterns of decompensation of liver cirrhosis

Poster Presentation

Presenter: Marta Tonon

1268

Safety, pharmacokinetics and pharmacodynamics of TNP-2092 capsule in chinese liver cirrhosis patients with hyperammonemia: a randomized, double-blind, placebo-controlled, dose-escalation phase Ib/IIa study

Poster Presentation

Presenter: Yanhua Ding

1296

Serological assessment of the collagen type III deposition predicts outcome in decompensated liver cirrhosis

Poster Presentation

Presenter: Mette Juul Nielsen

1321

Liver frailty index predicts poor outcomes in patients hospitalized for acute decompensation of cirrhosis

Poster Presentation

Presenter: Simone Incicco

1345

Urinary proteomics identifies oxidative stress and inflammation pathways as key factors differentiating acute-kidney injury-hepatorenal syndrome from acute tubular necrosis in patients with cirrhosis

Poster Presentation

Presenter: Laura Napoleone

1359

Risk factors for short-term post discharge clinical outcomes in patients hospitalized with decompensated chronic liver disease: interim results from Global CLEARED study

Oral Presentation

Presenter: Ashok Choudhury

1468

Kidney transplant alone recipients with advanced liver disease have similar outcomes to those without advanced liver disease - a single center study of 150 patients

Poster Presentation

Presenter: Rohit Nathani

1618

Clinical features of exacerbation of portal vein thrombosis after discontinuation of anticoagulants

Poster Presentation

Presenter: Takayuki Kondo

1684

Systemic inflammatory response syndrome and renal resistive index as early predictors of treatment response to terlipressin in hepatorenal syndrome-acute kidney injury

Poster Presentation



Presenter: krishnadas devadas

1765

A prospective study of global myocardial function in decompensated cirrhosis using advanced echocardiographic techniques and its clinical significance

Poster Presentation

Presenter: Jeyamani Ramachandran

1856

Dyserythropoiesis is underrecognized and contributes to severe anemia in liver cirrhosis

Oral Presentation

Presenter: Chhagan Bihari

2002

Identification of overt hepatic encephalopathy precipitating factors: a pooled analysis of 3 clinical trials of rifaximin plus lactulose

Poster Presentation

Presenter: Jasmohan S Bajaj

2010

Dementia frequently co-exists with hepatic encephalopathy but not other cirrhosis complications in US veterans with cirrhosis

Poster Presentation

Presenter: Adeyinka Adejumo

2037

Bacterial infections as a predisposing factor for the development of portal vein thrombosis in cirrhotic patients: a prospective study

Poster Presentation

Presenter: Leonardo De Marco

2050

Impact of the COVID-19 pandemic on the incidence and type of infections in hospitalized patients with cirrhosis

Poster Presentation

Presenter: Berta Cuyas

2052

Increased expression of podoplanin, a marker of dilated lymphatic vessels in duodenal biopsies is an independent predictor of three-month mortality in patients with cirrhosis

Poster Presentation

Presenter: Savneet Kaur

2107

Blood metabolomics unveils mitochondrial dysfunction as a potential key feature in the pathogenesis of hepatorenal syndrome

Poster Presentation

Presenter: Ann T Ma

2132

Hyperammonaemia is an independent biomarker of liver-related complications and mortality in clinically stable outpatients with cirrhosis

Poster Presentation

Presenter: Tom H Tranah

2222

Prospective evaluation of the EASL clinical guidelines algorithm of management of acute kidney injury in cirrhosis

Poster Presentation

Presenter: Ann T Ma

2312

MELD 3.0 accurately predicts short term survival of patients with end-stage liver disease

Poster Presentation

Presenter: Anna Vidovszky

2452

CyberLiver Animal Recognition Test (CL-ART): a novel remote monitoring tool to assess minimal hepatic encephalopathy

Poster Presentation

Presenter: Kohilan Gananandan

2503

Acute kidney injury during hospitalization in patients with liver cirrhosis is associated with increased mortality and chronic kidney disease on follow-up

Poster Presentation

Presenter: Anna Cederborg

2531

Ascites bacterial DNA and IL-6 are promising tools in the diagnosis of spontaneous bacterial peritonitis

Poster Presentation

Presenter: Niklas F Aehling

2558

Ascitic fluid mid-regional-pro-adrenomedullin (MR-pro-ADM): a novel rapid-assay sepsis biomarker to diagnose spontaneous bacterial peritonitis in cirrhotic patients

Poster Presentation

Presenter: Abderrahim Oussalah

2605

Effect of recruitment and selection policies on the volume of outcome of patients transplanted with ACLF-3

Oral Presentation

Presenter: Baptiste Michard

2715

Low incidence of adverse liver events in a real-world cohort of patients diagnosed with liver disease via a community diagnostic pathway

Poster Presentation

Presenter: Alexander Smith

2792

Non-invasive prediction of risk of liver-related events in non-alcoholic fatty liver disease patients

Poster Presentation

Presenter: Monica Pons

3052

Short term intravenous albumin effects in decompensated cirrhosis: about single hospitalization event

Poster Presentation

Presenter: Han Seul ki

3152

Myosteatosis is associated with sarcopenis, frailty and fat body composition abnormalities in liver cirrhosis

Poster Presentation

Presenter: Alexandra Alexopoulou

3339

Correction and prevention of hyponatremia in patients with cirrhosis and ascites - post hoc analysis of the ANSWER study database

Poster Presentation

Presenter: Giacomo Zaccherini

3415

In-hospital falls and impaired nutritional status are independently associated with in-hospital mortality in patients with liver cirrhosis

Poster Presentation

Presenter: Nada Abedin

3449

Effect of hepatitis B virus treatment on all causes and liver-related death among patients living with HBV with cirrhosis in British Columbia in a population-based cohort study

Poster Presentation

Presenter: Makuza Jean Damascene

3463

Secondary infections in hospitalized patients with cirrhosis: epidemiology, clinical characteristics and prognostic relevance

Poster Presentation

Presenter: Gustavo Pereira

3501

PD-1/PD-L1 pathway is related to infection development and early mortality in patients with cirrhosis

Poster Presentation

Presenter: Adria Juanola

3504

Real-world evidence on long-term albumin treatment in patients with decompensated liver cirrhosis in Italy

Oral Presentation

Presenter: Wim Laleman

3508

The use of decompensated cirrhosis admission care bundles improves the standard of inpatient care but utilisation is poor across the UK

Poster Presentation

Presenter: . The Trainee Collaborative for Research and Audit in Hepatology UK

3915

Circulating cell-free DNA levels increment with worsening cirrhosis severity and associate with platelet exhaustion and mortality

Poster Presentation

Presenter: Marilena Stamouli

[Cirrhosis and its complications: Experimental and pathophysiology](#)

Neurometabolic and gliovascular changes in murine hepatic encephalopathy

Oral Presentation

Presenter: Wouter Claeys

305

Extracellular vesicles from mesenchymal stem cells reduce neuroinflammation in hippocampus and restore cognitive function in hyperammonemic rats

Oral Presentation

Presenter: Paula Izquierdo-Altarejos

466

Increased platelet aggregation in decompensated cirrhosis indicates higher risk of further decompensation and liver-related mortality

Poster Presentation

Presenter: Alberto Zanetto

503

Lipidomics analyses of ATTIRE trial patients' plasma at day 1 demonstrates that reduced cholesterol esterification predicts development of hospital acquired infection

Oral Presentation

Presenter: Harriett Fuller

574

Renin/angiotensin system - coagulation - inflammation axis abnormalities: a possible explanation for susceptibility to severe COVID-19 in cirrhosis

Poster Presentation

Presenter: Lukas Hartl

611

Effect of engineered poly(beta-amino ester) nanoparticles containing a nitric oxide donor on systemic and portal hemodynamics

Oral Presentation

Presenter: Meritxell Perramón

745

Improvement of hepatic and extrahepatic functions and anti-inflammatory effects of nitazoxanide in disease models of LPS-induced systemic inflammation and acute-on-chronic liver failure

Poster Presentation

Presenter: Dean Hum

908

In silico characterization of the interactome of hepatic nonparenchymal cells reveals promising targets for antifibrotic therapy

Poster Presentation

Presenter: Oleksandr Petrenko

1157

Long-chain acylcarnitines promote leukocyte mitochondrial dysfunction: role in patients with acutely decompensated cirrhosis

Poster Presentation

Presenter: Ingrid Wei Zhang

1208

Reduced plasma extracellular vesicle CD5L content in patients with acute-on-chronic liver failure: interplay with specialized pro-resolving lipid mediators

Poster Presentation

Presenter: Joan Clària

1218

Peptidylglycine alpha-amidating monooxygenase and adrenomedullin measurements suggest cardiovascular dysfunction in advanced cirrhosis

Poster Presentation

Presenter: Søren Møller

1241

Combination of CCL4-induced decompensated cirrhosis with acute polymicrobial peritonitis as an optimized experimental model mimicking extrahepatic organ failures defined in ACLF

Poster Presentation

Presenter: Roger Flores-Costa

1328

Thrombin-induced platelet activation across distinct stages of portal hyperension and cirrhosis

Poster Presentation

Presenter: Ksenia Brusilovskaya

1340

Integrating single-cell RNA and spatial transcriptomic data defines altered cell state in human liver fibrosis

Oral Presentation

Presenter: Karen Piper Hanley

1480

Exploring metabolic space of advanced chronic liver disease regression

Poster Presentation

Presenter: Mojgan Masoodi

1499

Exacerbated response to patterned injury in the cirrhotic liver: potential susceptibility to ischemia

Poster Presentation

Presenter: Benjamin Leaker

1666

The regulatory protein and gene expression profile of skeletal muscle in chronic liver disease patients

Poster Presentation

Presenter: Sophie Allen

1690

Proteomic analysis of dysfunctional liver sinusoidal endothelial cells reveals substantial differences in the most common experimental models of chronic liver disease

Poster Presentation

Presenter: Mar Gil

1757

Long-term albumin administration improves survival, reduces TLR4 mediated hepatic inflammation and reduces gut translocation in models of cirrhosis

Poster Presentation

Presenter: Alexandra Phillips

1764

The prevalence and prognostic significance of vitamin C deficiency in patients with cirrhosis: a prospective observational cohort study

Poster Presentation

Presenter: declan connoley

1918

Wnt as activator of regeneration in cirrhosis of human liver: tissue collapse brings the Wnt source in hepatic veins to the site of the progenitor cell niche

Poster Presentation

Presenter: IanR Wanless

2020

The portal vein in patients with cirrhosis is not an extensively inflammatory or hypercoagulable vascular bed

Poster Presentation

Presenter: Ellen Driever

2061

Effect of liver stiffness on hepatocellular carcinoma phenotype in a biometric 3D model

Poster Presentation

Presenter: Jaafar Khaled

2122

Vascular endothelial growth factor C mediated restoration of mesenteric lymphatic vessels permeability and drainage improves gut immunity surveillance in experimental cirrhosis

Oral Presentation

Presenter: Pinky Juneja

2884

Worsening of low-grade systemic inflammation heralds decompensation in patients with compensated cirrhosis

Poster Presentation

Presenter: Rubén Sánchez-Aldehuelo

3149

miRNA associated with systemic inflammation may have prognostic utility in predicting decompensation in patients with chronic liver disease

Poster Presentation

Presenter: Oliver Tavabie

3178

Ascites reduction and anti-inflammatory effects after albumin infusion for the management of cirrhosis: evidence from an animal model

Poster Presentation

Presenter: Raquel Horrillo

3188

Patients with acutely decompensated cirrhosis present a distorted blood lipid landscape that affects the ability of albumin to promote inflammation resolution

Poster Presentation

Presenter: Mireia Casulleras

3232

Demonstration of gut-barrier dysfunction and endotoxemia in patients with cirrhosis presenting with acute variceal bleeding : a proof of concept

Poster Presentation

Presenter: Rajat Bansal

3597

Presence of NOD2 mutations is not associated with hepatic or systemic hemodynamic abnormalities of cirrhosis

Poster Presentation



Presenter: Robin Greinert

## Fibrosis

109

Hepatic angiocrine HGF attenuates liver fibrogenesis via modulation of PDK1/AKT axis

Poster Presentation

Presenter: Jianye Wang

110

Bisphosphonate-loaded nanogels attenuate liver fibrosis by repolarization of M2-type macrophages

Poster Presentation

Presenter: Leonard KAPS

125

Preclinical evaluation of the calpain inhibitor BLD-3051 as a therapeutic strategy for liver fibrosis

Poster Presentation

Presenter: Ravi Rajagopalan

168

Experimental fibrosis alters matrix-bound vesicles cargo that do not revert after histologic recovery

Poster Presentation

Presenter: TOSHIFUMI SATO

409

Hepatocyte cell-specific deletion of cathepsin D does not affect liver inflammation and fibrosis during cholestatic-induced liver fibrosis

Poster Presentation

Presenter: Maria Fernandez-Fernandez

499

The therapeutic potential of alpha v integrins in liver fibrosis

Poster Presentation

Presenter: Syedia Rahman

535

Dual inhibition of integrins alpha-v/beta-6 and alpha-v/beta-1 decreases portal pressure and liver fibrosis in rats with biliary cirrhosis

Poster Presentation

Presenter: Philipp Königshofer

607

Dual roles of PSMP/MSMP in the progression of hepatic fibrosis and hepatocellular carcinoma

Poster Presentation

Presenter: Shaoping She

690

NKT cells promote both type 1 and type 2 inflammatory responses in the non-obese diabetic inflammation and fibrosis (NIF) mouse model

Poster Presentation

Presenter: Sofia Mayans

783

Using qFibrosis analysis to predict disease and survival outcome of patients with hepatocellular carcinoma after curative treatment

Poster Presentation

Presenter: Dean Tai

790

Multi-target engagement effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in animal model of NASH/fibrosis

Poster Presentation

Presenter: Jong Suk Lee

791

Direct anti-inflammatory and anti-fibrotic effects of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in thioacetamide-induced mouse model of liver injury and fibrosis

Poster Presentation

Presenter: Jung Kuk Kim

794

Loss of bile salt export pump (BSEP/ABCB11) protects mice from development of carbon tetrachloride (CCl<sub>4</sub>) induced hepatic fibrosis

Poster Presentation

Presenter: Claudia Fuchs

804

Large-scale multicenter study for the clinical utility of the non-invasive biomarkers Gas6 and soluble Axl in hepatocellular carcinoma, liver fibrosis and end-stage liver disease

Poster Presentation

Presenter: Wolfgang Mikulits

881

Multispectral analysis of liver biopsies from patients with chronic hepatitis C reveals unique macrophage phenotypes and spatial interactions associated with fibrosis progression

Poster Presentation

Presenter: Omar Saldarriaga

892

Neutrophil-specific NLRP3 activation triggers liver inflammation and fibrosis

Poster Presentation

Presenter: Benedikt Kaufmann

926

Imaging of fibrosis in metabolic associated liver disease by a radiolabeled affibody targeting PDGFRB

Poster Presentation

Presenter: Olof Eriksson

931

Liver complications in greek patients with sickle cell disease: a multicenter retrospective analysis from eight thalassemia and sickle cell units across Greece

Poster Presentation

Presenter: Konstantinos Manganas

1000

Hemodynamic, molecular, and histological characterization of a toxic liver fibrosis regression model

Poster Presentation

Presenter: Philipp Königshofer

1060

Peroxidasin deficiency re-programs macrophages toward pro-fibrosis function and promotes collagen resolution in liver

Oral Presentation

Presenter: Mozhdeh Sojoodi

1084

The upper limit of normal of alanine aminotransferase (ALT) in diagnosing liver disease and fibrosis by the Intelligent Liver Function Test (iLFT) system

Poster Presentation

Presenter: Jeremy Lee

1108

Inhibition of 11beta-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH

Poster Presentation

Presenter: Haeng Ran Seo

1144

Anti-fibrotic effects of microRNA-9-5p and microRNA-122

Poster Presentation

Presenter: Dana Eidelstein

1164

Higher daily Aramchol dose results in higher effect size in fibrosis improvement in the ARMOR study open label part

Poster Presentation

Presenter: Vlad Ratziu

1184

Development of a high precision liver biopsy method to improve the accuracy of fibrosis staging and collagen profiling

Poster Presentation

Presenter: Morten Christensen

1303

MAIT cell inhibition promotes liver fibrosis regression by reprogramming macrophage phenotype

Poster Presentation

Presenter: Morgane Mabire

1441

The LiverPRO score, a multivariable model for prediction of significant fibrosis in primary care: derivation, validation and comparison with FIB-4 and ELF-test in 5,000 study participants

Poster Presentation

Presenter: Katrine Prier Lindvig

1497

The protective effect of time-caloric restriction in liver fibrosis induced by nitrosamines in rat model

Poster Presentation

Presenter: Christian Molina-Aguilar

1512

Macrophage MerTK promotes a profibrogenic cross-talk with hepatic stellate cells via soluble mediators

Poster Presentation

Presenter: Mirella Pastore

1518

Comparative fibrosis-reducing activities of farnesoid X receptor (FXR), peroxisome-proliferator activated receptor delta (PPAR) and thyroid hormone receptor (THR) agonists in the carbon tetrachloride mouse model

Poster Presentation

Presenter: Edward Cable

1594

A novel role for serine protease Kallikrein 8 in liver fibrosis through cleaving complement C3 and hepatic macrophage polarization

Poster Presentation

Presenter: Cichun Wu

1673

The modulation of NADPH oxidases by tyrosol-derived phenolic compounds prevents hepatic fibrogenesis

Poster Presentation

Presenter: Daniela Gabbia

1680

Exploring gender-related differences in liver fibrosis and regeneration through a new experimental carbon tetrachloride protocol in mice

Poster Presentation

Presenter: Katia Sayaf

1691

Multicenter external validation of FIB-6: a novel, machine-learning, simple bedside score to rule out severe liver fibrosis and cirrhosis in patients with MAFLD

Poster Presentation

Presenter: Gamal Shiha

1736

A bioengineered approach to re-create and study the extracellular matrix-immune cell crosstalk in normal and fibrotic liver

Poster Presentation

Presenter: Sara Campinoti

1872

Clinical and genetic factors associated with regression of fibrosis in ACLD after etiological therapy

Poster Presentation

Presenter: Yuly Mendoza

1882

Targeting the liver circadian clock by REV-ERB-alpha activation improves liver fibrosis by circadian gating of TGF-beta signaling

Oral Presentation

Presenter: Atish Mukherji

1911

The proteomic analysis of hepatic stellate cell differentiation from iPSCs identifies RORalpha as an antifibrogenic target

Oral Presentation

Presenter: Raquel A. Martinez Garcia de la Torre

1940

Stellate cell dynamics in progression and regression of hepatic fibrosis

Oral Presentation

Presenter: Laura Almale del Barrio

1960

Addressing the heterogeneity of fibrosis in liver biopsy specimens with qFibrosis -- a new paradigm for an old problem

Poster Presentation

Presenter: David E Kleiner

2017

Characterisation of the novel Galectin-3 inhibitor GB1107 on CCl4-induced liver fibrosis in mice

Poster Presentation

Presenter: Alison MacKinnon

2047

Quantitative digital pathology of 3D human NASH models establish continuous scores to evaluate the antifibrotic effects of Selonsertib, Firsocostat and Resmetiron

Poster Presentation

Presenter: Louis Petitjean

2126

Etiology-independent fibrosis severity scoring by quantitative digital pathology image analysis

Poster Presentation

Presenter: Adam Watson

2188

Liver stiffness and autoimmune profile in a cohort of patients with systemic sclerosis

Poster Presentation

Presenter: Davide Di Benedetto

2198

Performance of a p-SWE method implemented on a new ultrasound system for predicting advanced liver fibrosis

Poster Presentation

Presenter: Alexandru Popa

2202

Inhibition of tumour progression locus 2 (TPL2) halts the progression of liver fibrosis in a stringent long term choline deficient high-fat diet (CdHFD) rat model

Poster Presentation

Presenter: Milessa Silva Afonso

2204

Evaluation of the antifibrotic effects of naringenin, asiatic acid and icariin by using precision-cut liver slices of mouse and human

Poster Presentation

Presenter: Ke Luo

2272

Diagnostic efficacy of Mac-2 binding protein glycosylation isomer for predicting liver fibrosis in patients with metabolic associated fatty liver disease

Poster Presentation

Presenter: SE YOUNG JANG

2296

Multispectral imaging analysis of liver biopsies from patients with non-alcoholic steatohepatitis reveals enrichment of pathogenic macrophage phenotypes associated with disease progression

Poster Presentation

Presenter: Joseph Gosnell

2317

Machine learning methods for detailed characterization of TGF-beta-induced signatures in a large iPSC-derived hepatic stellate cell cohort

Oral Presentation

Presenter: Panagiotis Stanitsas

2383

Diabetes, but not prediabetes, is associated with significant liver fibrosis

Poster Presentation

Presenter: Won Sohn

2483

Lysophosphatidylserine may stimulate liver fibrosis

Poster Presentation

Presenter: Takako Nishikawa

2489

Quantitative assessment of liver fibrosis in NASH patients

Poster Presentation

Presenter: Luong Ruiz

2631

Sex and diagnosis-specific differences in liver elastography and attenuation

Poster Presentation

Presenter: Zhi Tan

2653

Progression of liver disease among patients with a new diagnosis of protease inhibitor ZZ alpha-1 antitrypsin deficiency

Poster Presentation

Presenter: Tiffany Wu

2794

Investigating the function of Endothelial-To-Mesenchymal transition during liver fibrogenesis using a Liver-On-A-Chip platform

Poster Presentation

Presenter: Neil Dufton

2864

Telomerase-null mice display defective immune activation following the induction of liver fibrosis with *S. mansoni*

Poster Presentation

Presenter: Willian Gomes

2908

Selectivity matters: novel ROCK2 inhibitor down-regulates established liver fibrosis via concurrent of targeting inflammatory, fibrotic and metabolic pathways

Poster Presentation

Presenter: Alexandra Zanin-Zhorov

2924

Biliary epithelial cell-specific RAGE controls ductular reaction-mediated fibrosis during cholestasis

Oral Presentation

Presenter: Wai Ling Macrina Lam

3008

Efficacy and safety of prolonged released pirfenidone in patients with compensated cirrhosis. A placebo controlled multicenter study in Mexico

Poster Presentation

Presenter: Linda Muñoz



3204

Second harmonic generation microscopy can quantify and subclassify early stages of NASH fibrosis progression: data from a screen-failure cohort of a NASH phase 2 study

Poster Presentation

Presenter: Quentin Anstee

3220

Perihepatic implantation of matrix-embedded endothelial cells reduce inflammation and collagen deposition in fibrotic mice

Poster Presentation

Presenter: Mireia Medrano-Bosch

3294

LncRNA XR\_592974.2 and circRNA \_2599 regulated hypoxic stress response in hepatic stellate cells by targeting the miRNA-145/JMY/P53 pathway

Poster Presentation

Presenter: Dan Zhou

3404

Aldafermin rebalances collagen turnover in patients with NASH and liver fibrosis in the ALPINE 2/3 study

Poster Presentation

Presenter:

3441

Magnetic resonance elastography (MRE) demonstrate the strongest correlation with digital pathology and NASH CRN fibrosis assessments, compared to transient elastography and other assessed non-invasive tests (NITs)

Poster Presentation

Presenter: Miljen Martic

3452

Discovery of AMS-III-1086, a novel LPA1 antagonist for the treatment of liver fibrosis and liver cirrhosis

Poster Presentation

Presenter: Jung-Hee Kim

3479

Multiplexed digital spatial protein profiling reveals potential non-invasive biomarkers to predict advanced fibrosis

Poster Presentation

Presenter: Chang Min Kim

3545

Integrated spatial-temporal mathematical liver lobule model for simulation of fibrotic wall formation

Poster Presentation

Presenter: Steven Dooley

3683

3D human NASH model as a screening-based discovery approach for selecting and prioritizing drug candidates

Poster Presentation

Presenter: Radina Kostadinova

3764

Autoantibodies to apolipoprotein A-1 in chronic hepatitis C infection: a role in hepatic fibrosis and cirrhosis?

Poster Presentation

Presenter: Simon Bridge

3765

Endothelin receptor A antagonist functionalized magnetic nanoparticles as a promising approach for the treatment of liver fibrosis

Poster Presentation

Presenter: Marit ten Hove

3941

Machine learned histological fibrosis score empowers characterization of baseline gene signatures associated with fibrosis progression or regression in a NASH F3/F4 clinical trial

Oral Presentation

Presenter: Michael D. Bereket

## Gut microbiota and liver disease

111

Altered fecal microbiome and metabolome in hepatitis B related chronic liver diseases

Poster Presentation

Presenter: Yue Shen

358

Bacterial infections in cirrhosis are associated with reduction in gut microbial phage-bacterial interactions

Oral Presentation

Presenter: Jasmohan S Bajaj

458

The therapeutic effect of *Lactobacillus plantarum* on metabolic phenotypes in non-alcoholic fatty liver disease mice model

Poster Presentation

Presenter: DongYun Kim

530

Stool microbiota, compared to salivary microbiota, show more extensive correlations with plasma metabolites in decompensated cirrhosis in a multinational cirrhosis cohort

Poster Presentation

Presenter: I. Jane Cox

658

The gut virome in non-alcoholic fatty liver disease: distinct changes in Phageocytavirus composition in a human microbiota associated animal model

Poster Presentation

Presenter: Hau-Tak Chau

1053

Altered gut microbiome, metabolome and bile acid composition in sarcopenia in liver cirrhosis

Oral Presentation

Presenter: Vanessa Stadlbauer

1453

Microbial produced ethanol: an underestimated burden on the liver

Oral Presentation

Presenter: Stijn Meijnikman

1797

Mitochondrial hyperactivation determines a transferable protective gut microbiota profile in metabolic-associated fatty liver disease development

Poster Presentation

Presenter: María Juárez-Fernández

2064

Fecal transplant-related reductions in Alcohol intake from human to mice are associated with alterations in the intestinal but not liver or prefrontal cortex transcriptome

Poster Presentation

Presenter: Jasmohan S Bajaj

2165

New insights from mapping of the mucosal gut microbiota in primary sclerosing cholangitis before and after liver transplantation

Poster Presentation

Presenter: Mikal Jacob Hole

2179

Designing a polymetabolic risk score for non-alcoholic steatohepatitis patients by differentiating their metabolic profiles from healthy controls

Poster Presentation

Presenter: Nadeen Habboub

2180

Intestinal hyperpermeability in cirrhosis is predictive for survival and associated with distinct microbiome changes

Poster Presentation

Presenter: Vanessa Stadlbauer

2304

Novel multi-technology meta-analysis identifies gut microbiome strains associated with clinical fibrosis in NAFLD patients

Poster Presentation

Presenter: Nicole Narayan

3029

A nine-strain bacterial consortium improves portal hypertension and insulin signaling and delays non-alcoholic fatty liver disease progression in vivo

Poster Presentation

Presenter: Aurora Barbera

3307

Dynamics of the gut-liver axis in rats with varying fibrosis severity

Poster Presentation

Presenter: Hongyan Xiang

3335

In-depth shotgun metagenomic analysis of the oral and gut microbiome identifies striking overlap in microbial community structure, virulence factors and antimicrobial resistance genes based on stage and severity of cirrhosis

Oral Presentation

Presenter: Vishal C Patel

3490

Impact of phenylacetic acid, a microbiota derived-metabolite, on hepatic endoplasmic reticulum-mitochondria interactions and steatosis

Poster Presentation

Presenter: Rémy Lefebvre

3567

Duodenal permeability is associated with mucosal microbiota in compensated cirrhosis

Poster Presentation

Presenter: Patricia Bloom

3853

Association between gut microbiome and variceal bleeding risk in compensated cirrhosis: a prospective multicenter study

Poster Presentation

Presenter: Xiaolong Qi

## Immune-mediated and cholestatic disease: Clinical aspects

280

Radiomics-based model for outcome prediction in primary sclerosing cholangitis

Oral Presentation

Presenter: Laura Cristoferi

304

Outcomes of pregnancy in patients with autoimmune hepatitis in the Netherlands

Poster Presentation

Presenter: Susan Fischer

311

Cholangiopathy after severe COVID-19: what do we know so far?

Poster Presentation

Presenter: Helma Pinchemel Cotrim

393

Enhanced liver fibrosis score correlates with transient elastography in patients with treated autoimmune hepatitis

Poster Presentation

Presenter: Anna Stoelinga

396

Rationale for evaluation of PLN-74809 treatment in participants with primary sclerosing cholangitis in Phase 2a study INTEGRIS-PSC

Poster Presentation

Presenter: Eric Lefebvre

413

Quality of life outcomes in patients with primary biliary cholangitis treated with setanaxib: post-hoc results from a phase 2 randomised, placebo-controlled trial

Oral Presentation

Presenter: David Jones

439

Acute hepatitis after COVID-19 vaccine: case series by the International autoimmune hepatitis group (IAIHG) and the European reference network on hepatological diseases (ERN RARE-LIVER)

Poster Presentation

Presenter: Benedetta Terziroli Beretta-Piccoli

475

Scheduled endoscopic program for patients with primary sclerosing cholangitis improves transplant-free survival and enables early risk stratification

Poster Presentation

Presenter: Burcin Özdirik

517

Immune response and safety in standard and third dose SARS-CoV-2 vaccination in patients with autoimmune hepatitis on immunosuppressive therapy, a prospective cohort study

Poster Presentation

Presenter: Kristin Jorgensen

520

Analyses of obeticholic acid treatment retention in UK patients based on medicine delivery data

Poster Presentation

Presenter: Carl Gibbons

542

Real-world prevalence of pruritus with obeticholic acid: a systematic literature review and meta-analysis

Poster Presentation

Presenter: Leighland Feinman

588

Cognitive symptoms in non-cirrhotic primary biliary cholangitis

Poster Presentation

Presenter: Naw April Phaw

643

Screening and surveillance of biliary neoplasia based on brush cytology in primary sclerosing cholangitis (PSC): prevalence and outcomes

Poster Presentation

Presenter: Martti Färkkilä

756

Impact of pruritus in primary sclerosing cholangitis (PSC): a multinational survey

Poster Presentation

Presenter: Kris Kowdley

900

A dynamic approach to modelling baseline disease status and ALT elevation over follow-up on clinical-event free survival in autoimmune hepatitis: a canadian multicentre cohort

Poster Presentation

Presenter: Christina Plagiannakos

934

Recurring intrahepatic cholestasis of pregnancy presents with distinct changes in the gut microbiota

Oral Presentation

Presenter: Hanns-Ulrich Marschall

956

Secondary sclerosing cholangitis following COVID-19 disease: a multicenter retrospective study

Poster Presentation

Presenter: Marcus Mücke

1097

The efficacy of combined treatment of bezafibrate and ursodeoxycholic acid was reduced in patients with primary cholangitis at advanced stage

Poster Presentation

Presenter: Kosuke Matsumoto

1146

Extrahepatic autoimmune diseases in autoimmune hepatitis: effect on mortality

Poster Presentation

Presenter: Rasmine Birn-Rydder

1148

Confidence in treatment is contributing to quality of life in patients with autoimmune liver diseases. The results of ERN-RARE Liver online survey

Poster Presentation

Presenter: Ewa Wunsch

1220

A pilot study of PBC symptom management with melatonin and fenofibrate: the PIMBLE study

Poster Presentation

Presenter: Amanda Nicoll

1306

Portal hypertension-associated clinical features in patients with primary biliary cholangitis are of distinct prognostic value

Poster Presentation

Presenter: Lukas Burghart

1313

The low incidence of HBV reactivation among anti-HBc+ subjects on immunotherapy reduces the impact of suboptimal screening rate

Poster Presentation

Presenter: Laia Aceituno

1348

The ABCB4 variant c.711 increases liver injury in PBC but not in PSC: prospective analysis with a median follow-up of 7 years in 331 patients

Poster Presentation

Presenter: Marcin Krawczyk

1357

A multicentric study to estimate mortality and graft loss risk after liver transplantation (LT) in patients with recurrent primary biliary cholangitis (PBC)

Poster Presentation

Presenter: Aldo J Montano-Loza

1380

Associations between novel serum biomarkers chitinase-2-like protein (YKL-40), type IV collagen, and thrombospondin-2 (TSP-2) with fibrosis stage and clinical outcomes in patients with primary sclerosing cholangitis (PSC)

Poster Presentation

Presenter: Michael Trauner

1386

MRCP+TM - derived biliary metrics are associated with disease severity and clinical outcomes in patients with primary sclerosing cholangitis

Poster Presentation

Presenter: Nora Cazzagon

1405

Safety and efficacy of the farnesoid X receptor (FXR) agonist cilofexor in a proof-of-concept study in patients with compensated cirrhosis due to primary sclerosing cholangitis (PSC)

Poster Presentation

Presenter: Cynthia Levy



1435

Association between patient-reported outcome measures and surrogate markers of liver fibrosis in large-duct primary sclerosing cholangitis

Poster Presentation

Presenter: Emmanuel Selvaraj

1451

Association between patient-reported outcome measures and severity of cholangiopathy in large-duct primary sclerosing cholangitis

Poster Presentation

Presenter: Emmanuel Selvaraj

1472

Ultrasound for the diagnosis of gallbladder polyps in PSC: polyps greater than 8 mm indicate malignancy

Poster Presentation

Presenter: Johannes Altenmüller

1474

Temporal changes in patient-reported outcome measures stratified by liver fibrosis severity in large-duct primary sclerosing cholangitis

Poster Presentation

Presenter: Emmanuel Selvaraj

1485

Temporal increase in interquartile range iron-corrected T1 in high-risk patients with large-duct primary sclerosing cholangitis

Poster Presentation

Presenter: Emmanuel Selvaraj

1529

Seladelpar treatment of patients with primary biliary cholangitis (PBC) for 2 years improves the GLOBE PBC score and predicts improved transplant-free survival

Poster Presentation

Presenter: Bettina Hansen

1541

Validation of a novel method of identifying patients with Primary Sclerosing Cholangitis (PSC) in a canadian population

Poster Presentation

Presenter: Harshil Patel

1546

The prevalence of primary biliary cholangitis (PBC) is on the rise: a canadian population-based study

Poster Presentation

Presenter: Bryce Tkachuk

1655

Rituximab is a safe and effective treatment for patients with autoimmune hepatitis: results from the Spanish registry for cholestatic and autoimmune hepatitis

Poster Presentation

Presenter: Mar Riveiro Barciela

1657

Autoimmune hepatitis diagnosed after COVID-19 vaccination. Results from the spanish registry for autoimmune and cholestatic hepatitis

Poster Presentation

Presenter: Ana Barreira

1699

A prospective trial of a gluten free diet in primary sclerosing cholangitis with associated colitis

Poster Presentation

Presenter: Timur Liwinski

1753

The international autoimmune hepatitis group retrospective registry: quality assessment and analysis of clinical characteristics and liver-related outcome

Poster Presentation

Presenter: Charlotte Slooter

1768

Liver inflammation activity in autoimmune hepatitis patients with normal ALT and IgG levels

Poster Presentation

Presenter: Jiacheng Liu

1824

Novel screening test for primary sclerosing cholangitis: the role of serology, liver function tests, histology and radiology

Poster Presentation

Presenter: Nina Barner-Rasmussen

1825

Low-dose IL-2 alleviates drug-induced primary biliary cholangitis in mice by improving Treg and Th17 balance

Oral Presentation

Presenter: Bo Feng

1916

More than just an itch: impact of cholestatic pruritus in primary biliary cholangitis (PBC) on health-related quality of life (HRQoL)

Poster Presentation

Presenter: Helen Smith

2024

Isolated IgG elevation is not associated with worse outcome in patients with autoimmune hepatitis

Poster Presentation

Presenter: ALVARO DIAZ GONZALEZ

2056

Linerixibat dose–response analysis of C4 concentrations as a quantitative approach to predict gastrointestinal tolerability

Poster Presentation

Presenter: Fernando Carreño

2062

Incidence and predictors of hepatocellular carcinoma development in patients with autoimmune hepatitis: a multicenter international study

Oral Presentation

Presenter: Francesca Colapietro

2248

Urinary sulfated progesterone metabolites are diagnostic markers for cholestatic pregnancy and markers of treatment response to ursodeoxycholic acid

Poster Presentation

Presenter: Luiza Borges Manna

2549

COVID-19 vaccine induced autoimmune hepatitis - a first case series from India

Poster Presentation

Presenter: Sowmya Iyengar

2566

Lymphoma in IgG4-related disease: should we be concerned?

Poster Presentation

Presenter: Arif Hussienbux

2578

Measurement properties of the PBC-10 in a dutch population

Poster Presentation

Presenter: Maria van Hooff

2592

Glucoregulatory disturbances in primary biliary cholangitis and non-alcoholic fatty liver disease compared with healthy individuals

Poster Presentation

Presenter: Anne-Sofie Houlberg Jensen

2675

Critical shortfalls in the management of PBC: results of the first nationwide, population-based study of care delivery across the U.K.

Oral Presentation

Presenter: Nadir Abbas

2987

Patient reported symptom burden in primary biliary cholangitis and how to inform trial design

Poster Presentation

Presenter: Aaron Wetten

3037

Should we seek complete liver tests normalization in primary biliary cholangitis? Data from ColHai registry

Poster Presentation

Presenter: Maria Carlota Londoño

3124

Post-COVID-19 cholangiopathy: does SARS-CoV-2 play a relevant role in histopathological findings?

Poster Presentation

Presenter: Helma Pinchemel Cotrim

3170

Examining the role of thiopurine metabolite testing in the management of patients with autoimmune hepatitis

Poster Presentation

Presenter: Andrew Roberts

3245

Long-term obeticholic acid (OCA) for primary biliary cholangitis (PBC) in a clinical trial improved event free survival (death, liver transplant and hepatic decompensation) compared to external controls from the GLOBAL PBC real-world database

Poster Presentation

Presenter: Carla Fiorella Murillo Perez

3256

Proportion of time and degree to which liver biochemistries are out-of-range predicts time to first occurrence of negative hepatic outcomes in people with primary biliary cholangitis

Poster Presentation

Presenter: Timothy Ritter

3419

Outcomes following immune checkpoint inhibitor re-challenge in patients who developed grade 3 and 4 hepatotoxicity

Poster Presentation

Presenter: Amy Hicks

3481

Home-based exercise in patients with refractory fatigue associated primary biliary cholangitis: final results from the EXerCise Intervention in cholestatic LivEr Disease (EXCITED) clinical trial

Poster Presentation

Presenter: Alice Freer

3606

Investigation of linciclib 40mg BID for cholestatic pruritus of primary biliary cholangitis (PBC); further data from the phase 2b GLIMMER study to support the phase 3 GLISTEN study

Poster Presentation

Presenter: James Fettiplace

3669

Development of a novel MRCP-score for patients with primary sclerosing cholangitis, and assessment of agreement and prognostic value

Poster Presentation

Presenter: ARISTEIDIS GRIGORIADIS

3709

Right and left lobe biopsies by mini-laparoscopy reveals clinically significant sampling error in staging and grading in AIH

Poster Presentation

Presenter: Johannes Hartl

3917

Health-related quality of life in patients with primary sclerosing cholangitis: a longitudinal population-based cohort study

Poster Presentation

Presenter: Bregje Mol

3928

A randomized control trial evaluating the impact of a web-based mind-body wellness intervention for patients with primary biliary cholangitis

Poster Presentation

Presenter: Makayla Watt

## Immune-mediated and cholestatic: Experimental and pathophysiology

193

Cholangiocytes cleave surface CD100 from biliary infiltrating T cells and mediate pathogenic Th17 differentiation

Oral Presentation

Presenter: Espen Melum

443

Over-responsiveness of the IL-6/STAT3 pathway in inflammatory CD4+ T cells of patients with primary sclerosing cholangitis

Poster Presentation

Presenter: Leona Dold

634

Dosing ileal bile acid transporter inhibitors in the fasted state minimizes gastrointestinal adverse effects while maintaining pharmacodynamic effect

Poster Presentation

Presenter: Cory Kostrub

1004

Magnesium accumulation by CNNM4 GalNAc-siRNA mediated silencing reduces cholestasis-associated liver fibrosis

Poster Presentation

Presenter: Marina Serrano-Macia

1116

Association of bile acids composition and synthetic pathway with therapeutic effect of bezafibrate in chronic cholestatic liver disease

Poster Presentation

Presenter: Manami Iida

1129

Reduced hepatic expression of PPAR alpha in primary biliary cirrhosis is modulated by miR-155

Poster Presentation

Presenter: Monika Adamowicz

1186

cholangiocytes-specific deletion of sphingosine-1-phospholipid receptor 1 attenuate cholestasis induced liver injury and fibrosis

Poster Presentation

Presenter: Yuan Zihang

1316

Pruriceptor activating compounds in the enterohepatic cycle in cholestatic itch

Poster Presentation

Presenter: Frank Wolters

1404

The spatial distribution and detailed composition of infiltrating immune cells define autoimmune- and checkpoint-therapy associated hepatitis

Oral Presentation

Presenter: Laurenz Krimmel

1787

Novel approach combining whole liver single-cell RNA sequencing and spatial gene profiling using Nanostring GEOMX enables identification of specific cell sub-populations and pathways regulated by CCL24

Oral Presentation

Presenter: Michal Segal-Salto

2118

Characterising the early inflammatory landscape of primary sclerosing cholangitis

Poster Presentation

Presenter: Calli Dendrou

2225

Deep learning for automatic diagnosis and morphologic characterisation of malignant biliary strictures using digital cholangioscopy: a pilot study

Oral Presentation

Presenter: Miguel Mascarenhas

2232

Extrahepatic bile duct injury in MDR2 knockout mice can be repaired with L-NAC treatment

Poster Presentation

Presenter: Orith Waisbourd-Zinman

2845

B cell reactivation in autoimmune hepatitis after immunosuppression withdrawal

Poster Presentation

Presenter: Elena Perpinan

3022

Intrabiliary injection of MAIT antigens induces cholangitis in mice

Poster Presentation

Presenter: Kathrine Sivertsen Nordhus

3129

Liver-specific Tsg101 depletion causes apoptosis, cell death and liver failure

Poster Presentation

Presenter: Surui Wang

3324

Single-cell profiling of liver B cells identifies distinct gene expression and reactivities of expanded B cell clonotypes in primary sclerosing cholangitis

Poster Presentation

Presenter: Brian K. Chung

3329

The IgG4-related cholangitis autoantigen laminin 511-E8 stabilizes the biliary bicarbonate umbrella in human cholangiocytes

Poster Presentation

Presenter: David Trampert

3376

Copper accumulation in chronic cholestatic disease augments liver damage by impairment of mitochondrial function

Poster Presentation

Presenter: Dennis Koob

3383

TGF beta 2 fuels inflammation and fibrosis in cholestatic liver disease through macrophage and myofibroblast recruitment and activation

Poster Presentation

Presenter: Jan Albin

3436

The rs429358 apolipoprotein E (APOE) polymorphism is associated with increased liver injury in patients with autoimmune hepatitis

Poster Presentation

Presenter: Maciej K. Janik



3523

The risk-variant rs56258221 at the BACH2-locus associates with skewed polarization of naive CD4+ T cells towards pro-inflammatory phenotypes in primary sclerosing cholangitis

Poster Presentation

Presenter: Jonas Bahn

3533

T regulatory cells promote bile duct regeneration through modulating ductular reaction in a model of cholestatic liver injury

Oral Presentation

Presenter: Wei-Yu Lu

3546

Serum sterols indicate modified cholesterol homeostasis in cirrhotic patients with PBC and correlate with response to treatment with ursodeoxycholic acid

Poster Presentation

Presenter: Wiktor Smyk

3571

Preserved MAIT cell proinflammatory function in children with autoimmune liver disease

Poster Presentation

Presenter: Suzan Warner

## Immunology

76

Increased expression of programmed cell death ligand 1 and galectin 9 in transplant recipients who achieved tolerance after immunosuppression withdrawal

Poster Presentation

Presenter: Nguyen Hai Nam

88

Acidic microenvironment aggravates the severity of hepatic ischemia/reperfusion injury by modulating PPAR- $\gamma$  signal

Poster Presentation

Presenter: Yunjie Lu

153

Toll-like receptor 3 polymorphisms rs5743305 and rs3775291 affect innate immune responses in whole blood analyses

Poster Presentation

Presenter: Sophia Barkow

421

IL-15 boosts HBV-specific CD8+ cell response by activated progenitor pool mitochondrial remodelling in on treatment e-Ag negative chronic hepatitis B

Poster Presentation

Presenter: Julia Peña Asensio

480

Mucosal-associated invariant T cells are rendered functionally exhausted within the tumour microenvironment in HCC in a cell-contact dependent manner

Poster Presentation

Presenter: Junika Pohl

516

Preclinical model for the study of immune responses specific for a hepatic-self-antigen

Poster Presentation

Presenter: Anaïs Cardon

533

Enforced cytotoxic signature of HBV pol455-specific CD8+ T cells in chronic HBV infection

Oral Presentation

Presenter: Kathrin Heim

600

CD8+ T cell acquisition of the LPS receptor within the hepatic stroma shapes anti-viral/anti-tumour potential

Oral Presentation

Presenter: Mala Maini

879

Proximity labelling reveals potential cis interactions of CD52 glycoprotein counter-receptors on circulating CD4+HLA-G+ regulatory T cells in acute decompensation of cirrhosis

Poster Presentation

Presenter: Tong Liu

948

Humoral and cellular immunity after vaccination against SARS-CoV-2 is reduced in patients with chronic liver disease

Poster Presentation

Presenter: Hevar Hamah Saed

999

Efficacy of branched-chain amino acid granules to restore innate immunity in cirrhosis-associated immune dysfunction: a randomized controlled trial

Poster Presentation

Presenter: NATTHAPAT RUJEERAPAIBOON

1012

A novel immunophenotyping of hepatocellular carcinoma based on amplified and mutated neoantigens for mRNA vaccine development

Oral Presentation

Presenter: He Jing

1023

The close correlation between sarcopenia and the phagocytic dysfunction in respond to bacterial pathogen Ecoli in cirrhotic patients

Poster Presentation

Presenter: NATTHAPAT RUJEERAPAIBOON

1039

Heterologous SARS-CoV-2 vaccine triggers more humoral immune responses among patients with liver cirrhosis

Poster Presentation

Presenter: Apichat Kaewdech

1073

Predictive immune biomarkers to safely discontinue nucleos(t)ide analogue treatment in HBeAg negative chronic hepatitis B (NUC-B study)

Poster Presentation

Presenter: Sandra Phillips

1165

MAIT-cells in blood are associated with a higher risk of infection in patients with cirrhosis

Poster Presentation

Presenter: Hannes Hagström

1192

Fatty acids directly limit mucosal-associated invariant T cell effector function in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Sebastian Deschler

1199

Multimodal single cell analysis reveals the basis for butyrate induction of TNF $\alpha$ -secreting regulatory T cells

Poster Presentation

Presenter: Mo Atif

1544

COVID-19 vaccination in liver cirrhosis: safety and immune and clinical responses

Poster Presentation

Presenter: Maria Ines Canha

1595

Building a case for pancreas and liver targeted interleukin-22 therapy in fatty liver disease

Poster Presentation

Presenter: Haresh Sajiir

1734

Patients with decompensated cirrhosis and liver transplant recipients demonstrate poor humoral and cellular immune response against COVID-19 vaccine

Poster Presentation

Presenter: Anand Kulkarni

1775

Presence of cirrhosis in chronic liver disease patients associates with a lower immune response to COVID-19 vaccines - a multicenter european study

Poster Presentation

Presenter: Rui Castro

1915

Heterogeneity of peripheral blood monocytes in patients with cirrhosis

Poster Presentation

Presenter: Anne Geng

1952

JAM-A is a multifaceted regulator in hepatic fibrogenesis, supporting LSEC integrity and stellate cell quiescence

Poster Presentation

Presenter: Jonathan Frederik Brozat

2048

Diminished function of cytotoxic T- and NK- cells in severe alcohol-associated hepatitis

Poster Presentation

Presenter: Adam Kim

2080

Multi-omics analysis of human livers reveals variation in intrahepatic inflammation across chronic hepatitis B infection phases

Poster Presentation

Presenter: Andre Boonstra

2102

Liver cirrhosis and cirrhosis etiology impacts the circulating immune mediators of early stage hepatocellular carcinoma

Poster Presentation

Presenter: Andre Boonstra

2124

Ebola virus infection promotes reduced gene expression of antigen presentation molecules in hepatic CD68+ macrophages in cynomolgus macaques

Poster Presentation

Presenter: Timothy Wanninger

2183

Differential changes in global and antigen-specific B cell frequencies and function associate with the outcome of HBV nucleos(t)ide analog treatment withdrawal

Oral Presentation

Presenter: Sabela Lens

2388

Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types: an EASL registry multicentre prospective cohort study

Oral Presentation

Presenter: Thomas Marjot

2397

Plasmalemma vesicle-associated protein expression is driven by senescent cell-endothelial crosstalk and shapes the immune landscape in chronic liver disease

Poster Presentation

Presenter: Alex Wilkinson

2594

Dysfunctional liver-resident CXCR6+ CD8 T cells during persistent viral liver infection

Poster Presentation

Presenter: Miriam Bosch

2630

Increased ILT2 expression contributes to dysfunction of CD56dimCD16+NK cells in chronic hepatitis B virus infection

Poster Presentation

Presenter: Yingzhi Zhang

2970

Classification of HCV-specific CD8+ T cells by the differential expression pattern of Slamf6 and CD69 predicts that the majority of cells are rather preterminally versus terminally exhausted regardless of disease stage

Poster Presentation

Presenter: Maximilian Knapp

3042

Phenotypes of NK cells and the activation profile of T cells in the early stages of alcohol liver diseases

Poster Presentation

Presenter: Paola Zuluaga

3080

T cell and humoral immune response to multiple SARS-CoV-2 variants including omicron (B.1.1.529) after two doses of COVID-19 vaccine in patients with cirrhosis and liver diseases requiring immunosuppression: data from the EASL COVID-Hep network

Oral Presentation

Presenter: Sam Murray

3105

TAPBPR shapes the hepatitis B immunopeptidome presented on HLA class I molecules

Poster Presentation

Presenter: Ricky Sinharay

3213

Fate of HDV-specific CD8+ T cells during bulevirtide monotherapy in patients with chronic hepatitis delta

Poster Presentation

Presenter: Valerie Oberhardt

3251

A spatio-temporal map of malaria infected mouse liver

Poster Presentation

Presenter: Franziska Hildebrandt

3563

Humoral and cellular immune responses to wild-type and omicron (B.1.1.529) SARS-CoV-2 variants following a fourth COVID-19 vaccination in liver transplant recipients and patients with autoimmune hepatitis

Oral Presentation

Presenter: Stavros Dimitriadis

3725

Elevated serum bilirubin levels and aminotransferases are associated with immuno-modulatory and suppressive subsets in pregnant females with intrahepatic cholestasis and hepatitis E virus infection

Poster Presentation

Presenter: Anoushka Saxena

## Liver development, physiology and regeneration

210

Three-dimensional conditions in a perfusion bioreactor to support maturation of human amnion epithelial stem cells into functional hepatocyte-like cells

Poster Presentation

Presenter: Sara Campinoti

315

Knockdown of Glyoxylate reductase/hydroxypyruvate reductase (GRHPR) accelerates liver regeneration and decreases chronic liver damage

Poster Presentation

Presenter: Viktoriia Iakovleva

484

Expression and function of axon guidance genes in the developing portal tract

Poster Presentation

Presenter: Lila Gannoun

1002

Monoacylglycerol lipase inhibition specifically in macrophages compromises liver regeneration by inducing interferon type 1 that negatively impacts on hepatocyte proliferation

Oral Presentation

Presenter: Manon Allaire

1010

Patients with chronic liver diseases are at risk for diabetes even before development of cirrhosis

Poster Presentation

Presenter: Georgia Bale

1068

Characterization of bioengineered liver constructs using hepatoblast organoids (HBOs) and human liver extracellular matrix (ECM) 3D-platforms

Poster Presentation

Presenter: Margarita Papatheodoridi

1085

Novel avenue towards liver regeneration and treatment of acute and chronic liver diseases: safety and PK profile from a first-in human (FIH) clinical trial for HRX-0215 as first in class MKK4 inhibitor

Poster Presentation

Presenter: Wolfgang Albrecht

1460

Complete vascular tree reconstruction in rat decellularized liver scaffolds using differential recellularization pressures

Oral Presentation

Presenter: Sandra Melitón Barbancho

1681

In vivo loss-of-function studies unravel protein tyrosine phosphatase delta as a regulator of liver regeneration during metabolic liver disease

Poster Presentation

Presenter: Armando Andres Roca Suarez

1981

Integrated proteomics and metabolomics analysis reveals canonical and novel regulatory pathways linked to liver regeneration in living donor liver transplant (LDLT) Donors

Poster Presentation

Presenter: Gaurav Tripathi

2035

Regulation of extracellular Nicotinamide adenine dinucleotide in patients with liver fibrosis: new insights into conventional hepatobiliary parameters

Poster Presentation

Presenter: Can Kamali

2300

Hyaluronan in the prenatal extrahepatic bile duct increases in response to injury

Poster Presentation

Presenter: Iris de Jong

2512

Embryogenesis of human fetal liver at various stages of gestation: a histomorphometric study

Poster Presentation

Presenter: Pooja Bhadoria

2637



Opposite PAR2 roles in liver regeneration from autoimmune or direct damage. Solving the conflict

Poster Presentation

Presenter: Gal Rechtes

2657

The hepatocellular vitamin D receptor regulates liver regeneration after partial hepatectomy

Poster Presentation

Presenter: Hari Elangovan

3107

Generation of universal low-immunogenic human cholangiocyte organoids for treatment of cholangiopathies

Poster Presentation

Presenter: Sandra Petrus-Reurer

3183

Selective induction of macrophage RNF41 stimulates liver regeneration in hepatectomized healthy and fibrotic mice

Poster Presentation

Presenter: Alazne Moreno-Lanceta

3201

Molecular basis of hepatic differentiation of human bone marrow mesenchymal stem cell in vivo

Poster Presentation

Presenter: Dongyan Shi

3423

Generation of functional ductal organoid with biliary tree network in decellularized liver scaffold

Poster Presentation

Presenter: Jiaxian Chen

3497

Dynamic alterations of metabolites revealed the vascularization progression of bioengineered liver

Poster Presentation

Presenter: Qian Zhou

3662

In vivo characterization and functional effects of the NAD<sup>+</sup> transporter, SLCA25A51

Poster Presentation

Presenter: Sarmistha Mukherjee

3761

Chronic injury induces plasticity between cholangiocytes and hepatocytes in the human liver

Poster Presentation

Presenter: VASILEIOS GALANAKIS

3856

Development of ECM mimicking 3D-hydrogel scaffolds for liver tissue engineering

Poster Presentation

Presenter: Nathan Carpentier

3867

CD44 plays critical role in liver regeneration through enhanced redox balancing

Poster Presentation

Presenter: Wan Seob Shim

## Liver transplantation and hepatobiliary surgery: Clinical aspects

101

Outcomes of living liver donors are worse than those of matched healthy controls: nationwide cohort study

Poster Presentation

Presenter: Jong Man Kim

115

Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation

Oral Presentation

Presenter: Manuel Rodríguez-Perálvarez

159

Pretransplant changes in serum protein glycosylation relate to risk of HCC recurrence after liver transplantation and provide a potential prognostic biomarker: a proof-of-concept study

Poster Presentation

Presenter: Verhelst Xavier

310

Liver transplantation for complications of hepatoportal sclerosis

Poster Presentation

Presenter: Andrew Keaveny

382

Discordance in categorization of acute-on-chronic-liver-failure in the national transplant database

Poster Presentation

Presenter: Brian Lee

407

Humoral response to 2-dose BNT162b2 mRNA vaccine for COVID-19 in liver transplant recipients

Poster Presentation

Presenter: Valentina Cossiga

432

A predictive model for mortality within one year of liver transplantation at the time of wait-listing for transplant: a novel approach using machine learning algorithms in a large US multi-ethnic cohort

Poster Presentation

Presenter: Sripriya Balasubramanian

445

Monitoring patients with anti HBs trough levels can minimise hepatitis B immune globulin therapy after liver transplant

Poster Presentation

Presenter: Erica Nicola Lynch

455

Formal referral networks optimise patient selection for liver transplantation

Poster Presentation

Presenter: Oliver Tavabie

528

Efficacy and safety of SARS-CoV-2 vaccination in liver transplant recipients

Poster Presentation

Presenter: Lucy Meunier

556

Immunogenicity and safety of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA SARS-CoV-2 vaccine in liver transplant recipients: a prospective study

Poster Presentation

Presenter: Supachaya Sriphoosanaphan

573

Multidrug resistant bacterial infections after liver transplantation: prevalence, impact and associated risk factors

Oral Presentation

Presenter: Rosa Martin- Mateos

936

Impact of COVID-19 on the liver transplant activity in the US: variation by the region, etiology, and cirrhosis complications

Poster Presentation

Presenter: Ashwani Singal

965

Perinatal outcomes in liver transplant patients-possible positive effect of aspirin prophylaxis

Poster Presentation

Presenter: Marius Braun

972

Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in liver transplant recipients

Poster Presentation

Presenter: Aitor Odriozola Herrán

1006

Early post liver transplant rescue treatment with sofosbuvir/velpatasvir/voxilaprevir in patients experienced to NS5A-inhibitors

Poster Presentation

Presenter: Margherita Saracco

1032

Inclusion of body composition parameters in MELD score leads to optimization of predictive performance in patients with cirrhosis

Poster Presentation

Presenter: Maryam Ebadi

1036

Long-lasting seropositivity after anti SARS-CoV-2 vaccination in pre liver transplant patients

Poster Presentation

Presenter: Alberto Calleri

1048

The outcome of living donor versus deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis

Poster Presentation

Presenter: Beshoy Effat Elkomos

1049

Impact of gender on survival of hepatocellular carcinoma

Poster Presentation

Presenter: Chaonan Jin

1090

Effectiveness of MRI methods in the assessment of hepatic steatosis in living liver donors

Poster Presentation

Presenter: Dıgdem Kuru Öz

1106

Long-term outcomes of donation after cardiac death and living donor liver transplant for primary sclerosing cholangitis

Poster Presentation

Presenter: Dilip Moonka

1112

Patients with acute-on-chronic liver failure have significantly greater healthcare resource utilization after liver transplantation

Poster Presentation

Presenter: Vinay Sundaram

1141

Use of statins after liver transplantation is associated with improved survival: results of a nationwide study

Poster Presentation

Presenter: Chiara Becchetti

1169

Liver transplantation for hepatocellular carcinoma with extended criteria: performance and applicability of the AFP score after official adoption by the French Organ Sharing Organization ABM: 5-year outcomes

Poster Presentation

Presenter: Christophe Duvoux

1207

Tacrolimus drug exposure level in the first year after liver transplantation is an independent risk factor for de novo malignancy in patients transplanted for alcohol-related liver disease

Poster Presentation

Presenter: Benedict Vanlerberghe

1234

SARS-CoV-2 vaccination in liver transplant recipients: factors affecting immune response and refusal to vaccine

Poster Presentation

Presenter: Maciej K. Janik

1248

The effect of clinicopathologic findings of hepatocellular carcinoma on posttransplant survival: a multicenter cohort from TAsL liver transplantation special interest group

Poster Presentation

Presenter: Murat Akyildiz

1249

Utility and prognostic value of diagnosing metabolic dysfunction-associated fatty liver disease in patients undergoing liver transplantation for alcohol-related liver disease

Poster Presentation

Presenter: Benedict Vanlerberghe

1349

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) specific cellular and humoral immunity in Coronavirus Disease-2019 (COVID-19) convalescence after liver transplantation - a prospective six month follow up

Poster Presentation

Presenter: Theresa Kirchner

1389

A third dose of the BNT162b2 mRNA vaccine significantly improved immune response among liver transplant recipients

Poster Presentation

Presenter: Yana Davidov

1412

Everolimus combined with low-dose tacrolimus controls histological graft injury and liver fibrosis as sufficiently as high-dose tacrolimus combined with mycophenolate after liver transplantation

Poster Presentation

Presenter: Fabian Dranicki

1484

The portrait of adult liver transplant recipients in the United States from 2002-2020

Poster Presentation

Presenter: Zobair Younossi

1502

Heterologous regimen viral-vector/mRNA produces significantly higher SARS-CoV-2 humoral response than homologous viral-vector and inactivated vaccines in liver transplant recipients

Poster Presentation

Presenter: Manuel Mendizabal

1539

Evolution of pretransplant cardiac risk factor burden and major adverse cardiovascular events in liver transplant recipients over time

Poster Presentation

Presenter: Claire Harrington

1714

Retransplantation (reLT) outcomes of patients who were initially transplanted for ACLF

Poster Presentation

Presenter: Gandhi Lanke

1779

The ratio of Activin A and Follistatin-related gene allows prediction of posthepatectomy liver failure and postoperative morbidity in patients prior to liver surgery

Poster Presentation

Presenter: Jonas Santol

1913

Derivation of a cardiac risk index for use in liver transplantation for non-alcoholic steatohepatitis

Poster Presentation

Presenter: Paul Levy

2023

The prognostic effect of adequate lymphadenectomy in clinically node-negative patients undergoing liver resection for intrahepatic cholangiocarcinoma

Poster Presentation

Presenter: Carlo Sposito

2067

Impact of MELD 3.0 Versus MELD-Na in patients with renal dysfunction

Poster Presentation

Presenter: Allison Kwong

2096

Sustainability of humoral immunity induced by the SARS-CoV-2 vaccine and response to booster dose among Liver Transplant recipients

Poster Presentation

Presenter: Liane Rabinowich

2099

Acute-on-chronic liver failure due to severe intrahepatic vaso-occlusion and recurrence of the initial disease: 2 major features in liver transplantation for severe sickle-cell-related hepatopathy

Poster Presentation

Presenter: Christophe Duvoux

2144

Post-operative complications and short-term survival in obese cirrhotic patients undergoing liver transplantation

Poster Presentation

Presenter: Carmen Alonso Martin

2147

Impact of comorbidities on liver transplantation: a prospective and multicentric study

Poster Presentation

Presenter: Magdalena Salcedo

2148

Liver transplant patients infection rate with SARS-CoV-2 is lower but depend upon the infection rate in the general population and have a better outcome

Poster Presentation

Presenter: Assaf Issachar

2162

Sarcopenia predict complications after hepatic resection for primary hepatocellular carcinoma (HCC) in patients with advanced chronic liver disease (ACLD) and clinically significant portal hypertension (CSPH)

Poster Presentation

Presenter: Federico Ravaioli

2192

A comparison of hispanic living liver donor candidates approved and denied at a high-volume urban transplant center

Poster Presentation

Presenter: Dana Toy

2217

Liver transplantation in HIV infected subjects: a long-term single center experience

Poster Presentation

Presenter: Noemi Gualandi

2230

SARS-CoV-2 infection in liver transplant recipients - a single center case series from Romania

Poster Presentation

Presenter: Ioana-Alexandra Husar-Sburlan

2282

Liver transplantation for hepatocellular carcinoma: outcome and prognostic factors for recurrence

Poster Presentation

Presenter: Veronica Paon

2292



The liver outcomes and equity (LOEq) index: neighborhood social determinants independently predict outcomes in liver transplantation

Poster Presentation

Presenter: Kali Zhou

2295

Prevalence, prognosis, clinical, biological and histological features of incidentally found hepatocellular carcinoma after liver transplantation

Poster Presentation

Presenter: Bénédicte Delire

2351

Survival benefit from liver transplantation for patients with and without hepatocellular carcinoma

Poster Presentation

Presenter: Ben Goudsmit

2353

Long-term outcomes of liver transplantation (LT) using grafts from donors with active and chronic hepatitis B virus (HBV) infection: multi-center cohort study

Poster Presentation

Presenter: Sujin Gang

2355

Safe use of hepatitis B surface antigen positive (HBsAg (+)) grafts in liver transplantation (LT): a nationwide study based on KOTRY (Korean Organ Transplantation Registry) data

Poster Presentation

Presenter: Sujin Gang

2465

A panel of three micro RNAs allows robust prediction of overall survival after liver resection

Poster Presentation

Presenter: David Pereyra

2473

Liver transplantation for primary sclerosing cholangitis and predictors of disease recurrence

Poster Presentation

Presenter: Julie Zhu

2561

Predictive factors of antibody response after anti-SARS-CoV-2 vaccine in liver transplant recipients

Poster Presentation

Presenter: Ilias Kounis

2591

Immunotherapy before solid organ transplantation: an international transplant community-focused survey

Poster Presentation

Presenter: Tommy Ivanics

2597

Evaluating the predictive performance and transferability of machine learning-based prediction models using national liver transplant data registries

Poster Presentation

Presenter: Tommy Ivanics

2607

Liver transplant recipients have a higher incidence of lung cancer than general population

Poster Presentation

Presenter: Jose Ignacio Herrero

2663

Managing HBV/HDV co-infection post liver transplant - Exploring a decade of experience

Poster Presentation

Presenter: Almuthana Mohamed

2680

Durability of SARS-CoV-2 specific immune response following different primary prime-boost vaccine platforms and subsequent humoral response to booster dose among liver transplant recipients

Poster Presentation

Presenter: Supachaya Sriphoosanaphan

2760

Long-term outcomes (beyond 5 years) of liver transplant recipients - a transatlantic multicentre study

Poster Presentation

Presenter: Naaventhana Palaniyappan

2950

COVID vaccination among liver transplant recipients: A EASL - ESOT/ELITA - ILTS multi society survey

Poster Presentation

Presenter: Carmen Vinaixa

2969

Outcome of choledochal cysts with intrahepatic involvement (type IV-A) after extrahepatic cyst excision and roux-en-Y hepaticojejunostomy in adults

Poster Presentation

Presenter: Utpal Anand

3084

The impact of COVID-19 on the duration of the liver transplant process in patients presenting for inpatient liver transplant evaluation

Poster Presentation

Presenter: Katherine Cooper

3086

Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote transplantation tolerance in humans

Poster Presentation

Presenter: Tiong Yeng Lim

3136

Clinical significance of three-dimensional printing of the portal venous system in patients with extrahepatic portal hypertension

Poster Presentation

Presenter: Binita Chaudhary

3190

CMV reactivation is associated with lower hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT)

Poster Presentation

Presenter: Victoria Aguilera Sancho

3210

Nutritional intake after liver transplant: systematic review with meta-analysis and meta-regression

Poster Presentation

Presenter: Lynsey Spillman

3227

Recurrence of primary sclerosing cholangitis after liver transplantation: a french cohort study including 571 patients

Poster Presentation

Presenter: Florian Veyre

3288

Impact of muscle mass on survival of patients with hepatocellular carcinoma after liver transplantation beyond the Milan criteria

Poster Presentation

Presenter: Berend Beumer

3366

Liver transplantation (LT) and ethnicity in the United States: the impact of non-alcoholic steatohepatitis

Poster Presentation

Presenter: Zobair Younossi

3390

Hepatic evaluation of patients with telomeropathies

Poster Presentation

Presenter: Olivia Portolese

3400

Survival benefit-based priority of liver transplantation in HBV-related acute-on-chronic liver failure

Poster Presentation

Presenter: Jun Li

3405

Third dose of SARS-COV2 mRNA-vaccine in liver transplant recipients: can it bridge the response gap?

Poster Presentation

Presenter: Raffaella Lionetti

3412

Does m-RNA vaccination protect from Sars-Cov2 (asymptomatic) infection in liver transplant recipients?

Poster Presentation

Presenter: Ubaldo Visco Comandini

3469

Can endothelial biomarkers before liver transplantation together with classical cardiovascular risk factors be useful to predict cardiovascular risk after liver transplantation

Poster Presentation

Presenter: Victoria Aguilera Sancho

3532

Reduced neutralization efficacy against SARS-CoV-2 Omicron variant after third boost of mRNA BNT162 vaccine among liver transplant recipients

Poster Presentation

Presenter: Yana Davidov

3579

Patients with polycystic liver disease have longer waiting times but better clinical outcomes following liver transplantation in the UK

Poster Presentation

Presenter: Matthew Gittus

3678

Predictive factors of tumor recurrence after liver transplantation for hepatocellular carcinoma: analysis of a multicenter prospective study including 371 patients

Poster Presentation

Presenter: Thomas Decaens

3680

Evaluation of predictive factors for postoperative nausea and vomiting in hepatobiliary cancer patients

Poster Presentation

Presenter: Luciano Beltrão Pereira

3684

Social determinants of health and racial disparities in liver transplant: a nation wide analysis

Poster Presentation

Presenter: Mahmoud Mansour

3716

Protein-energy malnutrition is associated with worse outcomes in patients admitted for liver transplant: analysis of national inpatient sample

Poster Presentation

Presenter: Nikolaos T. Pyrsopoulos

3745

Factors contributing to late evaluation in liver transplant candidates undergoing inpatient liver transplant evaluation

Poster Presentation

Presenter: Katherine Cooper

3777

Missed referrals for liver transplant evaluation are associated with worse outcomes in patients needing inpatient liver transplant evaluation

Poster Presentation

Presenter: Katherine Cooper

Liver transplantation and hepatobiliary surgery: Experimental and pathophysiology

519

Immune responses before and after liver transplantation: a cohort study of the induced immune response

Poster Presentation

Presenter: Dina Leth Møller

1200

Bile duct on a chip: engineering a microfluidic platform for studying biliary epithelium in a dish

Poster Presentation

Presenter: Jorke Willemse

1478

Andrographolide can potentially rescue unusable liver grafts by reducing fat content, enhancing mitochondrial function, and inhibiting Th1/Th17 immunity

Poster Presentation

Presenter: Zhenlin Huang

1871

Trends and causes of etiology in adult liver transplant patients: multicenter study

Poster Presentation

Presenter: Mesut Akarsu

2273

Modeling ischemic cholangiopathy in human cholangiocyte organoid for screening of novel cholangio-protective agents

Oral Presentation

Presenter: Shaojun Shi

2456

A new avatar mouse model to predict the liver immune homeostasis and histologic inflammation of liver transplant patients

Poster Presentation

Presenter: Soon Kyu Lee

2649

The crucial role of PARP [poly(ADP-ribose polymerase)] on the post-ischemic liver injury and inflammation

Poster Presentation

Presenter: Michitaka Ozaki

2689

Orthotopic transplantation of the functional bioengineered liver prolonged survival in rats with total hepatectomy

Oral Presentation

Presenter: Beibei Guo

2754

Hepatocellular carcinoma and the risk of cancer onset after liver transplantation - role of immune activation and aging profiles

Poster Presentation

Presenter: Sarah Shalaby

3904

Mitochondrial transplantation attenuates murine in vivo hepatic ischemia/reperfusion injury

Poster Presentation

Presenter: Avinash Mukkala

## Liver tumours: Clinical aspects except therapy

163

Validation of a glycomics-based test associated with risk of HCC development in cirrhosis

Poster Presentation

Presenter: Verhelst Xavier

225

Benefits of tailored HCC surveillance programs on case-fatality rate and cancer-specific mortality using a modelling approach

Poster Presentation

Presenter: Massih Ningarhari

274

T cell receptor sequencing reveals HCC diversity according to BCLC stages within liver tissue and peripjeral blood

Poster Presentation

Presenter: Yijin Wang

437

NanoView EV Chip-based profiling in liver cancer differentiation - HCC from intrahepatic CCA - small EVs vs large EVs

Poster Presentation

Presenter: Bingduo Wang

511

Radiomic model based on contrast-enhanced CT imaging to predict early recurrence for patients with hepatocellular carcinoma after radical resection

Oral Presentation

Presenter: Liying Ren

591

Myosteatosi and excessive visceral adipose tissue as prognostic factors in patients with hepatocellular carcinoma treated with sorafenib

Poster Presentation

Presenter: Min Kyu Kang

624

Long term imaging outcomes of liver imaging reporting and data system categories in a prospective hepatocellular carcinoma surveillance cohort

Poster Presentation

Presenter: Sang Hyun Choi

650

Diagnostic accuracy of protein-induced by vitamin K absence (PIVKA-II) for hepatocellular carcinoma (HCC) among caucasian cirrhotic patients with or without diagnostic serum a-fetoprotein (AFP) levels

Poster Presentation

Presenter: antonia syriha

799

Circulating vesicles hold etiology-related protein biomarkers of cholangiocarcinoma risk, early diagnosis and prognosis mirroring tumour cells

Oral Presentation

Presenter: Ainhua Lapitz

875

An easy to use score to predict survival in patients with hepatocellular carcinoma before the first transarterial chemoembolization session: AFP-DIAM score

Poster Presentation

Presenter: Estelle Rebillard

884

Measurement of protease activity using novel plasma biosensors can accurately detect hepatocellular carcinoma

Poster Presentation

Presenter: Tram Tran

960

On treatment alpha-fetoprotein reductions predict immunotherapy efficiency in patients with hepatocellular carcinoma

Poster Presentation

Presenter: Bernhard Scheiner



991

Gender differences in hepatocellular carcinoma : is it all due to adherence to surveillance? A study of 1,716 patients over 3 decades

Poster Presentation

Presenter: Wei-Lun Liou

1008

Non-alcoholic fatty liver disease and increased risk of incident primary liver tumours: a meta-analysis of observational cohort studies

Poster Presentation

Presenter: Andrea Dalbeni

1009

Characterization of gut microbiota and exploration of potential predictive model for hepatocellular carcinoma microvascular invasion

Poster Presentation

Presenter: Ningning Zhang

1046

Evaluation of the effectiveness of surveillance according to the ultrasound liver imaging reporting and data system (US LI-RADS) visualization score in patients with chronic hepatitis B

Oral Presentation

Presenter: Min Kyung Park

1122

Training, validation and testing of a multiscale three-dimensional deep learning algorithm in accurately diagnosing hepatocellular carcinoma on computed tomography

Oral Presentation

Presenter: Wai-Kay Seto

1223

Machine learning algorithm based on dual screening for hepatocellular carcinoma using circulating cell-free DNA and cfDHCC scoring system

Poster Presentation

Presenter: HYUK SOO EUN

1227

Sarcopenia impairs survival and treatment efficacy in patients with hepatocellular carcinoma undergoing immunotherapy

Poster Presentation

Presenter: Bernhard Scheiner

1284

Comparable efficacy between on-going vs. initiation of antiviral therapy at the time of curative treatment for hepatitis B virus-related hepatocellular carcinoma

Poster Presentation

Presenter: Mi Na Kim

1342

Immune-related adverse events and clinical outcomes in unresectable hepatocellular carcinoma: a single-institute retrospective analysis

Poster Presentation

Presenter: Antonella Cammarota

1411

Multistage epigenome-wide association study identifies highly accurate epigenomic signatures in association with hepatocellular carcinoma: The HCC epigenome score

Poster Presentation

Presenter: Abderrahim Oussalah

1523

Interleukin-6 as a new marker for advanced sarcopenic HCC patients with different cirrhotic aetiology

Poster Presentation

Presenter: Andrea Dalbeni

1559

Time-trends in cholangiocarcinoma incidence - a danish nationwide cohort study

Poster Presentation

Presenter: Morten Daniel Jensen

1564

A novel hierarchical fusion strategy of deep learning networks to detect hepatocellular carcinoma from dynamic computed tomography images

Poster Presentation

Presenter: I-Cheng Lee

1569

Prospective randomized controlled trial of biomarkers for early detection of hepatocellular carcinoma

Oral Presentation

Presenter: Hooman Farhang Zangneh

1625

Changing global epidemiology of liver cancer from 1990-2019: NASH is the fastest growing cause of liver cancer

Poster Presentation

Presenter: Daniel Huang

1707

Liver resection for single large hepatocellular carcinoma: a prognostic factors study

Poster Presentation

Presenter: Giuliana Amaddeo

1962

Characterization and clinical correlation of the immune contexture in intrahepatic cholangiocarcinoma using multiplex immunohistochemistry

Poster Presentation

Presenter: Charlotte Hoffmann

2041

Deep view on HCC gene signatures and their comparison with other cancers

Poster Presentation

Presenter: Yuquan Qian

2095

Lifestyle factors and population attributable risk of hepatocellular carcinoma in lean vs non-lean populations

Oral Presentation

Presenter: Kali Zhou

2139

Causes of death after Intrahepatic cholangiocarcinoma diagnosis : a population-based study

Poster Presentation

Presenter: Prasun Jalal

2149

Genes modulating liver fat accumulation and lipogenesis predict development of hepatocellular carcinoma among direct antiviral agents treated cirrhotics C with and without viral clearance

Poster Presentation

Presenter: Antonio Acquaviva

2181

Potential role of soluble triggering receptor expressed on myeloid cells 2 in risk stratification of patients with hepatocellular carcinoma

Poster Presentation

Presenter: Francesca Baorda

2186

Bone mineral density is a predictor of mortality in female patients with cholangiocarcinoma undergoing palliative treatment

Poster Presentation

Presenter: Markus Jördens

2233

Multiparametric ultrasound approach using a tree based decision classifier for the inconclusive focal liver lesions evaluated by contrast enhanced ultrasound

Poster Presentation

Presenter: Tudor-Voicu Moga

2238

Adherence to hepatocellular carcinoma screening in patients with hepatitis C cirrhosis treated with direct-acting antivirals against hepatitis C

Poster Presentation

Presenter: Elisaul Suarez Zambrano

2308

Closely monitored alpha-fetoprotein allows early detection of hepatocellular carcinoma recurrence after orthotopic liver transplantation

Poster Presentation

Presenter: Magdalena Hahn

2310

Predictors of survival of patients with hepatocellular carcinoma in best supportive care

Poster Presentation

Presenter: Claudia Campani

2390

Serum exosomal miRNA-720 as a diagnostic marker for hepatocellular carcinoma

Poster Presentation

Presenter: Jeong Won Jang

2530

Prospective evaluation of combining three biomarkers and image tools for early detection of hepatocellular carcinoma: an interim analysis

Poster Presentation

Presenter: Hyung Joon Yim

2873

Germline genetic risk factors for the development of hepatocellular carcinoma among patients with cirrhosis: a genome-wide association study of U.S. veterans

Poster Presentation

Presenter: David Kaplan

2977

Mixed reality for ultrasound-guided biopsies and ablations of liver tumors: proof of concept using HoloLens as head-mounted display during liver interventions

Poster Presentation

Presenter: Fabiola Lugano

3249

A natural experiment investigating the impact of waiting time on post-transplant survival for patients with hepatocellular carcinoma: randomization by blood group

Poster Presentation

Presenter: Berend Beumer

3283

Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different BCLC stages undergoing curative hepatectomy

Poster Presentation

Presenter: Grace Lai-Hung Wong

3345

A comparative analysis of Elecsys GALAD and Elecsys GAAD score to detect early-stage hepatocellular carcinoma in an international cohort

Poster Presentation

Presenter: Teerha Piratvisuth

3446

Use of machine learning to predict the histopathological ImmunoScore in hepatocellular carcinoma on multiparametric MRI

Poster Presentation

Presenter: Annabella Shewarega

3505

Validation of the prognostic role of a new distinct assessment of liver function in non surgical HCC patients

Oral Presentation

Presenter: Bernardo Stefanini

3690

Type 2 diabetes combined with portal vein tumor thrombosis worsens prognosis in patients with hepatocellular carcinoma

Poster Presentation

Presenter: Debora Angrisani

3734

Factors associated with HCC stage at presentation and survival in an ethnically diverse UK population

Poster Presentation

Presenter: Jessica Spiers

3742

British Association for the Study of Liver disease electronic survey on hepatocellular carcinoma UK surveillance practice

Poster Presentation

Presenter: Robert Scott

3753

Value of 18-F fluorodeoxyglucose/choline positron emission tomography imaging for predicting hepatocellular carcinoma recurrence after liver transplantation

Poster Presentation

Presenter: Alina Pascale

3919

Sugar sweetened beverage consumption and liver cancer risk

Poster Presentation

Presenter: Xuehong Zhang

3925

Safety and effectiveness of vaccines against SARS-COV-2 in patients with liver cancer. VacHep registry: response analysis 4 weeks after the second dose.

Poster Presentation

Presenter: ELENA DIAGO SEMPERE

## Liver tumours: Experimental and pathophysiology

57

Mixed HCC-CCA originates from hepatic progenitor cells, is dependent on IL6 signaling and is ablated by senolytic agents

Oral Presentation

Presenter: Nofar Rosenberg

277

Cancer-associated fibroblasts nurture LGR5 marked liver tumour-initiating cells and promote their metastasis

Poster Presentation

Presenter: Qiuwei Pan

328

Molecular insights into the tumour suppressor role of Protein Phosphatase 2A B56 delta complex in human liver, and its clinically relevant inhibition by cancerous inhibitor of PP2A

Poster Presentation

Presenter: Judit Domenech Omella

336

Identification of new dominant neoantigens in hepatocellular carcinoma based on a single plasmid system with co-expressing patient's HLA and antigen

Poster Presentation

Presenter: Pu Chen

457

Polypeptide N-acetylgalactosaminyltransferase 14 mediated O-glycosylation on prohibitin-2 serine 161 modulates cell growth, migration and drug susceptibility in hepatocellular carcinoma

Poster Presentation

Presenter: Chau-Ting Yeh

532

Gut bacteria modulate anti-tumour immunity in patients with hepatocellular carcinoma

Poster Presentation

Presenter: Dhruti Devshi

553

Lack of the E3-ubiquitin ligase TRIM21 promotes higher emergence of hepatocellular carcinoma nodules in diabetic mice with non-alcoholic steatohepatitis

Poster Presentation

Presenter: Ghania Kara-Ali

609

Role of autophagy-mediated neuropilin-1 degradation on lenvatinib efficacy in human hepatocarcinoma

Poster Presentation

Presenter: Paula Fernández-Palanca

628

Different acylcarnitines tissue profiles as metabolomics signatures of human hepatocellular carcinoma in non-alcoholic fatty liver disease according to fibrosis level

Poster Presentation

Presenter: Benjamin Buchard

641

Hepatocellular carcinoma alters granulopoiesis to produce neutrophils with an immature phenotype

Poster Presentation

Presenter: Daniel Geh

711

Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumour-stroma crosstalk in experimental models

Oral Presentation

Presenter: Paula Olaizola

731

Hippo inactivation drives BMI1-associated proliferative hepatocarcinogenesis in chronic hepatitis B virus infection

Poster Presentation

Presenter: Ruth Broering

788

RNA-Seq based transcriptome analysis revealed inhibiting methionine aminopeptidase 2 prevented hepatocellular carcinoma with inhibited angiogenesis

Poster Presentation

Presenter: Yongtao Wang

844

Proteomic analysis of bile in the rat thioacetamide model reveals new mechanisms in human cholangiocarcinogenesis

Poster Presentation

Presenter: Leticia Colyn

855

Expression of hepatitis B surface antigen in vivo and in vitro induces endoplasmic reticulum stress, impairs autophagy and promotes proliferation

Poster Presentation

Presenter: Ruth Broering

857

Induction of branching morphogenesis in cholangiocarcinoma organoids in vitro improves similarity with the original tumour

Oral Presentation

Presenter: Gilles van Tienderen

861



Cross-talk between cholangiocarcinoma cells and extracellular microenvironment drives desmoplastic matrix deposition

Poster Presentation

Presenter: Gilles van Tienderen

877

DNA methylation regulates lncRNAs compromising hepatic identity during hepatocarcinogenesis

Poster Presentation

Presenter: Miriam Recalde

895

Inhibiting IRE1a-endonuclease activity potentiates the effect of doxorubicin in hepatocellular carcinoma

Poster Presentation

Presenter: MARIA KOPSIDA

918

Genetic ablation of miR-22 fosters hepatic carcinogenesis in mice

Poster Presentation

Presenter: Monika Gjorgjieva

938

Focal nodular hyperplasia: a response to portal vein thrombosis followed by a sequence of arterio-portal shunting, hyperperfusion, focal retrograde sinusoidal blood and Wnt flow, and Wnt-induced activation of the bud maturation sequence

Poster Presentation

Presenter: IanR Wanless

1017

Hepatocellular carcinoma and neutrophils - towards understanding positive and negative impacts on treatments and progression

Poster Presentation

Presenter: Helen Louise Reeves

1179

Dynamic organotypic culture of primary liver cancer as a personalised immunocompetent drug screening platform for immuno-oncology

Poster Presentation

Presenter: Ravi Jagatia

1187

High plasma level of osteopontin, a potential biomarker in hepatocellular carcinoma, is associated with weakened anti-tumour immunity

Poster Presentation

Presenter: Tengfei Si

1209

The uptake of extracellular lipids promotes cholangiocarcinoma progression

Poster Presentation

Presenter: Mikel Ruiz de Gauna

1269

Peroxiredoxin 2 is a target for hepatocellular carcinoma chemoprevention

Poster Presentation

Presenter: Eugénie Schaeffer

1287

Loss of Actin-Binding LIM protein (ABLIM) plays a potential role in migratory cholangiocyte transformation

Poster Presentation

Presenter: Lea Duwe

1398

Modulation of the cholangiocarcinoma stem-like compartment by monounsaturated fatty acids.

Poster Presentation

Presenter: Giulia Lori

1560

Cyclophilin D knockout promotes cell death pathways in preventing HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH

Poster Presentation

Presenter: Winston Stauffer

1746

Ribosomal protein encoding genes: potential drivers of primary sclerosing cholangitis associated cholangiocarcinoma

Poster Presentation

Presenter: Megan Illingworth

1774

Stemness features during cholangiocarcinoma progression in vivo: characterization of primary and metastatic stem-like cells

Poster Presentation

Presenter: Chiara Raggi

1840

miR34a-5p is a target of E2F2 transcription factor in MAFLD-related HCC

Poster Presentation

Presenter: Maider Apodaka-Biguri

1975

TIA1 in fatty liver disease and hepatocellular carcinoma

Poster Presentation

Presenter: Dobrochna Dolicka

2083

Mitochondrial damage, revealed as key factor in cabozantinib efficacy against hepatocellular carcinoma, is potentiated by the BH3-mimetic navitoclax

Poster Presentation

Presenter: Anna Tutusaus

2207

PMEPA1: an oncogene in hepatocellular carcinoma linked to TGF-beta signaling

Oral Presentation

Presenter: Carmen Andreu-Oller

2228

Mutations in BAP1 drive tumour sensitivity to programmed cell death in patient-derived cholangiocarcinoma organoids

Poster Presentation

Presenter: Shaojun Shi

2267

Integrative clustering of multiple genomic data using organoid model with application to subtype analysis in intrahepatic cholangiocarcinoma

Poster Presentation

Presenter: Hee Seung Lee

2349

Role of soluble adenylyl cyclase in the formation and growth of liver tumours

Poster Presentation

Presenter: Jung-Chin Chang

2417

A targeted screen identifies Dmbt1 as an oncogene in cholangiocarcinoma

Poster Presentation

Presenter: Pooya Shokoohi

2418

ACSL4-dependent ferroptosis promotes HCC progression

Poster Presentation

Presenter: Julia Piche

2497

Identification of risk factors for HBV-derived HCC using HLA-DPB1 genotype and HBV peptides for genome medicine

Poster Presentation

Presenter: Masaya Sugiyama

2506

Early Kupffer cell depletion does not affect hepatocellular carcinoma progression in mice

Poster Presentation

Presenter: Bart Vanderborght

2508

RELB activation drives tumour aggressiveness and predicts prognosis in hepatocellular carcinoma

Poster Presentation

Presenter: Luisa Nader

2571

Cross-talk between MerTK-expressing stromal cells and cholangiocarcinoma

Oral Presentation

Presenter: Mirella Pastore

2974

An aggressive subgroup of CTNNB1-mutated hepatocellular carcinomas with STEM-cell phenotype and immune tolerance

Poster Presentation

Presenter: Lise Desquilles

2979

Cold shock protein YB-1 upregulates MDR1 transcription and thus contributes to chemoresistance against cisplatin treatment in cholangiocarcinoma

Poster Presentation

Presenter: Steven Dooley

3027

MAP17 promotes metastasis in hepatocellular carcinoma by modulating the epithelial-mesenchymal-amoeboid transition

Oral Presentation

Presenter: Claudia Gil-Pitarch

3071

Inhibition of Wee1 induces antitumoral effects in preclinical models of hepatocellular carcinoma independently of p53 mutational status

Poster Presentation

Presenter: Julia Sophie Schneider

3186

Extracellular concentration of nicotinamid adenine dinucleotide modulates CD203a on TH17 cells and is associated with recurrence of hepatocellular carcinoma

Poster Presentation

Presenter: Felix Krenzien

3275

Detection of cholangiocarcinoma in mice with protease activity probes

Poster Presentation

Presenter: Jesse Kirkpatrick

3295

Development of hepatocellular carcinoma in the extended GAN diet-induced obese mouse model of NASH with advanced fibrosis

Poster Presentation

Presenter: Andreas Nygaard Madsen

3302

RuvBL1 haploinsufficiency improves mTOR-driven NASH-HCC development in mice

Poster Presentation

Presenter: Alice Guida

3358

Non-canonical TGF- $\beta$  signalling contributes to pro tumorigenic Smad3 linker phosphorylation in cholangiocarcinoma

Poster Presentation

Presenter: Sophie Alex

3381

Synergistic anti-tumor activity with a combination of anti-PD1 antibody and the cyclophilin inhibitor, rencofilstat, in the Hep53.4 fatty liver model of hepatocellular carcinoma

Poster Presentation

Presenter: Daren Ure

3398

Rencofilstat, a pan-cyclophilin inhibitor, exerts diverse metabolic and transcriptional anti-tumor activities in a murine NASH-HCC model

Poster Presentation

Presenter: Daren Ure

3473

TGF- $\beta$ -SOX9 axis-inducible SCUBE3 promotes proliferation, invasion and metastasis in hepatocellular carcinoma via epithelial-to-mesenchymal transition

Poster Presentation

Presenter: Pan Xu

3493

Establishing quantitative image analysis methods for tumor microenvironment evaluation

Poster Presentation

Presenter: Caner Ercan

3511

Characterizing and targeting CD44v6+ cells in liver carcinoma

Poster Presentation

Presenter: Akshaya Srikanth

3549

Coordinating expression of tumorsuppressive microRNAs in hepatocellular carcinoma - a new role for p63 and p73 and their interaction with therapeutic agents

Poster Presentation

Presenter: Kunst Claudia

3560

Critical investigation on the usability of hepatoma cell lines HepG2 und Huh7 as models for the metabolic representation of resectable hepatocellular carcinoma

Poster Presentation

Presenter: Andrea Scheffschick

3627

Different immunological microenvironment in patients with different cirrhosis etiology and hepatocellular carcinoma

Poster Presentation

Presenter: Andrea Dalbeni

3696

Trusting your gut - a new direction in multikinase inhibitors therapy in hepatocellular carcinoma

Poster Presentation

Presenter: Iuliana Nenu

3726

Single cell RNAsequencing derived signature of hepatocyte de-differentiation predicts development of hepatocellular carcinoma in patients with liver cirrhosis

Poster Presentation

Presenter: Natascha Röhlen

3749

Cytokine levels and circulating DNA in plasma could be used as serological biomarkers of response to immunotherapy in hepatocellular carcinoma

Poster Presentation

Presenter: Elena Vargas Accarino

3824

NKG2A hampers tumor surveillance of liver-infiltrating natural killer (NK) cells via TLR4 signaling pathway after liver transplantation

Poster Presentation

Presenter: Xinxiang YANG

## Liver tumours: Therapy

307

Yttrium-90 radioembolization versus drug-eluting beads chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase 2 randomized controlled trial

Oral Presentation

Presenter: Elisabeth Dhondt

380

Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

Oral Presentation

Presenter: Laura Izquierdo-Sánchez

598

Systemic treatments with tyrosine kinase inhibitors and platinum-based chemotherapy in patients with unresectable or metastatic hepato-cholangiocarcinoma

Poster Presentation

Presenter: Elia Gigante

625

The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma

Poster Presentation

Presenter: Claudia Fulgenzi

671

Combination of crafity score with alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Poster Presentation

Presenter: Wei Teng

811

Survival of patients with advanced hepatocellular carcinoma treated with sorafenib in France during 2009-2018: analysis of the French hospital and claim database

Poster Presentation

Presenter: Jean-Pierre Bronowicki

1042

Textbook outcome after major hepatectomy for perihilar cholangiocarcinoma - definitions and influencing factors

Poster Presentation

Presenter: Christian Benzing

1043

A preferable signature of gut microbiota and bile acids predicted better outcomes of unresectable hepatocellular carcinoma to immune checkpoint inhibitors

Oral Presentation

Presenter: Pei-Chang Lee

1047

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

Poster Presentation

Presenter: Mathew Vithayathil

1120

Outcome predictors of gemcitabine-based or fluoropyrimidine-based chemotherapy for unresectable intrahepatic cholangiocarcinoma

Poster Presentation

Presenter: Chen-Ta Chi

1210

Transcatheter arterial chemoembolization (TACE) followed by conformal radiotherapy versus TACE alone for hepatocellular carcinoma: a western controlled trial

Oral Presentation

Presenter: Cyrille Feray

1276



Transarterial radioembolisation in non resectable hepatocellular carcinoma in curative strategies: a single centre experience

Poster Presentation

Presenter: Helene Regnault

1286

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study

Poster Presentation

Presenter: Antonio D'Alessio

1356

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

Oral Presentation

Presenter: Antonio D'Alessio

1579

Comparative effectiveness of treatment for early-stage intrahepatic cholangiocarcinoma

Poster Presentation

Presenter: Yi-Te Lee

1632

Twenty-year trends in radiofrequency ablation for treatment-naive hepatocellular carcinoma within the Milan criteria

Poster Presentation

Presenter: SE YOUNG JANG

1672

Incidence of hepatocellular carcinoma reduced in chronic hepatitis B patients treated with entercavir plus Biejia-Ruangan: extended follow-up of a multicenter, randomised, double-blinded, placebo-controlled trial

Poster Presentation

Presenter: Dong Ji

1687

In vitro and in vivo preclinical efficacy of PD-L1-targeted liposomal doxorubicin as a combined therapy for the treatment of hepatocellular carcinoma

Poster Presentation

Presenter: Daniela Gabbia

1815

LiMAX facilitates patient selection prior radioembolization for patients with hepatocellular carcinoma in liver cirrhosis

Poster Presentation

Presenter: Catherine Leyh

1829

The efficacy of molecular targeted therapies after atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC) in Japan

Poster Presentation

Presenter: Kaoru Tsuchiya

1894

The LiMAx level before transarterial chemoembolization or radioembolization is a predictor for short-time survival in patients with early stage HCC

Poster Presentation

Presenter: Janett Fischer

1923

Implementation of a new prognostic scoring system after major hepatectomy in curative intent for perihilar cholangiocarcinoma

Poster Presentation

Presenter: Christian Benzing

1986

The effect of discordance between preoperative imaging and postoperative pathology on the prognosis of hepatocellular carcinoma

Poster Presentation

Presenter: Woo Sun Rou

2112

Early Nivolumab addition to Regorafenib in patients with hepatocellular carcinoma progressing under 1st line therapy (GOING trial). Interim analysis and safety profile

Poster Presentation

Presenter: Marco Sanduzzi Zamparelli

2274

Impact of endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy

Poster Presentation

Presenter: Christian Möhring

2314

Interleukin 10 and Interferon Gamma levels are elevated in patients with hepatocellular carcinoma showing response to treatment with atezolizumab and bevacizumab

Poster Presentation

Presenter: Sabine Lieb

2381

Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma: a real-world analysis

Poster Presentation

Presenter: Benedetta Stefanini

2407

Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an observational study

Poster Presentation

Presenter: David J. Pinato

2480

GALAD score correlates with therapy response for transarterial and systemic therapies in patients with hepatocellular carcinoma

Poster Presentation

Presenter: Anne Olbrich

2621

Liver transplantation for patients with fibrolamellar hepatocellular carcinoma: a comprehensive multicenter analysis to support future decision making

Oral Presentation

Presenter: Marco Claasen

2624

Antiviral and antitumor activity of SCG101, an autologous HBV-specific T cell receptor engineered T cell (TCR-T) therapy in HBV-related advanced hepatocellular carcinoma (HCC) patients after receiving  $\geq 2$  prior lines of systemic therapies

Poster Presentation

Presenter: Shunda Du

2668

Combination of systemic immune-inflammation index and albumin-bilirubin score predict prognosis of sequential therapy with sorafenib and regorafenib in unresectable hepatocellular carcinoma

Poster Presentation

Presenter: Tai-An Cheng

2745

Risk factors for hepatic encephalopathy in hepatocellular carcinoma after sorafenib or lenvatinib treatment: a real-world study

Poster Presentation

Presenter: Yinying Lu

2846

Induce the endogenous tumor suppressor miR-34a by small molecules to inhibit liver metastasis

Poster Presentation

Presenter: Dayana Yaish

2971

The impact of treatment and treatment status on health state utility in patients with unresectable hepatocellular carcinoma: an EQ-5D analysis from Himalaya

Oral Presentation

Presenter: Lei Qin

3016

Current trends and in-hospital mortality of transarterial chemoembolization (TACE) in Germany: a systematic analysis of hospital discharge data between 2010 and 2019.

Poster Presentation

Presenter: Sven H Loosen

3079

Pre-treatment cross-talk between the tumoural and peripheral immune system predicts response to checkpoint inhibition in advanced HCC: a single-cell study

Poster Presentation

Presenter: Sarah Cappuyns

3214

The influence of fasting on tumor-targeted drug delivery

Poster Presentation

Presenter: Svea Becker

3561

CXCR2 inhibition sensitises NASH-HCC to immunotherapy

Poster Presentation

Presenter: Jack Leslie

3612

Prediction of treatment response using contrast-enhanced ultrasonography in patients treated with Atezolizumab and Bevacizumab for unresectable hepatocellular carcinoma

Poster Presentation

Presenter: Hitomi Takada

3687

Efficacy and safety of Atezolizumab plus Bevacizumab-based sequential treatment for unresectable hepatocellular carcinoma: a simulation model

Poster Presentation

Presenter: Ciro Celsa

## Molecular and cellular biology

249

Role of Monocyte chemoattractant protein-induced protein 1 in liver fibrosis and activation of hepatic stellate cells

Poster Presentation

Presenter: Natalia Pydyn

436

The genomic landscape of IDH1 mutant intrahepatic cholangiocarcinoma: a multicentre comprehensive analysis

Poster Presentation

Presenter: Margherita Rimini

536

Isolation of hepatocytes from various liver tissues by a novel, semi-automated perfusion technology

Poster Presentation

Presenter: Ralf Weiskirchen

612

Human amnion-derived mesenchymal stem cells pre-conditioning inhibits inflammation and apoptosis of immune and parenchymal cells in an in vitro model of liver ischemia/reperfusion

Poster Presentation

Presenter: Giovanni Zito

700

NFATc1 drives progressive liver inflammation and fibrosis by regulating pro-apoptotic stress responses

Oral Presentation

Presenter: Muhammad Umair latif

705

Ptpn1 deletion protects oval vells against lipoapoptosis by favoring lipid droplet formation and dynamics

Poster Presentation

Presenter: Pilar Valdecantos

712

Accurate detection of HBV splice variant DNA by using long-read sequencing

Poster Presentation

Presenter: Sanne Hulspas

820

Primary cilia in biliary regeneration - a potential approach to improve outcomes in liver transplantation

Oral Presentation

Presenter: Hannah Esser

831

The identification and characterization of novel bile acid-derived Farnesoid X Receptor agonists

Poster Presentation

Presenter: Dannielle Kydd-Sinclair

1064

Human antigen R (HuR) is a master regulator of hepatic glucose metabolism

Oral Presentation

Presenter: Sofia Lachiondo-Ortega

1130

MiR-122, the regulator of the immune privileged liver

Oral Presentation

Presenter: Eithan Galun

1182

SARS-CoV-2 induces pericyte procoagulant response associated with portal vein microthrombosis and intrapulmonary vascular dilations in fatal COVID-19

Poster Presentation

Presenter: Massimiliano Cadamuro

1238

Dual ileal/renal-liver bile acid transporter inhibitors with different transporter selectivity in vitro differentially increase faecal and urinary bile acid excretion in organic anion transporting polypeptide 1a/1b knockout mice in vivo

Poster Presentation

Presenter: Ellen Strängberg

1239

Integrated bile lipidome and meta-proteome analysis classifies lipid species and microbial peptides predictive of carcinoma of the gall bladder

Poster Presentation

Presenter: Nupur Sharma

1270

Novel anti-cholestatic treatment strategies by combining inhibition of the Apical sodium-dependent bile acid transporter with stimulation of urinary bile salt excretion or lowering bile salt synthesis

Oral Presentation

Presenter: Roni Kunst

1290

The effects of apurimic/apirimidinic endonuclease 1 as a sensitizer to sorafenib in hepatocellular carcinoma

Poster Presentation

Presenter: Nataliya Rohr-Udilova

1354

Soluble guanylyl cyclase expression and signaling in different types of liver fibrosis

Poster Presentation

Presenter: Ksenia Brusilovskaya

1408

Impact of maternal obesity on liver disease in the offspring: a comprehensive transcriptomic analysis and validation of results

Poster Presentation

Presenter: Beat Moeckli

1515

Liver directed in utero AAV gene therapy for maple syrup urine disease in a neonatal lethal murine model

Poster Presentation

Presenter: Kate Mullany

1612

Patient-derived hepatocellular carcinoma organoids as predictors of Treatment Response

Poster Presentation

Presenter: Kyung Joo Cho

1637

Dissecting A-to-I RNA editome of liver macrophages in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Achilleas Fardellas

1702

The role of OFD1 and loss of primary cilia in cholangiocarcinoma: a novel promising therapeutic target

Oral Presentation

Presenter: Pietro Carotenuto

1711

Restoring bone marrow hematopoietic stem cells (BM-HSC) reserve augments regression of fibrosis and regeneration in animal model of cirrhosis

Poster Presentation

Presenter: Nidhi Nautiyal

1738

Human resident liver macrophages protect against metabolic stress in obesity

Poster Presentation

Presenter: Emelie Barreby

1741

Reversal of epithelial-mesenchymal transition in a cholangiocarcinoma cell line by genetic targeting of sulfatide synthesis

Poster Presentation

Presenter: Gloria Álvarez-Sola

1760

Unravelling the circadian transcriptome and epigenome of the human liver

Poster Presentation

Presenter: Atish Mukherji

1796

Single-cell dynamics of interacting mesenchymal and leukocyte populations in advanced NASH

Poster Presentation

Presenter: Kim Ravnskjaer

1802

Dysregulated glutamine metabolism in intrahepatic cholangiocarcinoma: a perspective for targeted therapy

Poster Presentation

Presenter: Michela Anna Polidoro

1849

Microfluidic 3-dimensional bioprinting and 2-dimensional micropatterns as tools to bioengineer biliary ducts

Poster Presentation

Presenter: Pascale Dupuis-Williams

1863



Mcpip1 fl/fl LysM Cre mice as an animal model of TNF $\alpha$ -dependent liver endothelial cell dysfunction in humans with chronic inflammation

Poster Presentation

Presenter: Jerzy Kotlinowski

1906

Peroxisome proliferator activated receptor gamma regulates patatin-like phospholipase domain-containing protein 3 in adipocytes in vitro and in vivo in a mouse model of nonalcoholic steatohepatitis

Poster Presentation

Presenter: Emmanuel Dauda Dixon

1948

Animal variants of sodium-taurocholate co-transporting polypeptide permitting hepatitis B virus infection

Poster Presentation

Presenter: Fuwang Chen

2007

Cholangiocarcinoma-on-chip: a platform for 3D liver tumour model

Poster Presentation

Presenter: Michela Anna Polidoro

2279

Regulation of cholangiocyte ciliogenesis by soluble adenylyl cyclase

Poster Presentation

Presenter: Hang Lam Li

2313

Regulation of cholangiocyte ciliogenesis by soluble adenylyl cyclase

Poster Presentation

Presenter: Hang Lam Li

2316

CRISPR perturbation in iPSC-derived hepatic stellate cells reveals role for TNF-driven interferon response in chronic liver disease

Poster Presentation

Presenter: Kelly Haston

2726

The selective PPAR-delta agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 through the FGF21 pathway

Oral Presentation

Presenter: Bernd Schnabl

2741

A meta-analysis to identify novel candidate genes in the development of hepatocellular carcinoma

Poster Presentation

Presenter: Andrew Walakira

2962

Signal transducer and activator of transcription 3 (STAT3)-driven hepatic transcriptional changes are indicative of a shift from immune tolerance to immune activation in chronic hepatitis B virus (HBV) infection

Poster Presentation

Presenter: Jinglin Tang

3101

Polymeric nanomicelles formulation of LY2157299-Galunisertib improves therapeutic outcome by greater reducing fibrosis and ameliorating fatty degeneration in a CCL4-induced hepatic-fibrosis rat-model

Poster Presentation

Presenter: Marco Fidaleo

3309

Hepatic inflammation elicits production of proinflammatory netrin-1 through exclusive activation of translation

Poster Presentation

Presenter: Romain Barnault

3403

Glycine ameliorates paracetamol-induced liver injury in non-alcoholic fatty liver disease by supporting glutathione biosynthesis

Poster Presentation

Presenter: Alia Ghrayeb

3428

3D bioprinted hepatocyte and mesenchymal stem cell spheroids as a cell therapy for liver disease

Poster Presentation

Presenter: Sam Wadsworth

3483

Hepatocyte-specific deletion of the anti-apoptotic Mcl-1 in mice induces polyploidization, mitotic errors and chromosomal instability.

Poster Presentation

Presenter: Laure-Alix Clerbaux

3484

Fibroblast growth factors are therapeutic targets for radiofrequency ablation induced tumorigenesis

Poster Presentation

Presenter: Aurelia Markezana

3492

Modulation of microRNA-223 in human hepatic stellate cells as a novel approach to control liver fibrosis

Poster Presentation

Presenter: Chaiyaboot Ariyachet

3593

Characterization of TGR5-mediated Ca<sup>2+</sup> signaling in cholangiocytes

Poster Presentation

Presenter: Olivier DELLIS

3818

Inhibition of NLRP3 inflammasome by GPR40 agonists

Poster Presentation

Presenter: Jeongwoo Park

3894

Pharmacologic inhibition of HSD17B13 is hepatoprotective in mouse models of liver injury

Poster Presentation

Presenter: Manuel Roqueta-Rivera

## NAFLD: Clinical aspects except therapy

62

The prevalence of non-alcoholic fatty liver disease in the United Kingdom: a systematic review and meta-analysis

Poster Presentation

Presenter: Yusef Alenezi

162

Hepatic steatosis is not associated with increased mortality in the elderly - time for a paradigm shift?

Oral Presentation

Presenter: Laurens van Kleef

214

Health-related quality of life is impaired in people living with HIV and hepatic steatosis

Poster Presentation

Presenter: Maurice Michel

299

Moderate alcohol consumption is associated with significant fibrosis progression in non-alcoholic fatty liver disease - a cohort study with over 17 years of follow-up

Poster Presentation

Presenter: Julia Blomdahl

324

Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: korean military population-based cross-sectional study

Poster Presentation

Presenter: Jaejun Lee

388

Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis

Poster Presentation

Presenter: James Thomas

468

Association of non-alcoholic fatty liver disease and fibrosis with incident dementia and cognitive function: the Rotterdam Study

Poster Presentation

Presenter: Laurens van Kleef

497

High meat consumption is prospectively associated with non alcoholic fatty liver disease and liver fibrosis markers

Poster Presentation

Presenter: Dana Ivancovsky Wajcman

568

Relevance of diabetes medication on recruitment criteria for clinical studies in patients with nonalcoholic fatty disease and type 2 diabetes mellitus

Poster Presentation

Presenter: Michael Holzhey

651

The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective study using UK Biobank data

Oral Presentation

Presenter: Theresa Hydes

743

Comorbidity severity scores and cardiovascular comorbidities in patients with non-alcoholic steatohepatitis (NASH), with and without cirrhosis, in a real-world setting

Poster Presentation

Presenter: Jeffrey Lazarus

767

NAFLD association with renal impairment in type 2 diabetes patients

Poster Presentation

Presenter: Jesús Rivera

779

The impact of liver fibrosis on the immune response to SARS-CoV-2 vaccination in metabolic associated fatty liver disease patients

Poster Presentation

Presenter: Marta Freitas

803

Non-alcoholic steatohepatitis is also becoming a major liver transplant indication in Spain, a historically low risk area

Poster Presentation

Presenter: Laura Martínez-Arenas

853

Total healthcare cost and characteristics associated with higher change in cost in patients with non-alcoholic steatohepatitis

Poster Presentation

Presenter: Zobair Younossi

864

Nonalcoholic fatty liver disease (NAFLD) / nonalcoholic steatohepatitis (NASH) is associated with worse outcomes in patients hospitalised for COVID-19: a real-world analysis of a large population from the premier healthcare database

Poster Presentation

Presenter: Frank Tacke

914

Estimating the prevalence of advanced fibrosis due to nonalcoholic fatty liver disease in the United States population

Poster Presentation

Presenter: Naim Alkhouri

920

Non-alcoholic fatty liver disease associated liver fibrosis is linked with the severity of coronary artery disease mediated by systemic inflammation

Poster Presentation

Presenter: Xianbin Cai

954

Prevalence of portal vein thrombosis in non-alcoholic fatty liver disease related cirrhosis: a meta-analysis of observational studies

Poster Presentation

Presenter: Roberta Stupia

1058

Real-world prevalence of metabolic associated fatty liver disease (MAFLD) and fibrotic-nonalcoholic steatohepatitis (NASH) in patients with obesity (PwO) in an outpatient specialist clinic in Italy

Poster Presentation

Presenter: Federico Ravaioli

1099

Young-onset diabetes mellitus increases the risk of liver-related events in patients with non-alcoholic fatty liver disease

Oral Presentation

Presenter: Xinrong Zhang

1162

Postprandial dysfunction in metabolic associated fatty liver disease (MAFLD)

Poster Presentation

Presenter: Josephine Grandt

1387

Lean non-alcoholic fatty liver disease patients from the global NASH registry

Poster Presentation

Presenter: Zobair Younossi

1394

Burden of hepatocellular cancer in patients with type-2 diabetes mellitus: a 2011-2020, french, longitudinal, retrospective, national, cohort study

Oral Presentation

Presenter: Lucia Parlati

1400

Automated FIB-4 calculator and targeted provider education improved referral of at-risk fibrotic NAFLD patients

Poster Presentation

Presenter: Cindy Piao

1425

Long term outcomes of non-alcoholic fatty liver disease (NAFLD) and metabolic associated fatty liver disease (MAFLD)

Poster Presentation

Presenter: Zobair Younossi

1429

MARC1 and HSD17B13 variants have protective effects on liver injury in the obese: results from a prospective cohort of patients undergoing bariatric surgery

Poster Presentation

Presenter: Marcin Krawczyk

1432

The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease (NAFLD): data from national health and nutrition examination survey (NHANES) 2005-2018

Poster Presentation

Presenter: Zobair Younossi

1820

Non-alcoholic fatty liver disease patients have worse health-related quality of life compared to the general population irrespective of their fibrosis stage: results from a prospective multicenter UK study

Oral Presentation

Presenter: Margarita Papatheodoridi

1837

Metabolic dysfunction-associated fatty liver disease increases cardiovascular risk regardless of classical risk factors

Poster Presentation

Presenter: María Del Barrio Azaceta

1861

Changes in hepatic fat fraction as assessed by MRI-PDFF are correlated with changes in markers of hepatic inflammation, disease activity and fibrosis in biopsy-proven non-cirrhotic NASH with fibrosis

Poster Presentation

Presenter: Samuel Daniels

1870

The metabolic dysfunction-associated fatty liver disease definition, regardless of its clinical subclassification, identifies patients at high risk for liver disease progression

Poster Presentation

Presenter: María Del Barrio Azaceta

2036

Assessment of the prevalence of nonalcoholic fatty liver disease, its severity, and comorbidities in lean americans: national health and nutrition examination surveys (NHANES) with transient elastography assessment from 2017 to 2018

Poster Presentation

Presenter: Emily Truong

2044

Coagulation imbalance is associated with hepatic fibrosis and vascular complications in patients with type2 diabetes and NAFLD

Poster Presentation

Presenter: Rosa Lombardi

2070

Presence of two or more metabolic risks regardless of fatty liver is a risk factor for significant hepatic fibrosis

Poster Presentation

Presenter: Huiyul Park

2140

Pregnancy as a unique opportunity to identify NAFLD in women: a prospective assessment

Poster Presentation

Presenter: Tatyana Kushner

2467

N-terminal propeptide of type III collagen (PRO-C3) based risk for liver fibrosis predict cardiovascular events in nonalcoholic fatty liver disease

Poster Presentation

Presenter: Francesco Baratta

2470

Genetic risk of fatty liver disease and mortality in the general population

Poster Presentation

Presenter: Helene Gellert-Kristensen

2541

Role of NAFLD-associated genetic variants on renal function in patients with nonalcoholic fatty liver disease



Poster Presentation

Presenter: Laura D'Erasmus

2543

The association between nonalcoholic fatty liver disease and insulin resistance within normal glucose level population

Poster Presentation

Presenter: chun-yi Wang

2616

Chronic pruritus represents a major burden in non-cholestatic hepatobiliary disorders

Poster Presentation

Presenter: Andreas E Kremer

2648

Nonalcoholic fatty liver disease impact on cardiovascular disease death: a population-based study

Poster Presentation

Presenter: Chaonan Jin

2773

Impact of intermittent fasting on anthropometric and clinical outcomes in non-alcoholic fatty liver disease: systematic review and meta-analysis

Poster Presentation

Presenter: Marcia Lange

2916

Hypertension and diabetes mellitus are associated with high FIB-4 index in a health checkup examination cohort without known liver disease

Poster Presentation

Presenter: Shunsuke Sato

2972

Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease

Poster Presentation

Presenter: Huapeng Lin

3070

The burden of liver fibrosis in the obese population

Poster Presentation

Presenter: Gres Karim

3073

Undiagnosed NAFLD in the obese population: in sight, out of mind

Poster Presentation

Presenter: Gres Karim

3177

Different effects of low muscle mass on the risk of non-alcoholic fatty liver disease and liver cirrhosis in a prospective cohort

Poster Presentation

Presenter: Hun Jee Choe

3365

A higher Fibrosis-4 (FIB-4) score is associated with higher healthcare costs and hospitalizations in patients with nonalcoholic steatohepatitis (NASH)

Poster Presentation

Presenter: Elliot Tapper

3385

Hepatic fat as a novel marker for high-risk coronary atherosclerosis in familial hypercholesterolaemia: a CT-based study

Poster Presentation

Presenter: Gavin Huangfu

3417

Lack of awareness of a NAFLD pandemic in a high risk group. Is it time to act in primary care?

Poster Presentation

Presenter: Maria Guerra Veloz

3451

Sarcopenia is associated with the severity of metabolic associated fatty liver disease in elderly residents

Poster Presentation

Presenter: xiaohui liu

3569

Nonalcoholic fatty liver disease and type 2 diabetes: low referral rate of patients at increased risk of progressive liver disease

Poster Presentation

Presenter: Lucy Gracen

3618

Prevalence of non-alcoholic steatohepatitis in patients undergoing laparoscopic cholecystectomy for gallstone with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Utpal Anand

3720

Comparison of hepatic and cardiovascular damage between HIV patients with steatosis and NAFLD: role of metabolic alterations and low visceral adiposity

Poster Presentation

Presenter: Felice Cinque

3736

NAFLD patients scheduled for bariatric surgery present with a milder disease phenotype as compared to not morbidly obese NAFLD patients: analysis of a large real-world cohort

Poster Presentation

Presenter: Monika Rau

3763

Mortality prediction in non-alcoholic fatty liver disease using SteatoSITE: an integrated gene-to-patient data commons for high-definition non-alcoholic fatty liver disease research

Poster Presentation

Presenter: Maria Jimenez Ramos

3766

Impact of screening and treatment of obstructive sleep apnea in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Kelsey Collins

3783

Effects of SARS-CoV2 pandemic in a cohort of italian NAFLD patients

Poster Presentation

Presenter: Bernardo Stefanini

3835

Comorbidities and malignancy among NAFLD patients compared to general population

Poster Presentation

Presenter: Naim Abu-Freha

3896

The most recent and in-depth meta-analytic assessment of the global epidemiology of nonalcoholic fatty liver disease (NAFLD)

Poster Presentation

Presenter: Zobair Younossi

[NAFLD: Diagnostics and non-invasive assessment](#)

11

Identifying advanced liver disease in asymptomatic patients in primary care: an evaluation of patient outcomes 24 months after implementing a primary care liver pathway and community liver service

Poster Presentation

Presenter: Tina Reinson

30

Predictive survival-time modelling of Non-Alcoholic Steatohepatitis (NASH) fast progressors using real-world evidence

Poster Presentation

Presenter: Nils Svängård

92

Impact of type 2 diabetes on the accuracy of non-invasive tests of liver fibrosis: a comprehensive analysis of 1,051 biopsy proven NAFLD patients showing clinical implications

Oral Presentation

Presenter: Jerome Boursier

121

Online education significantly improved gastroenterologists' knowledge of the diagnostic and monitoring techniques used in liver fibrosis

Poster Presentation

Presenter: James White

156

Health outcomes and risk assessment in chronic liver disease (HERALD): a large Swedish research platform

Poster Presentation

Presenter: Emilie Toresson Grip

181

Impact of alcohol use on the diagnostic performance of serum-based indices for fatty liver disease

Poster Presentation

Presenter: Oscar Danielsson

201

Liver stiffness on magnetic resonance elastography and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants

Poster Presentation

Presenter: Veeral Ajmera

245

Utilising features of metabolic syndrome to cost-effectively improve metabolic dysfunction-associated fatty liver disease diagnosis rates

Poster Presentation

Presenter: Cassandra Baiano

325

Machine learning algorithms identify novel biomarker combinations for NAFLD

Oral Presentation

Presenter: Jenny Lee

345

Non-invasive assessment of type VII collagen degradation is related to NAFLD activity but not fibrosis stage

Poster Presentation

Presenter: Mette Juul Nielsen

374

Reliability of histologic disease activity measures in non-alcoholic fatty liver disease (NAFLD) and development of an expanded NAFLD activity score

Poster Presentation

Presenter: Rohit Loomba

488

Evaluating future risk of NAFLD fibrosis in adolescents: prediction and decision curve analysis

Poster Presentation

Presenter: Kushala Abeysekera

547

Fibroscan-AST (FAST) score predicts liver-related outcomes in 1683 HIV-infected patients at risk for NAFLD

Oral Presentation

Presenter: Giada Sebastiani

561

Quantification of hepatic steatosis in patients with non-alcoholic fatty liver disease: comparison of sound speed, attenuation coefficient and continuous CAP measurements with MRI-PDFF

Poster Presentation

Presenter: Rémi Collin

679

Community NAFLD screening programme in patients with type 2 diabetes mellitus indicates high burden of undiagnosed liver disease

Poster Presentation

Presenter: Emma McCormick

695

Non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus in Greenland

Poster Presentation

Presenter: Rasmus Hvidbjerg Gantzel

785

A baseline signature of metabolites involving the gut-liver axis predicts MRI-PDFF response to FASN inhibitor TVB-2640: results from the FASCINATE-1 study

Poster Presentation

Presenter: Rohit Loomba

801

Enhanced Liver Fibrosis test in predicting severe liver-related outcomes in the general population

Poster Presentation

Presenter: Kustaa Saarinen

812

Radiowater perfusion PET of the liver, and its value as a biomarker to discriminate between NAFLD and NASH, and activity and fibrosis grade

Poster Presentation

Presenter: Olof Eriksson

903

The combination of the ELF and FIB-4 scores have high predictive performance for significant fibrosis in patients with NAFLD

Poster Presentation

Presenter: Zobair Younossi

904

The potential role of fatigue in identifying patients with NASH and advanced fibrosis who experience disease progression

Poster Presentation

Presenter: Zobair Younossi

923

Association of the biological age and the level of global deoxyribonucleic acid methylation with metabolic parameters in patients with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Anastasiia Radchenko

951

LEARN algorithm: a novel option for predicting non-alcoholic steatohepatitis

Poster Presentation

Presenter: Gang Li

959

Head to head comparison between MEFIB versus MAST for identification of high-risk patients with NAFLD

Poster Presentation

Presenter: Rohit Loomba

993

MRI assessment (cT1) with LiverMultiScan following VCTE improves the diagnostic yield for high-risk NASH

Poster Presentation

Presenter: Naim Alkhouri

1143

The PNPLA3 (rs738409) G/G-genotype is associated with presence of NASH and increased long-term risk of cirrhosis in NAFLD

Poster Presentation

Presenter: Hannes Hagström

1149

Hepatic expression of secreted calcium-binding protein 2 by hepatic stellate cells is associated with human non-alcoholic fatty liver disease progression

Poster Presentation

Presenter: Frederik Larsen

1154

Clinicians' perspectives on barriers and facilitators for the adoption of non-invasive liver tests: a mixed-method study

Poster Presentation

Presenter: Yasaman Vali

1250

Multiparametric MRI biomarker corrected T1 as a prognostic marker in chronic liver disease

Poster Presentation

Presenter: Naim Alkhouri

1315

Validation of the new 2021 EASL algorithm for the non-invasive diagnosis of advanced liver fibrosis in non-alcoholic fatty liver disease

Oral Presentation

Presenter: Clémence M Canivet

1335

Ectopic fat deposition in the liver and pancreas and the presence of excess visceral adipose tissue significantly increase hospitalisation risk following COVID-19

Poster Presentation

Presenter: Tom Waddell

1365

Genomic and metabolomic profiles and their correlations with preclinical signs of endothelial dysfunction measured by peripheral arterial tonometry in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Mario Masarone

1367

Determinants of liver stiffness measurements in patients with NAFLD - an individual patient data meta-analysis

Poster Presentation

Presenter: Ferenc Mozes

1385

Knowledge of liver fibrosis stage among adults with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis improves adherence to life style changes

Poster Presentation

Presenter: Jeffrey Lazarus

1403

The MRI and AST (MAST) score is correlated with noninvasive and histologic markers of fibrosis in patients with advanced fibrosis due to NASH

Poster Presentation

Presenter: Mazen Nouredin

1420

Independent determinants of CAP values in healthy individuals with dysmetabolism

Poster Presentation

Presenter: Cristiana Bianco

1471

Performance of liver-related clinical scores in the SAPHIR study

Poster Presentation

Presenter: Lorenz Balcar

1481



Correlations of 2D-Shear wave and transient elastography liver stiffness measurements in patients with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Dimitrios Karagiannakis

1498

Utility of FIB-4 thresholds to identify patients with at-risk F2-F3 NASH based on screening data from a 2000 patient biopsy confirmed cohort of resmetirom Phase 3 clinical trial, MAESTRO-NASH

Oral Presentation

Presenter: Jörn Schattenberg

1500

Performance of the Enhanced Liver Fibrosis (ELF) test in real world practice versus clinical trials of non-alcoholic steatohepatitis

Poster Presentation

Presenter: Zobair Younossi

1506

Machine learning using simple non-invasive tests of fibrosis and B-mode ultrasound for the prediction of adverse liver-related outcomes in NAFLD

Poster Presentation

Presenter: Heather M Kosick

1548

Incorporating a two-tiered liver fibrosis assessment into annual diabetes review in primary care - 3 year follow up study

Poster Presentation

Presenter: Dina Mansour

1549

New scoring system using MRI with AST for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis

Poster Presentation

Presenter: Kento Imajo

1599

Impact of artificial intelligence assistive tool on the histopathologic review of fibrosis in non-alcoholic steatohepatitis patients

Poster Presentation

Presenter: Elaine Chng

1601

PRO-C3 based sequential algorithm can screen high-risk NASH and severe fibrosis in asian NAFLD population

Poster Presentation

Presenter: Liang-Jie Tang

1603

Real-world use of the FIB-4 calculator in primary care workflows to screen for advanced non-alcoholic fatty liver disease in a large US health system

Poster Presentation

Presenter: George Therapondos

1719

In silico identification and validation of plasma Ficolin-2 (FCN-2) as non-invasive biomarker of fibrosis in Non-alcoholic Fatty Liver Disease (NAFLD)

Poster Presentation

Presenter: Noel Salvoza

1721

A lower cut-off of liver stiffness measurement (8/13) kPa performs better than Baveno 6 criteria for advanced chronic liver disease in patients with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Sagnik Biswas

1735

High prevalence of multi-organ steatosis and fibroinflammation, identified by multi-parametric magnetic resonance imaging, in people with type 2 diabetes

Poster Presentation

Presenter: Nicole Eichert

1805

Plasma TREM2, a novel non-invasive biomarker for diagnosis of NASH in NAFLD patients with elevated liver stiffness

Poster Presentation

Presenter: Charlotte Wernberg

1813

Unbiased clustering of exhaled breath profiles in metabolic dysfunction-associated fatty liver disease identifies a patient phenotype at higher risk of disease progression

Poster Presentation

Presenter: Rohit Sinha

1822

The pericellular basement of the hepatocytes is highly affected by bariatric surgery in obese patients with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Ida Lønsmann Lønsmann

1855

A re-appraisal of the diagnostic performance of ultrasonography for fatty liver disease

Poster Presentation

Presenter: Chul-min Lee

1886

Cost utility analysis for screening for fibrotic NASH in the type 2 population from European countries

Poster Presentation

Presenter: Mazen Nouredin

1890

Free Light Chains as a potential biomarker of inflammation and fibrosis in non-alcoholic steatohepatitis

Poster Presentation

Presenter: Antonio Liguori

1893

12-week very low calorie diet in NAFLD induces rapid improvements in biomarkers of necro-apoptosis and fibrogenesis of a magnitude comparable to those seen in phase 2 drug trials

Poster Presentation

Presenter: Jadine Scragg

1907

Signature of circulating hepatic proteins detects fibrosing-steatohepatitis in progressive non-alcoholic fatty liver disease

Poster Presentation

Presenter: Olivier Govaere

1968

Peripheral blood mononuclear cells mitochondrial copy number and adenosine triphosphate inhibition test in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Eileen Yoon

1989

Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era

Poster Presentation

Presenter: Dae Won JUN

1990

Assessing the applicability of non-invasive diagnostic tests (NITs) in non-alcoholic fatty liver disease: an international qualitative study

Poster Presentation

Presenter: Maja Thiele

2012

Evaluation of the performance of a novel digital pathology method for the continuous quantification of steatosis, ballooning and inflammation in liver biopsies and its correlation with NASH-CRN scores in patients with NASH

Poster Presentation

Presenter: Louis Petitjean

2029

Can combination of M2BPGi and APRI help endocrinologists refer patients with advanced hepatic fibrosis to hepatologists?

Poster Presentation

Presenter: Mi Mi Kim

2090

The relationship between foetal head circumference growth trajectories and nonalcoholic fatty liver disease in adolescents

Poster Presentation

Presenter: Jeffrey Lee

2152

Liver stiffness assessed by transient elastography predicts clinical events in patients with T2DM and NAFLD

Poster Presentation

Presenter: Jesús Rivera

2226

Repeated noninvasive liver biopsy surrogate LIVERFAST correlates with BMI and liver enzyme improvements

Poster Presentation

Presenter: Victor de Lédinghen

2290

Increased liver stiffness on vibration controlled transient elastography (Fibroscan) as a predictor of all-cause mortality in people with fatty liver disease

Poster Presentation

Presenter: Michael Braude

2298

Magnetic resonance imaging-based biomarker accurately identifies patients with nonalcoholic steatohepatitis and significant liver fibrosis: a multicentre, international, validation study

Poster Presentation

Presenter: David Marti-Aguado

2475

Diagnostic accuracy of MRE for staging hepatic fibrosis in patients with NAFLD

Poster Presentation

Presenter: Manuel Romero Gomez

2482

Aldafermin quantitatively improves inflammation in a 24-week clinical trial in patients with nonalcoholic steatohepatitis

Poster Presentation

Presenter: Tian Lan

2528

Clinical and economic evaluation of community-based preventative screening strategies for non-alcoholic fatty liver disease in people with Type-2 diabetes mellitus

Poster Presentation

Presenter: Roberta Forlano

2529

Confounding factors in diagnostic performance of magnetic resonance elastography for staging liver fibrosis in patients with non-alcoholic fatty liver disease: an individual patient data meta-analysis

Poster Presentation

Presenter: Manuel Romero Gomez

2567

Is it possible to identify nonalcoholic steatohepatitis and the associated degree of fibrosis by noninvasive methods in patients with MAFLD?

Poster Presentation

Presenter: Marta Casado

2747

Mitochondria-derived methylmalonic acid is associated with advanced fibrosis risks in metabolic dysfunction-associated fatty liver disease (MAFLD): results from the NHANES 1999-2004

Poster Presentation

Presenter: Qi Huang

2777

Plasma sgp130 is an independent predictor of non-alcoholic fatty liver disease severity

Poster Presentation

Presenter: Aysim Gunes

2941

Translational fibrosis phenotypes between the 3D human NASH spheroidal model and clinical NASH samples

Poster Presentation

Presenter: Louis Petitjean

3078

Results of the Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) study 1.1 on the reproducibility and repeatability of shear-wave and transient elastography in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Anthony Samir

3094

Disease severity assessment of metabolic dysfunction-associated fatty liver disease in Taiwan

Poster Presentation

Presenter: Jee-Fu Huang

3146

Head to head comparison of MEFIB, MAST, and FAST for detecting candidates with stage 2 fibrosis or higher among patients with NAFLD

Oral Presentation

Presenter: Rohit Loomba

3155

An adult-based genetic risk score for hepatic fat associates with liver and lipid traits in Danish children and adolescents

Poster Presentation

Presenter: Yun Huang

3161

Independent association of physical activity with nonalcoholic fatty liver disease and alanine aminotransferase levels

Poster Presentation

Presenter: Jun Kyu Lee

3182

NASH patient's itinerary: Comparison of strategies for screening, referring and management

Poster Presentation

Presenter: Manuel Romero Gomez

3193

FIB-4 outperforms other serum non-invasive fibrosis tests in metabolic associated fatty liver disease

Poster Presentation

Presenter: Nikoletta Maria Tagkou

3207

Prediction of ten-year risk of severe liver disease in the general population using commonly available biomarkers

Oral Presentation

Presenter: Hannes Hagström

3211

Developing an algorithm to predict NAFLD in clinical trial volunteers - interim report NCT04873258

Poster Presentation

Presenter: Dominic Pimenta

3233

Linear slope of serial FIB-4 measurements predicts liver-related complications and correlates with cirrhosis-associated genetic variants among patients with ALT-based NAFLD phenotype

Oral Presentation

Presenter: David Kaplan

3259

ELF to identify NASH and fibrosis in non-alcohol related fatty liver disease

Poster Presentation

Presenter: Richard Parker

3279

In a nonalcoholic steatohepatitis (NASH) clinical trial, baseline and screen failure magnetic resonance elastography (MRE) liver stiffness values calculated as weighted means were not different from values calculated as simple means

Poster Presentation

Presenter: Michael Middleton

3306

Optical analysis of liver magnetic resonance images (MRI) 3T to detect steatohepatitis features: the program DeMILI 3.0.

Poster Presentation

Presenter: Isabel Fernández-Lizaranzu

3377

Shear wave elastography, transient elastography and enhanced liver fibrosis test use in the assessment of non-alcoholic fatty liver disease (NAFLD) in real- world practices

Poster Presentation

Presenter: Zobair Younossi

3411

Influence of pregnancy on NAFLD-associated lipidomic signatures

Poster Presentation

Presenter: Tatyana Kushner

3429

Performance of the Steatosis-Associated Fibrosis Estimator (SAFE) to predict F2 fibrosis and higher in a cohort of South Korean patients with non-alcoholic fatty liver disease (NAFLD)

Poster Presentation

Presenter: Vivek Charu

3453

Performance of fibrometer-derived biomarker panels for assessment of fibrosis stage in NAFLD: NIMBLE stage 1 and the NASH CRN collaborative Study

Poster Presentation

Presenter: Rohit Loomba

3471

Presence of auto-antibodies has no impact on histological parameters in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Ajeet Singh Bhadoria

3529

Non-invasive fibrosis scores as prognostic biomarkers of liver events, cardiovascular events and all-cause mortality in people with obesity and/or type 2 diabetes in the UK: a longitudinal cohort study

Oral Presentation

Presenter: Quentin Anstee

3554

The fibrosis-4 cut-off value for significant fibrosis is dependent on the type of non-alcoholic fatty liver disease patients

Poster Presentation

Presenter: Leen Heyens

3633

Marked underestimation of liver fat content as measured by magnetic resonance versus histology— a systematic review and meta-analysis

Poster Presentation

Presenter: Sami Qadri



3637

Diagnostic accuracy of non-invasive tests for fibrotic NASH - An individual participant data meta-analysis

Poster Presentation

Presenter: Ferenc Mozes

3686

Correlation of ultrasound derived fat fraction (UDFF) with MRI (PDFF): possibilities and analysis of confounding factors

Poster Presentation

Presenter: Reinhard Kubale

3702

Diagnostic accuracy of non-invasive tests for cirrhotic NASH - an individual participant data meta-analysis

Poster Presentation

Presenter: Ferenc Mozes

3705

FIB-4 combined with positron emission tomography biomarkers detects fibrotic NASH

Poster Presentation

Presenter: Souvik Sarkar

3710

Longitudinal ALT trajectories are generally stable among patients with non-alcoholic fatty liver disease (NAFLD): an investigation using artificial recurrent neural networks

Poster Presentation

Presenter: Michael Fried

3723

Diagnostic performance of AGILE 3+ score for identification of advanced fibrosis and prediction of liver-related events in patients with non-alcoholic fatty liver disease

Poster Presentation

Presenter: Ciro Celsa

3748

Identification of new potential biomarkers to follow steatohepatitis in patients with non-alcoholic/metabolic-associated fatty liver disease

Poster Presentation

Presenter: Douglas Maya

3854

Validation of AI-assisted method of liver fat measurement in adults with type 2 diabetes

Poster Presentation

Presenter: Tim St Pierre

3890

Novel digital pathology quantitative image analysis and AI method detects the treatment effects of NASH drug candidates with a performance that benchmarks imaging-based measurements

Poster Presentation

Presenter: Mathieu Petitjean

3944

Machine learning encoding of liver biopsy images enables prediction of molecular measurements in a NASH F3/F4 fibrosis clinical cohort

Poster Presentation

Presenter: Michael D. Bereket

## NAFLD: Experimental and pathophysiology

185

The DNA damage response is involved in the metabolic dysregulation of MAFLD patients via inefficient fatty acid oxidation

Poster Presentation

Presenter: Beatriz Gómez Santos

206

Hepatic miR-144 drives fumarase activity preventing NRF2 activation during obesity

Poster Presentation

Presenter: Valerio Azzimato

209

TNFR1 inhibition reduces lipogenesis and improves insulin resistance and fibrosis in NAFLD

Poster Presentation

Presenter: Heike Bantel

478

Obesity alters the partitioning of glycerol metabolism pathways in NAFLD

Poster Presentation

Presenter: Jack Carruthers

495

Human induced pluripotent stem cell-derived mesenchymal stem cells ameliorates mitochondrial oxidative dysfunction in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Min Kyung Park

683

Skeletal muscle-derived myokine affects insulin sensitivity and lipogenesis in a human hepatocyte spheroid model

Poster Presentation

Presenter: Jean-Baptiste Potier

728

Patient-derived liver organoids to reveal PNPLA3 I148M role in Non-Alcoholic Fatty Liver Disease

Poster Presentation

Presenter: Elia Casirati

747

Transcriptomic analysis confirms that PNPLA3 I148M variant is associated with impaired mitochondrial function and antioxidant response in 3D cultured human hepatic stellate cells and liver tissue of patients with NAFLD

Poster Presentation

Presenter: Elisabetta Caon

749

Unravelling the role of Protein Kinase D2 in the control of hepatic insulin sensitivity

Oral Presentation

Presenter: Patricia Rada

769

HTD1801 (berberbine ursodeoxycholate), a unique single molecule with multiple beneficial effects in metabolic and liver diseases

Poster Presentation

Presenter: Leigh MacConell

842

Metabolic, biochemical, histopathological and transcriptomic effects of long-acting FGF21 analogue in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH

Poster Presentation

Presenter: Malte H. Nielsen

939

NAFLD-induced encephalopathy is associated with low-grade brain tissue hypoxia and inflammation, as well as cerebrovascular, glial, metabolic and behavioural alterations

Poster Presentation

Presenter: Anna Hadjihambi

974

The inhibition of the epigenetic effectors DNMT1 and G9a as a potential therapeutic strategy against the nonalcoholic fatty liver development

Oral Presentation

Presenter: José María Herranz

1019

The presence of interferon alters the progression of non-alcoholic fatty liver disease

Poster Presentation

Presenter: Michelle Møhlenberg

1125

Targeted metabolomics reveals alterations in one-carbon metabolism in NAFLD patients

Poster Presentation

Presenter: Mikkel Werge

1132

Metabolic NAFLD subtypes align with cardiovascular and genetic risk factors

Poster Presentation

Presenter: José M. Mato

1170

Deletion of ATR in hepatocytes improves NAFLD features by increasing mitochondrial function

Poster Presentation

Presenter: Maeva Saroul

1189

The AXL inhibitor bemcentinib reduces inflammation and fibrosis by inducing a dynamic change in macrophages and CD8<sup>+</sup>T cells subsets during experimental NASH

Poster Presentation

Presenter: Sturla M. Groendal

1206

Human Liver Organoids with myeloid lineages model the multi-cellular crosstalk in Non-Alcoholic Steatohepatitis

Poster Presentation

Presenter: Milad Rezvani

1215

Senescence, hand in hand with hepatic iron overload during the progression of NAFLD

Poster Presentation

Presenter: Miren Bravo

1216

Increased liver content of omega-3-derived lipid mediators associates with enhanced mitochondrial oxidative phosphorylation, fatty acid oxidation and metabolic efficiency

Poster Presentation

Presenter: Cristina López-Vicario

1240

Factors associated with increased gut permeability and severity of liver disease in diabetic patients with NAFLD

Poster Presentation

Presenter: Roberta Forlano

1319

Increased burden of inherited IRF3 rare genetic variants in Europeans with severe Non-alcoholic fatty liver disease

Poster Presentation

Presenter: Alessandro Cherubini

1332

Sex-dependent hepatoprotective role of IL-22 in NAFLD-related fibrosis

Poster Presentation

Presenter: Mohamed Nouredin Hassan Ali Abdelanbi

1341

Identification of novel targets in adipose tissue involved in non-alcoholic fatty liver disease progression

Poster Presentation

Presenter: Jose M Arbones Mainar

1346

Isoleucine and valine correct hepatic lipid processing, reduce liver steatosis and suppress inflammation in obese mice with manifest NASH

Poster Presentation

Presenter: Eveline Gart

1355

Butyrate protects against diet-induced NASH and liver fibrosis and suppresses specific non-canonical TGF $\beta$  signaling pathways in human hepatic stellate cells

Poster Presentation

Presenter: Eveline Gart

1426

Experimental non-alcoholic fatty liver disease causes regional liver functional deficits while total metabolic liver function is preserved

Poster Presentation

Presenter: Peter Lykke Eriksen

1449

Hepatic lipid fingerprint reveals sex-dependent lipid droplet composition in metabolic associated fatty liver disease

Poster Presentation

Presenter: Elisabet Rodríguez-Tomàs

1493

Lipidomics and proteomics reveal mitochondrial dysfunction in liver and visceral adipose tissue from patients with nonalcoholic steatohepatitis

Poster Presentation

Presenter: Helena Castañé

1643

Targeting liver glutaminase 1 modulates hepatic ammonia in experimental Non-Alcoholic Steatohepatitis

Poster Presentation

Presenter: Maria Mercado-Gómez

1645

Clinical relevance of an animal model of nonalcoholic steatohepatitis (NASH) and digital pathology with artificial intelligence (DP-AI) analyses of hepatic fibrosis

Poster Presentation

Presenter: Deming Xu

1682

Small changes in the metabolism of bile acids by the gut microbiota are associated to NASH pathogenesis

Poster Presentation

Presenter: Justine Gillard

1685

Unravelling the landscape of adipose tissue macrophages in human non-alcoholic fatty liver disease

Poster Presentation

Presenter: Markus Boesch

1698

Atorvastatin attenuates diet-induced non-alcoholic steatohepatitis in ApoE\*3-Leiden mice by reducing hepatic inflammation

Poster Presentation

Presenter: José A. Inia

1762

Carnitine signature in liver corretales with nonalcoholic fatty liver disease progression

Poster Presentation

Presenter: Andrea Jiménez Franco

1773

Type 2 diabetes and religious fasting: effects on metabolism and liver steatosis

Poster Presentation

Presenter: Svenja Sydor

1783

The I48M PNPLA3 variant mitigates Niacin beneficial effects: how the genetic screening in non-alcoholic fatty liver disease (NAFLD) patients gains value

Poster Presentation

Presenter: Erika Paolini

1785

The co-presence of PNPLA3, MBOAT7 and TM6SF2 loss-of-functions impairs mitochondrial morphology and number in severe NAFLD patients

Poster Presentation

Presenter: Miriam Longo

1812

The association of spleen volume with sex, age, type 2-diabetes, and non-alcoholic fatty liver disease - initial results from more than 35,000 UK Biobank participants

Poster Presentation

Presenter: Lars Johansson

1835

Targeting adipose tissue macrophages ameliorates hepatic injury in a murine model of NAFLD

Poster Presentation

Presenter: Celia Martínez Sánchez

1836

Multiplex immunostaining and transcriptomic profiling identify novel immune cell markers for non-alcoholic steatohepatitis and primary sclerosing cholangitis

Poster Presentation

Presenter: Adrien Guillot

1845

Phospholipid fingerprints reveal sex differences in the adipose tissue phospholipid composition from morbidly obese patients

Poster Presentation

Presenter: Gerard Baiges

1865

Ubiquitination of GSDMD regulated by NEDD4 is involved in hepatocyte pyroptosis of nonalcoholic steatohepatitis

Poster Presentation

Presenter: Rui Jin

1935

Unraveling the transcriptional dynamics of NASH pathogenesis affecting atherosclerosis development

Poster Presentation

Presenter: Geurt Stokman

1978

Repeated weight cycling in obese mice improves hepatic inflammation

Poster Presentation

Presenter: Geurt Stokman

1996

The functional roles of BMP10 in the pathogenesis of nonalcoholic fatty liver disease

Poster Presentation

Presenter: Wenjun Zhang

1998

Pharmacokinetics, safety, and tolerability of BMS-986263, a lipid nanoparticle containing HSP47 siRNA, in participants with severe hepatic impairment

Poster Presentation

Presenter: Giridhar Tiruchera

2009

Amino acid glycine suppresses steatohepatitis and tumorigenesis in hepatocyte-specific phosphatase and tensin homolog knockout mice

Poster Presentation

Presenter: Kazuyoshi Kon

2054

Advanced quantitative phenotypic fibrosis and steatosis scoring is more superior to histology-based conventional staging in NASH animal models

Poster Presentation



Presenter: Li Chen

2068

Molecular characterization of metabolic associated fatty liver disease as an immune-mediated inflammatory disease: IMID associated fatty liver disease

Oral Presentation

Presenter: Enrique García-Nieto

2074

Chemical suppression of adipose triglyceride lipase improves nonalcoholic steatohepatitis in a diabetic and hyperlipidemic mouse model

Poster Presentation

Presenter: Emmanuel Dauda Dixon

2077

Methionine adenosyltransferase 1a antisense oligonucleotides induce the fibroblast growth factor 21-driven recovery from obesity and associated hepatoesteatosis

Poster Presentation

Presenter: Xabier Buque

2113

NLRP3 inflammasome dependent cell death in myeloid cells drives liver inflammation and fibrosis in murine steatohepatitis

Poster Presentation

Presenter: Benedikt Kaufmann

2346

Two diseases, one model - assessing the suitability of FOZ mice to examine CVD in NAFLD

Poster Presentation

Presenter: Sebastian Bott

2350

Oleic acid-induced acute lung injury in Ob/Ob mice fed with high-fat-diet exacerbate bile acid uptake and liver injury that was reversed by antagonizing their entry

Poster Presentation

Presenter: Johnny Amer

2352

The ubiquitin-like modifier FAT10 is upregulated during NASH and impairs PPAR-alpha activity

Poster Presentation

Presenter: Ludivine Clavreul

2395

TNF-alpha knockout mice are protected from diet-induced NAFLD in a model of non-obese NAFLD

Poster Presentation

Presenter: Katharina Burger

2481

Low dose thyroid hormone improves hepatic mitochondrial fatty acid oxidation and rescues nonalcoholic fatty liver disease in mice

Poster Presentation

Presenter: Raghu Ramanathan

2527

Three-dimensional imaging of cleared human liver tissues reveals extensive fibrosis heterogeneity in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Buket Yigit

2551

In vivo functional genetic screen with a pooled-shRNA library for therapeutic targets of non-alcoholic fatty liver disease

Poster Presentation

Presenter: Yong-An Lee

2585

Hepatic insulin resistance is the basis of bile acid dysmetabolism in non-alcoholic fatty liver disease

Poster Presentation

Presenter: Sami Qadri

2604

Heterogeneity of phosphatidylcholine metabolism in non-alcoholic fatty liver disease

Oral Presentation

Presenter: Sami Qadri

2704

Is there a murine model that fully recapitulates human NASH? An unbiased bioinformatics approach to rank pre-clinical models based on proximity to human disease

Oral Presentation

Presenter: Michele Vacca

2748

Non-alcoholic fatty liver disease features a reduced reverse polyunsaturated fatty acid transport (free fatty acids/high-density lipoprotein) from the periphery to the liver

Poster Presentation

Presenter: Gabriele Mocciaro

2776

FXR binding and transcription in the liver is significantly altered in obese patients with NAFLD

Poster Presentation

Presenter: Martin Wagner

2787

EphB2 is a novel signaling receptor in nonalcoholic steatohepatitis liver fibrosis

Oral Presentation

Presenter: Patrice Mimche

2855

Novel endosomal trafficking adaptor for the regulation of NAFLD to NASH progression

Poster Presentation

Presenter: Karsten Motzler

2963

GL0034, A novel long-acting glucagon-like peptide 1 receptor agonist exhibits significant efficacy in aged db/db mouse model of non-alcoholic fatty liver disease (NAFLD)

Poster Presentation

Presenter: Rajamannar Thennati

2973

Development of an ex vivo model for non-alcoholic fatty liver disease using precision-cut liver slices

Poster Presentation

Presenter: Mei Li

2986

Insights to molecular mechanism of Essentiale: In vitro studies in hepatic cell lines HepaRG and steatotic HepaRG

Poster Presentation

Presenter: Dominik Wupperfeld

3053

Anti-inflammatory effect of simvastatin-ezetimibe combination therapy via inhibition of macrophage in NASH related mouse model

Poster Presentation

Presenter: Han Seul ki

3123

Enzymatic activity dysfunction of the mitochondrial respiratory chain, in the full spectrum of the metabolic associated fatty liver disease

Poster Presentation

Presenter: Alberto García Picazo

3215

Obeticholic acid reduces hepatic matrix metalloproteinase activity in a diet-induced ob/ob mouse model of NASH

Poster Presentation

Presenter: Marta Cagna

3240

Validation of the ADAPT score for the diagnosis of clinically significant fibrosis in patients with nonalcoholic fatty liver disease (NAFLD)

Poster Presentation

Presenter: Arun Sanyal

3269

Lipid-induced phenotypic differences in human non-alcoholic fatty liver disease models determined by matrix-assisted laser desorption/ionization mass spectrometry

Poster Presentation

Presenter: Ruth Walker

3296

Therapeutic inhibition of complement component 5 does not reduce NASH progression but does attenuate atherosclerosis development in Ldlr<sup>-/-</sup>.Leiden mice

Poster Presentation

Presenter: Florine Seidel

3305

Dysregulation of the urea cycle enzymes determines a more severe NAFLD phenotype in a DIAMOND preclinical model

Poster Presentation

Presenter: Rocío Gallego-Durán

3313

The PNPLA3 I148M variant increases intrahepatic lipolysis and beta oxidation and decreases de novo lipogenesis and hepatic mitochondrial function in humans

Poster Presentation

Presenter: Panu Luukkonen

3330

The overexpression of TM6SF2 and/or MBOAT7 wild-type genes re-establishes the mitochondrial dynamics in an in vitro NAFLD model.

Poster Presentation

Presenter: Erika Paolini

3338

The different modulation of KLB expression impacts on liver damage in NAFLD patients and in an in vitro model: a novel druggable target?

Poster Presentation

Presenter: Marica Meroni

3348

MPEP, an mGlu5 receptor allosteric modulator, reduces hepatic steatosis in obese high-fat-diet mice

Poster Presentation

Presenter: Laura Giuseppina Di Pasqua

3370

Quantitative multimodal anisotropy imaging enables automated fibrosis assessment of H&E-stained tissue

Poster Presentation

Presenter: Justin Lee

3408

The role of immune semaphorins in NAFLD - a pilot study

Poster Presentation

Presenter: Ivana Knezevic Stromar

3491

Evaluation of semisynthetic high-fat diets in development of a 4-week mouse NASH model

Poster Presentation

Presenter: Ozren Majstorović

3500

Tyrosinase mutations, a novel predisposing genetic factor for enhanced nonalcoholic steatohepatitis susceptibility

Poster Presentation

Presenter: Kaushalya Kulathunga

3513

The neolignan honokiol can improve intestinal barrier dysfunction in fructose-induced liver damage in mice

Poster Presentation

Presenter: Anja Baumann

3540

Regulation of NEAT1 in NAFLD by RNA-binding proteins

Poster Presentation

Presenter: Lisa Ahne

3547

SIRT5 rs12216101 T>G variant is associated with mitochondrial dysfunction and disease severity in patients with NAFLD

Poster Presentation

Presenter: Federico Salomone

3551

Zonated quantification of immunohistochemistry in steatotic livers

Poster Presentation

Presenter: Cédric Peleman

3559

The role of XBP1 in regulating the progression of non-alcoholic steatohepatitis

Poster Presentation

Presenter: HAOMING ZHOU

3573

Reprogramming necroptosis limits immune responses and prevents liver cancer development

Oral Presentation

Presenter: Tom Lüdde

3584

CD1d knockdown promotes NAFL lipid synthesis by activating the IL6-JAK1-STAT3 signal pathway and reduces inflammatory factors in NASH by decreasing macrophage polarisation towards M1 and increasingn polarisation towards M2

Poster Presentation

Presenter: Dandan Shan

3586

CD161 expressing CD4+ CD25hi T cells accumulate in the liver of obese patients with NASH

Poster Presentation

Presenter: Rafael Kaeser

3605

Exposure to the SARS-CoV-2 spike protein in an in vitro model of steatosis enhances hepatocyte oxidative stress: implications for COVID-19 and accelerated disease progression

Poster Presentation

Presenter: Angus Jacobs

3625

Retrospective AI-based measurement of NASH histology (AIM-NASH) analysis of biopsies from Phase 2 study of Resmetirom confirms significant treatment-induced changes in histologic features of non-alcoholic steatohepatitis

Poster Presentation

Presenter: Janani Iyer

3631

Non-alcoholic fatty liver disease (NAFLD) progression to non-alcoholic steatohepatitis (NASH) and NASH-related hepatocellular carcinoma (HCC) evolves following a differential activation of endoplasmic reticulum stress responses

Poster Presentation

Presenter: Alexander Finnemore

3665

Recapitulating insulin resistance in a 3D human liver model for efficacy testing of drug candidates

Poster Presentation

Presenter: Radina Kostadinova

3698

Utilization of gluconeogenic glucose-6-phosphate via pentose phosphate pathway is increased in mice fed a high fat/high sugar diet compared to a high sugar diet alone

Poster Presentation

Presenter: Getachew Debas Belew

3747

A novel microwell platform to analyse single-cell secretion dynamics and cell communication in NAFLD progression

Poster Presentation

Presenter: Richell Booijink

3762

Pro-inflammatory liver-homing T cells in peripheral blood, liver and adipose tissue in patients with NASH and changes in post-bariatric surgery samples

Poster Presentation

Presenter: James Hallimond Brindley

3788

Machine learning-enabled continuous scoring of histologic features facilitates prediction of clinical disease progression in patients with non-alcoholic steatohepatitis

Poster Presentation

Presenter: Janani Iyer

3808

Increasing plasma concentration of aldo-keto reductase family 1 member B10 and its significance in the progression of non-alcoholic fatty liver disease

Poster Presentation

Presenter: Hye Eun Lee

## NAFLD: Therapy

10

The effect of glucagon on rates of hepatic mitochondrial oxidation and pyruvate carboxylase flux in man assessed by positional isotopomer tracer analysis (PINTA)

Poster Presentation

Presenter: Kitt Falk Petersen

130

Identification of biomarkers of histological response in patients with non-cirrhotic NASH treated with Lanifibranor

Poster Presentation

Presenter: Jerome Boursier

133

TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in nonalcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study

Poster Presentation

Presenter: Kris Kowdley

136

Favorable lipid and pruritus profile of liver-distributed farnesoid X receptor agonist TERN-101 at clinically efficacious doses in nonalcoholic steatohepatitis phase 2a LIFT study

Poster Presentation

Presenter: Kris Kowdley

137

Liver-distributed farnesoid X receptor agonist TERN-101 demonstrates potent target engagement with a favorable exposure-response profile in nonalcoholic steatohepatitis patients

Poster Presentation

Presenter: Cara H. Nelson

194

EDP-297: a novel, highly potent, farnesoid X receptor agonist, results of a phase 1 study in healthy subjects

Poster Presentation

Presenter: Alaa Ahmad



258

Weight loss with semaglutide treatment or time-restricted feeding differentially improves non-alcoholic steatohepatitis in diet-induced obese insulin resistant mice

Poster Presentation

Presenter: Francois Briand

276

ECC4703, a full thyroid hormone receptor beta (THRb) agonist, demonstrated excellent selectivity and liver targeting properties and improvement of plasma lipid, NAFLD activity score and fibrosis in NASH animal model

Poster Presentation

Presenter: Jianfeng Xu

300

LIVRQNaC increases fatty acid oxidation in a primary human hepatocyte model of non-alcoholic steatohepatitis

Poster Presentation

Presenter: Matthew Russell

430

Assessment of therapeutic effect of liraglutide in newly established cell culture model of nonalcoholic and drug-induced fatty liver disease

Poster Presentation

Presenter: Tea Omanovic Kolaric

460

Efx treatment improved histopathology and noninvasive markers of liver injury and fibrogenesis to a similar extent in NASH patients with high-risk PNPLA3 genotypes, compared to those with lowest genetic risk: a post-hoc analysis of balanced study

Poster Presentation

Presenter: Erik Tillman

566

Oxygen-nutrient mismatch: a novel concept to explain how Obeticholic acid benefits NASH treatment

Poster Presentation

Presenter: Gerond Lake-Bakaar

653

Metabolomic changes in NASH phenotype liver-on-a-chip caused by INI-678, a small molecule HSD17B13 inhibitor, supports a role for HSD17B13 in inflammation and fibrosis

Oral Presentation

Presenter: Heather Hsu

742

Sustained reduction of triglyceride and LDL cholesterol from single administration of the novel long-acting FGF21 analogue 0499

Poster Presentation

Presenter: Kirsten Dahl

758

Combination of an Acetyl-CoA carboxylase inhibitor and obeticholic acid reduced lipids and bile acids and altered lipid and amino acid metabolism in the liver of humanized mice

Poster Presentation

Presenter: Wen-Wei Tsai

816

Magnesium modulation by CNNM4 silencing in DIAMOND mice via GalNAc-siRNA therapy: a new and effective therapeutic approach against MAFLD

Oral Presentation

Presenter: Jorge Simón

856

Identification of a fibrosis endotype in NAFLD patients more prone to interventions aimed at reducing fibrogenesis

Poster Presentation

Presenter: Ida Villesen

910

The pan-PPAR agonist lanifibranor improves markers of cardiometabolic health in patients with NASH independent of weight change

Poster Presentation

Presenter: Michael Cooreman

912

Lanifibranor therapy reduces the FibroScan-aspartate aminotransferase (FAST) score associated with histological 'NASH resolution and improvement of fibrosis' and biomarker response

Poster Presentation

Presenter: Michael Cooreman

935

Dissecting the effects and mechanism-of-action of statin use on fatty liver disease: a multidimensional study

Oral Presentation

Presenter: Ibrahim Ayada

945

Effect of smartphone-assisted lifestyle intervention in patients with metabolic-associated fatty liver disease (MAFLD): a preliminary analysis of a randomized controlled trial

Poster Presentation

Presenter: Suraphon Assawasuwannakit

1100

Efficacy and mechanism of time-restricted fasting in non-alcoholic liver disease

Poster Presentation

Presenter: Jiang Deng

1119

Functionalizing novel cancer related genes in liver disease and liver regeneration

Poster Presentation

Presenter: Nooshin Nourbakhsh

1121

Safety, pharmacokinetics and efficacy of the novel pan-phosphodiesterase inhibitor ZSP1601 in 36 NASH patients: a double-blinded, placebo-controlled, multiple-dose escalation phase Ib study

Oral Presentation

Presenter: Yanhua Ding

1134

Effect of long-term dietary intervention on liver pathology and markers of hepatocellular senescence in the GAN diet-induced obese mouse model of NASH

Poster Presentation

Presenter: Kristoffer Voldum-Clausen

1202

Fecal microbiota transplant using endoscopic-placement hydrogel reduces liver fibrosis with no changes in steatosis in a rat model of steatohepatitis with fibrosis

Poster Presentation

Presenter: Ramon Bartolí

1236

Reversing diet-induced steatohepatitis and CCl<sub>4</sub> induced fibrosis with AN1284 treatment

Poster Presentation

Presenter: Adi Yehezkel

1251

A non-calorie restricted low carbohydrate high fat diet improves nonalcoholic fatty liver disease (NAFLD) activity score (NAS) and HbA1c in type 2 diabetes: a six-month randomised controlled trial

Oral Presentation

Presenter: Camilla Dalby Hansen

1281

Spontaneous and drug-induced histological changes in nonalcoholic steatohepatitis: an assessment by meta-analysis of trials

Poster Presentation

Presenter: Grazia Pennisi

1391

Synergistic activity of GLP-1 peptide analog XW003 and the long-lasting GIP receptor agonist XW017 in a diet induced obese mouse model

Poster Presentation

Presenter: Martijn Fenaux

1399

Preclinical pharmacology of low molecular weight GLP-1 receptor agonist XW014

Poster Presentation

Presenter: Martijn Fenaux

1419

Multiple doses of thyroid hormone receptor-beta agonist TERN-501 were well-tolerated and resulted in significant dose-dependent changes in serum lipids and sex hormone binding globulin in a first-in-human clinical study

Oral Presentation

Presenter: Cara H. Nelson

1428

Integrated transcriptomics of CRV431 treatment in a Phase 2a NASH trial confirms anti-fibrotic effect of pan-cyclophilin inhibition and identifies CRV431-specific biomarkers

Poster Presentation

Presenter: Patrick Mayo

1442

Biomarkers, imaging and safety in a well-compensated NASH cirrhotic cohort treated with resmetirom, a thyroid hormone receptor beta agonist, for 52 weeks

Oral Presentation

Presenter: Stephen Harrison

1520

Pharmacokinetic (PK) and pharmacodynamics (PD) of BIO89-100, a novel glycoPEGylated FGF21, in nonalcoholic steatohepatitis (NASH) patients with compensated cirrhosis

Poster Presentation

Presenter: Naim Alkhouri

1542

Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist, achieves rapid and potent reductions in body weight and liver fat: results of a placebo-controlled, double-blind, first-in-human (FIH) clinical trial

Oral Presentation

Presenter: Stephen Harrison

1709

HEC96719, a novel tricyclic farnesoid X receptor agonist for treatment of non-alcoholic steatohepatitis: results of preclinical study and phase I trial

Poster Presentation

Presenter: Yan Wang

1903

Effect of saroglitazar in reducing liver enzymes and liver stiffness in non-alcoholic fatty liver disease: a single arm prospective study

Poster Presentation

Presenter: krishnadas devadas

1946

Intrahepatic microcirculation disorders and hyperammonemia and their correction at nonalcoholic steatohepatitis patients with initial stages of liver fibrosis

Poster Presentation

Presenter: Tatiana Ermolova

2082

Ticagrelor, but not clopidogrel, attenuated hepatic steatosis in a model of non-alcoholic fatty liver disease

Poster Presentation

Presenter: Hyunwoo Oh

2111

Lemon balm extract ALS-L1023, an angiogenesis inhibitor, inhibits liver fibrosis in a non-alcoholic fatty liver disease model

Poster Presentation

Presenter: Hyo Young Lee

2250

Hepatocyte-specific JNK signaling is protective during progression of NASH

Poster Presentation

Presenter: Ines Volkert

2583

Semaglutide use in adjunct to multidisciplinary lifestyle interventions improves weight and body composition in NAFLD patients

Poster Presentation

Presenter: Rochelle Wong

3064

Novel thyroid hormone receptor-beta agonist TG68 safely induces hepatic fat reduction in a non-alcoholic steatohepatitis rat model

Poster Presentation

Presenter: Andrea Marco Caddeo

3109

Safety and pharmacokinetics (PK) of single and multiple ascending oral doses of ALG-055009, a thyroid hormone receptor beta agonist for the treatment of non-alcoholic steatohepatitis (NASH) , in healthy volunteers and subjects with hyperlipidemia

Poster Presentation

Presenter: Hakim Charfi

3184

Semaglutide 2.4 mg once weekly improved liver and metabolic parameters, and was well tolerated, in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

Oral Presentation

Presenter: Rohit Loomba

3286

Identification of new therapeutic targets for hepatic regenerative medicine in Non-Alcoholic Fatty Liver Disease (NAFLD)

Poster Presentation

Presenter: Shainan Hora

3357

The effects of dietary vitamin E intake on NAFLD and sex differences in serum metabolic profile

Poster Presentation

Presenter: Carolin Victoria Schneider

3410

Favorable safety profile of TERN-201, a highly selective inhibitor of vascular adhesion protein-1, in the nonalcoholic steatohepatitis phase 1b AVIATION study

Poster Presentation

Presenter: Mazen Nouredin

3431

A mediterranean diet intervention has beneficial effects on biomarkers of cardiovascular risk and hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD)

Poster Presentation

Presenter: Laura Haigh

3535

Pegozafermin improved liver histology, liver-related non-invasive tests (NITs) and metabolic profiles in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH)

Poster Presentation

Presenter: Rohit Loomba

3583

Impact of resmetirom-mediated reductions in liver volume and steatosis compared with placebo on the quantification of fibrosis using second harmonic generation in a serial liver biopsy study

Oral Presentation

Presenter: Dean Tai

3654

Pegozafermin led to significant metabolic benefits, in addition to robust beneficial effects on the liver, in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH)

Poster Presentation

Presenter: Naim Alkhouri

3869

Reduced triglycerides and LDL cholesterol from once-weekly administration of the well-tolerated novel FGF21 analogue 0499

Poster Presentation

Presenter: Kirsten Dahl

3916

Multimodality assessment of hepatic fibrosis: ranked paired reading and artificial intelligence identifies fibrosis improvement with aramchol missed by conventional staging

Poster Presentation

Presenter: Vlad Ratziu

3924

Efficacy and safety of leronlimab in patients with nonalcoholic steatohepatitis: topline results of NASH01 clinical trial

Poster Presentation

Presenter: Mazen Nouredin

## Non-invasive assessment of liver disease except NAFLD

18

Use of the enhanced liver fibrosis test to risk stratify patients in the intelligent liver function test pathway: ruling out cirrhosis and advanced fibrosis

Poster Presentation

Presenter: Madeline Pearson

263

Comparison of CT, blood test, elastometry and their combination for non-invasive staging of liver fibrosis

Poster Presentation

Presenter: Paul Cales

264

Reliability criteria of non-invasive tests for liver fibrosis

Poster Presentation

Presenter: Paul Cales

306

Metabolomic profiling of capillary dry blood samples for the differential diagnoses of hepatocellular carcinoma and liver diseases

Poster Presentation

Presenter: Philipp Brunnbauer

597

Stable rates of cirrhosis diagnosed by Fibroscan despite changing trends in liver disease epidemiology: a single centre retrospective cohort study

Poster Presentation

Presenter: Joan Ericka Flores

659

Comparative assessment of noninvasive methods (NIMs)- LIVERFASt, liver stiffness measurement (LSM) with transient elastography (TE, Fibroscan) ELF and FiB-4 - in a prospective cohort with chronic liver diseases (CLD) from a tertiary liver center

Poster Presentation

Presenter: Wattana Sukeepaisarnjaroen

689

Diagnostic accuracy of non-invasive imaging modalities for the diagnosis of liver cirrhosis compared to histological assessment in a clinical setting

Poster Presentation

Presenter: Mira Thing



755

Use of Fibrosis-4 (FIB-4) in liver fibrosis screening: which thresholds to choose?

Poster Presentation

Presenter: Denis Ouzan

880

Plasma cell-free DNA methylation as biomarker for hepatocellular carcinoma

Poster Presentation

Presenter: María Gárate-Rascón

1034

A derivation and validation study of paired liver and plasma proteomics in 659 individuals reveals circulating biomarkers for alcohol-related liver disease

Poster Presentation

Presenter: Maja Thiele

1114

Development and validation of a hepatic vascular geometrical model for noninvasive diagnosis of clinically significant portal hypertension in cirrhosis (CHESS1802)

Poster Presentation

Presenter: Chengyan Wang

1172

Development and validation of a machine learning-based model for varices screening in compensated cirrhosis (CHESS2001): an international multicenter study

Oral Presentation

Presenter: Yifei Huang

1190

The diagnostic accuracy of ElastQ 2-D shear wave elastography for liver fibrosis risk assessment in a mixed etiology, multinational cohort

Poster Presentation

Presenter: David JM Bauer

1191

Machine learning models for prediction of severe portal hypertension in patients with compensated cirrhosis

Poster Presentation

Presenter: Oleksandr Petrenko

1235

Reproducibility and applicability of spleen stiffness measurement by vibration controlled transient elastography in patients with and without chronic liver disease

Poster Presentation

Presenter: Giulia Francesca Manfredi

1307

Association of long term methotrexate therapy with liver fibrosis markers: a multi-centre prospective case-control study

Oral Presentation

Presenter: Edmond Atallah

1708

Diagnostic performance of non-invasive liver fibrosis biomarkers: a bayesian individual patient data meta-analysis of hepatitis B cohorts in sub-saharan Africa (HEPSANET)

Oral Presentation

Presenter: Alexander Stockdale

1726

Validation of the continuous controlled attenuation parameter (CAPc) using the MRI-PDFF as reference

Poster Presentation

Presenter: Edouard Bardou-Jacquet

1866

A novel non-invasive index for the prediction of liver fibrosis in chronic hepatitis B patients with concurrent nonalcoholic fatty liver disease

Poster Presentation

Presenter: Jie Li

1891

Comparison between two 2D-SWE techniques using transient elastography as a reference method for liver stiffness assessment

Poster Presentation

Presenter: Alina Popescu

2042

Shear wave elastography is a useful and accurate tool to triage patients with acute liver failure syndromes

Poster Presentation

Presenter: FRANCESCA MARIA TROVATO

2206

A novel simple and reliable 2D-shear wave elastography (SWE) and ultrasound-guided coefficient attenuation parameter (SCAP) technique for patients with chronic liver disease

Poster Presentation

Presenter: Christiane Stern

2260

ADAPT, a score incorporating PRO-C3, for the early detection of liver fibrosis in a large population-based study

Oral Presentation

Presenter: Ann T Ma

2419

Gadoxetic acid-enhanced MRI-derived Functional Liver Imaging Score (FLIS) and spleen diameter provide complementary information for risk stratification in ACLD

Oral Presentation

Presenter: Mattias Mandorfer

2533

Artificial intelligence-assisted jaundice detection by smartphone images

Poster Presentation

Presenter: Tung-Hung Su

2940

Liver stiffness predicts incident severe liver disease in patients with chronic liver disease

Oral Presentation

Presenter: Axel Wester

3622

Dynamics of liver stiffness predicts hepatocellular carcinoma and ascites occurrence in patients with hepatitis C virus related cirrhosis treated with direct-acting antiviral agents

Poster Presentation

Presenter: Alberto Nicoletti

3644

Novel and accurate measurement of differential protease activity in diagnosed HCC patients compared to non-HCC cirrhotic patients

Poster Presentation

Presenter: Amit Singal

3649

FIB-4 predicts severe hematological toxicity and 6-month mortality in older patients with cancer: ELCAPA-LIVER.

Poster Presentation

Presenter: Victoire De Salins

3721

The concordance within one blood test improves reliability evaluation of liver fibrosis

Poster Presentation

Presenter: Paul Cales

## Nurses and Allied Health Professionals

471

The main thing is to be alive - exploring patients' experiences with weight gain after liver transplantation: a qualitative study

Poster Presentation

Presenter: Sonja Beckmann

738

Development of a nurse led hepatology ambulatory review service

Poster Presentation

Presenter: Bryony Butler

739

Development of a nurse led daycase abdominal paracentesis service

Poster Presentation

Presenter: Victoria Wharton

840

Advanced liver disease: master's students' perception. An exercise of introspection

Oral Presentation

Presenter: Eva Roman

1278

Nurse-led inpatient fibrosis assessment for patients with suspected alcohol related liver disease and previous poor engagement with services

Oral Presentation

Presenter: Rebecca Fennell

1667

Quality of life in patients with advanced cirrhosis. Relationship with the development of complications

Poster Presentation

Presenter: Ana Belén Rubio

1973

Effects of the COVID-19 pandemic on the activity of an advanced practice nurse clinic on liver cirrhosis

Poster Presentation

Presenter: Martina Perez

1977

STIGMATIZATION IS COMMON IN PATIENTS WITH METABOLIC ASSOCIATED FATTY LIVER DISEASE AND CORRELATES WITH QUALITY OF LIFE

Poster Presentation

Presenter: Marta Carol

2000

Natural history of hepatic steatosis associated to metabolic syndrome. Longitudinal study with 5 years of follow-up.

Oral Presentation

Presenter: Marta Cervera

3530

Effect of e-health-based interventions on weight loss in patients with NAFLD: a systematic review and meta-analysis of randomized controlled trials

Poster Presentation

Presenter: Ferya Celik

3699

The effort for HCV elimination- dedicated nurse based protocol , single center experience

Oral Presentation

Presenter: Assaf Issachar

3711

Implementing a cirrhosis order set: a qualitative analysis of provider-identified barriers and facilitators

Poster Presentation

Presenter: Ashley Hyde

## Public Health

122

Testing coverage and strategy required to sustain Hepatitis C elimination in an injecting network of people who inject drugs: a network-based model

Poster Presentation

Presenter: Ryan Buchanan

145

Hepatocellular carcinoma screening trends in individuals with cirrhosis in North Carolina

Poster Presentation

Presenter: Christine Hsu

212

Smoking, alcohol consumption and combined association risk for developing liver cancer in chronic hepatitis B: a prospective study

Oral Presentation

Presenter: cao maomao

243

Cost- effectiveness evaluation of the hepatitis C elimination strategy in Cyprus in the era of affordable direct-acting antivirals

Poster Presentation

Presenter: Ilias Gountas

297

Rethinking the management of chronic hepatitis B in the context of rural sub-saharan Africa: results from a social justice mixed methods study in rural Senegal (the AmBASS-PeCSen study)

Poster Presentation

Presenter: Marion Coste

318

Incidence, prevalence and mortality of chronic liver diseases in Sweden between 2005 and 2019

Oral Presentation

Presenter: Hannes Hagström

470

Randomized controlled trial of home-based hepatitis C self-testing for key populations in Malaysia

Oral Presentation

Presenter: Xiaohui Sem

512

Global survey of healthcare workers' attitudes to treatment of chronic hepatitis C infection in children and adolescents

Poster Presentation

Presenter: Farihah Malik

655

Impact of community-based campaign in United States to increase hepatitis B virus screening and linkage to care among Asian immigrants from high endemic countries

Poster Presentation

Presenter: Sung Kwon

666

The prognostic implications of liver function test abnormalities in patients admitted to hospital with COVID-19

Poster Presentation

Presenter: Raza Malik

667

A novel prognostic model including liver function parameters accurately predicts 30-day mortality in patients admitted with COVID-19

Poster Presentation

Presenter: Raza Malik

668

Low health literacy is associated with higher healthcare service utilisation and costs among patients with cirrhosis

Poster Presentation

Presenter: Elizabeth Powell

688

A modelling approach to estimate alcohol-related liver morbidity and mortality in France

Poster Presentation

Presenter: Claire Delacôte

694

A model to predict drinking population at-risk of liver disease in France: a tool for decision-making public health policies

Poster Presentation

Presenter: Claire Delacôte

770

Blood donors in Europe have substantially higher risk of exposure to HEV than in North America: results from a systematic review and meta-analysis

Poster Presentation

Presenter: Annika Wolski

771

Abdominal obesity is key when evaluating interactions between alcohol use and obesity for liver disease

Oral Presentation

Presenter: Fredrik Åberg

898

A population based-study of rates and trends of hepatitis C in immigrants and the Canadian-born in Quebec, Canada, 1998-2018

Poster Presentation

Presenter: Ana Maria Passos-Castilho

976

HBV screening in west african migrant community and faith-based organizations increases HBV vaccination among this high-risk population in greater Barcelona, Spain

Poster Presentation

Presenter: Camila Picchio

979

Community-based HBV testing among west african migrants in greater Barcelona, Spain increases linkage to specialist care and vaccination: the HBV-COMSAVA model

Poster Presentation

Presenter: Camila Picchio

989

The impact of COVID-19 pandemic control measures on HCV treatment initiation in British Columbia, Canada

Poster Presentation

Presenter: Naveed Janjua

1076

Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease

Poster Presentation

Presenter: Zobair Younossi

1110

Associations of food insecurity and fast-food consumption with diet quality in adults with nonalcoholic fatty liver disease in a large population-based U.S. cohort

Poster Presentation

Presenter: Ani Kardashian

1126

Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy

Poster Presentation

Presenter: Roberta D'Ambrosio

1198



Structured early detection of compensated advanced chronic liver disease - results of the SEAL program

Oral Presentation

Presenter: Anita Arslanow

1230

Real life pooling of plasma samples for hepatitis C RNA detection as a screening strategy of hepatitis C active chronic infection

Poster Presentation

Presenter: Federico Garcia Garcia

1237

Epidemiology of hepatocellular carcinoma in Portugal

Poster Presentation

Presenter: Mario Jorge Silva

1261

"Zero C" hospital project: an innovative screening and referral model in hospitalized patients at different divisions

Poster Presentation

Presenter: VALERIO ROSATO

1325

LINK-B: a hepatitis B program to test and link to care patients lost of follow up

Poster Presentation

Presenter: Ana Barreira

1368

Testing for liver disease in primary case: fibrosis first

Poster Presentation

Presenter: Ian Rowe

1395

Hepatitis C care cascade analysis among adult women in Georgia

Poster Presentation

Presenter: Ketevan Stvilia

1476

Progress in HCV screening in the national hepatitis C elimination program in Georgia during the COVID-19 pandemic, 2019-2021

Poster Presentation

Presenter: Maia Tsreteli

1547

Could a multi-target blood test make hepatocellular carcinoma surveillance programs more effective? A modelling-based virtual trial

Poster Presentation

Presenter: Jagpreet Chhatwal

1581

Evaluation of immune response and disease flares in metabolic-associated fatty liver disease patients following SARS-CoV-2 vaccination: a prospective cohort study

Poster Presentation

Presenter: Qianru Zhu

1609

A model, screen test and treat hepatitis C elimination project among under-served communities in Islamabad-the federal capital of Pakistan

Poster Presentation

Presenter: Huma Qureshi

1619

The HCV care cascade for children and young people in British Columbia, Canada: a large, linked administrative population-based cohort study

Oral Presentation

Presenter: Dahn Jeong

1622

The disease burden of hepatitis B and hepatitis C from 2015 to 2030: the long and winding road

Oral Presentation

Presenter: Devin Razavi-Shearer

1634

Hepatitis B and hepatitis C testing practices and seroconversions among dialysis facilities in Georgia

Poster Presentation

Presenter: Maia Butsashvili

1660

Innovative linkage model to re-engage loss-to-follow-up individuals in the national hepatitis C elimination program of Georgia

Poster Presentation

Presenter: Maia Tsreteli

1675

Clinical impact and cost-effectiveness of hepatitis C testing in an emergency department in Barcelona, Spain

Oral Presentation

Presenter: Jordi Llaneras

1722

Combined COVID-19 vaccination and HIV and hepatitis C virus screening intervention for high-risk populations at a mobile testing unit in Madrid, Spain

Poster Presentation

Presenter: Jeffrey Lazarus

1730

A model to eradicate HCV in undocumented migrants and low-income refugees in Italy

Poster Presentation

Presenter: Nicola Coppola

1754

Enhancing the cascade of hepatitis C care in community-recruited high-risk people who inject drugs during the COVID-19 pandemic: the Alexandros program

Poster Presentation

Presenter: Angelos Hatzakis

1789

SVR4 and SVR12 monitoring by using dried blood spot test: is it the best alternative for people who use drugs?

Poster Presentation

Presenter: Jeffrey Lazarus

1795

Genetics of liver fat and volume associate with altered metabolism and whole body magnetic resonance imaging

Oral Presentation

Presenter: Shafqat Ahmad

1880

Collateral benefit of Georgia national hepatitis C elimination program - improving blood transfusion safety in the country of Georgia

Poster Presentation

Presenter: Maia Alkhazashvili

1896

Outcomes of a community led comprehensive HCV and HBV care provision model, including same-day "test and treat" to facilitate micro-elimination of HCV among people who inject drugs in Manipur, India

Poster Presentation

Presenter: Rajkumar Nalinikanta

1905

A novel hepatitis C intervention in Denmark to test and treat people who inject drugs

Poster Presentation

Presenter: Jeffrey Lazarus

1910

Peer-led hepatitis C services reach poorly served populations at scale: a model for tackling health inequalities

Poster Presentation

Presenter: Leila Reid

1943

Cost-effectiveness of integrated treatment for hepatitis C virus among people who inject drugs in Norway: an economic evaluation of the INTRO-HCV trial

Poster Presentation

Presenter: Aaron G. Lim

1985

Characterization of HCV recent infections and re-infections among high-risk population from Georgia using global hepatitis outbreak and surveillance technology

Poster Presentation

Presenter: Adam Kotorashvili

2016

Prevalence and predictors of significant liver fibrosis : a population-based cross-sectional study

Poster Presentation

Presenter: Aayushi Rastogi

2053

Association between liver cirrhosis and cardiovascular events in a large German cohort - a population based study

Oral Presentation

Presenter: Kabbani Abdul-Rahman

2098

Prognostic value of liver function test for COVID-19 hospitalized patients with respiratory disease

Poster Presentation

Presenter: CARLOS ALVENTOSA MATEU

2109

Effectiveness of COVID-19 viral vector vaccine Ad.26.COVS vaccine and comparison with mRNA vaccines in patients with cirrhosis

Poster Presentation

Presenter: Binu John

2116

Humoral, cellular, clinical responses and safety to SARS-CoV-2 messenger RNA vaccines in patients with compensated and decompensated cirrhosis: a long-term single center prospective study

Poster Presentation

Presenter: Massimo Iavarone

2133

The protective role of dairy protein on sarcopenic obesity in middle-aged and older women: a community-based, 12-year, prospective cohort study

Poster Presentation

Presenter: Jun-Hyuk Lee

2166

Detection of microplastics in cirrhotic liver tissue

Poster Presentation

Presenter: Thomas Horvatits

2175

Patient Navigators: an innovative approach to improve hepatitis C case finding leveraging existing human immunodeficiency virus service delivery models to reach last mile patients in Nasarawa State, Nigeria

Poster Presentation

Presenter: Chukwuemeka Agwuocha

2205

The Community Pop-Up Clinic (CPC): a unique strategy to achieve HCV elimination in the inner city

Poster Presentation

Presenter: Brian Conway

2216

The number of public health policies reduces the burden and mortality of alcohol-associated liver disease worldwide: a call for action

Oral Presentation

Presenter: Luis Antonio Diaz

2247

The global burden of liver cancer (LC) and chronic liver diseases (CLD) is driven by non-alcoholic steatohepatitis (NASH) and alcohol liver disease (ALD)

Oral Presentation

Presenter: Zobair Younossi

2252

Age, gender and region-specific HBsAg and anti-HCV seroprevalence in Ghana: a nationwide hospital based cross-sectional study

Poster Presentation

Presenter: Yvonne Nartey

2253

The elimination of hepatitis C in the Cherokee Nation: the impact of harm reduction

Poster Presentation

Presenter: Devin Razavi-Shearer

2297

Effectiveness of mRNA vaccines in patients with cirrhosis with rising prevalence of SARS-CoV-2 delta variant

Poster Presentation

Presenter: Binu John

2365

Epidemiology and management of hepatitis B and C in primary care in the Netherlands - data from the Rijnmond primary care database

Poster Presentation

Presenter: Sylvia Brakenhoff

2369

Point of care testing for hepatitis C in the priority settings of mental health, prisons and drug and alcohol facilities

Poster Presentation

Presenter: Catherine Ferguson

2378

Association of novel lifestyle- and whole foods base inflammation scores with metabolic dysfunction-associated fatty liver disease: a population-based study among Iranian adults

Poster Presentation

Presenter: Ehsaneh Taheri

2440

Assessment of COVID-19 impact and response on hepatitis B virus and hepatitis C virus prevention and treatment from nationwide survey in Japan

Poster Presentation

Presenter: Md Razeen Ashraf Hussain

2450

Knowledge, attitude and practice regarding COVID-19 vaccination among HCV infected patients in Georgia

Poster Presentation

Presenter: Lasha Gulbiani

2522

CRIVALVIR-FOCUS: low HIV and chronic Hepatitis B and C infection prevalence among women in reproductive and sexual health services in Valencia, Spain

Poster Presentation

Presenter: Miguel Garcia-Deltoro

2601

mRNA COVID-19 vaccine effectiveness in liver transplant patients

Poster Presentation

Presenter: Muhammad Khan

2728

Hepatitis C elimination in diabetic population from a shared care cascade cohort- under Changhua-Integrated Program to Stop hepatitis C infection (CHIPS-C)

Oral Presentation

Presenter: Tsung-Hui Hu

2784

The impact of vaccination on the global and regional pediatric prevalence of hepatitis B from 1985-2022

Poster Presentation

Presenter: Devin Razavi-Shearer

2785

Eliminating chronic hepatitis B in the northern territory of Australia through a holistic care package delivered in partnership with the community

Poster Presentation

Presenter: Jane Davies

2807

Prevalence of hepatitis B and C virus in the Uzbekistan Hepatitis Elimination Program (UHEP) patients

Poster Presentation

Presenter: Erkin Musabaev

2814

Is hepatic steatosis individually a risk factor for colorectal adenoma?

Poster Presentation

Presenter: Anuroop Yekula

2937

Hepatitis B birth dose coverage remains dramatically low in The Gambia and has been disrupted by the COVID-19 pandemic

Poster Presentation

Presenter: Maud Lemoine

2957

Hepatitis B prevalence and the impact of vaccination in Georgia: results from a nationwide serosurvey

Poster Presentation

Presenter: Nino Khetsuriani

3021

Evaluation of the clinical and economic value of sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic hepatitis C in Spain during the last 5 years

Poster Presentation

Presenter: Rafael Esteban

3056

National hepatitis elimination profiles: progress towards HBV and HCV elimination in five European countries

Poster Presentation

Presenter: Lindsey Hiebert

3059

Hepatitis C prevalence and elimination in Pakistan; a bottom-up approach accounting for provincial variation

Poster Presentation

Presenter: Ellen Mooneyhan

3076

Economic investment and strategies to eliminate hepatitis C in Mexico

Poster Presentation

Presenter: Ellen Mooneyhan

3102

Evaluation of access to treatment for hepatitis C: a large retrospective cohort from a tertiary care hospital in Turkey

Poster Presentation



Presenter: Merve Eren Durmuş

3114

Reducing the risk of liver cirrhosis and hepatocellular carcinoma after treatment for smoking cessation in patients with chronic hepatitis B or C infection: a 12-year follow-up study

Poster Presentation

Presenter: Yuan Tsung Tseng

3205

The value of increased HCV testing and treatment strategies in Spain to achieve elimination goals

Poster Presentation

Presenter: Ankita Kaushik

3354

Association between immunosuppressants and poor antibody responses to inactivated SARS-CoV-2 vaccines in patients with autoimmune liver diseases

Poster Presentation

Presenter: Hu Li

3380

Need to implement the screening strategy to advance HCV elimination in Italy: a cost-consequences analysis

Poster Presentation

Presenter: Loreta Kondili

3382

Measuring the alcohol related hospital burden in Ireland and the impact of Minimum Unit Pricing (MUP)

Poster Presentation

Presenter: Tobias Maharaj

3384

"Like what? You think I have that?" - Impact of stigma on pharmacy-based identification and treatment of hepatitis C in Victoria, British Columbia

Poster Presentation

Presenter: Tamara Barnett

3406

Feasibility and effectiveness of hepatitis C micro-elimination among 19 prisons of northern India

Poster Presentation

Presenter: Kanudeep kaur

3426

Evaluation of global progress towards HBV and HCV elimination

Poster Presentation

Presenter: Sarah Blach

3564

Progress towards HCV elimination in the country of Georgia: insights from modelling and national survey

Poster Presentation

Presenter: Josephine Walker

3652

No effect of HBsAg positivity on antibody response after COVID-19 vaccine

Poster Presentation

Presenter: Ganbolor Jargalsaikhan

3661

The impact of treatment and health policies for Hepatitis C Virus on hospitalizations in the last decade: data analysis of records of hospital discharge (SDO) at Italian national level

Poster Presentation

Presenter: Claudia Simonelli

3732

Assessing the cost-effectiveness of integrated screening of viral hepatitis C, HIV, and tuberculosis

Poster Presentation

Presenter: Ketevan Goginashvili

3738

Improved clinical and economic outcomes in an intensive care unit with a focus on hepatology through interprofessional cooperation between physicians, staff nurses, and pharmacists

Poster Presentation

Presenter: Schmid Stephan

## Rare liver diseases (including paediatric and genetic)

95

A pilot study of biliary atresia newborn screening using dried blood spot matrix metalloproteinase-7

Poster Presentation

Presenter: Chee Seng Lee

339

In vitro rescue of nonsense variations by drug-induced readthrough of premature termination codons in progressive familial intrahepatic cholestasis type 2

Poster Presentation

Presenter: Emmanuel Gonzalès

366

Search for biomarkers and prognostic indicators of liver degeneration in glycogen storage disease type Ia

Poster Presentation

Presenter: Roberta Resaz

401

ACOX2 deficiency-induced liver fragility (ADILF), a not-so-rare inborn error in bile acid metabolism that responds to ursodeoxycholic acid treatment

Oral Presentation

Presenter: Marta Alonso-Peña

543

Alpha-1 antitrypsin (AAT) augmentation therapy and liver phenotype in individuals with homozygous Pi\*Z AAT mutation (Pi\*ZZ genotype)

Poster Presentation

Presenter: Malin Fromme

571

Impact of acute hepatic porphyria attack frequency on patient-reported outcomes: results from the porphyria worldwide patient experience research (POWER) study

Poster Presentation

Presenter: Amy Dickey

580

Efficacy and safety of givosiran in patients with acute hepatic porphyria: 36-month results of the phase 3 ENVISION randomised clinical trial

Oral Presentation

Presenter: Manish Thapar

713

Senolytic therapies have a place in pediatric biliary cirrhosis

Poster Presentation

Presenter: Giulia Jannone

719

Large-scale, multi-centric prospective validation of the polycystic liver disease complaint-specific assessment (POLCA)

Poster Presentation

Presenter: Antoon Billiet

763

Improvements in quality of life in odevixibat responders and nonresponders: an analysis of pooled data from the PEDFIC 1 and PEDFIC 2 studies

Poster Presentation

Presenter: Cara L. Mack

847

Total, primary, and secondary serum bile acid changes and pruritus improvement during odevixibat treatment in patients with progressive familial intrahepatic cholestasis

Poster Presentation

Presenter: Henkjan J. Verkade

850

Changes in hepatic parameters, growth, sleep, and biochemical markers with odevixibat treatment across patients with various types of progressive familial intrahepatic cholestasis

Poster Presentation

Presenter: Lorenzo D'Antiga

865

Analysis of quality of life, hepatic biochemical markers, and sleep in patients with progressive familial intrahepatic cholestasis who had a pruritus response with odevixibat treatment

Poster Presentation

Presenter: Girish Gupte

1081

Longitudinal follow-up data on adults with classic, severe alpha-1 antitrypsin deficiency (Pi\*ZZ genotype)

Poster Presentation

Presenter: Malin Fromme

1101

In vivo CRISPR/Cas9 editing of the TTR gene with NTLA-2001 in patients with transthyretin amyloidosis- dose selection considerations

Oral Presentation

Presenter: Edward J Gane

1158

Gender dependent neurological and hepatic improvement in Wilson disease patients treated with Trientine dihydrochloride: post hoc results from a prospective study

Poster Presentation

Presenter: Karl Heinz Weiss

1197

Efficacy and safety of odevixibat over 72 weeks of treatment in patients with progressive familial intrahepatic cholestasis

Poster Presentation

Presenter: Richard J. Thompson

1204

In vitro rescue of the bile acid transport function of some ABCB11 variants by CFTR potentiators: a targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2

Poster Presentation

Presenter: Emmanuel Gonzalès

1246

Plasma-based proteomics profiling of patients with Wilson's disease

Poster Presentation

Presenter: Jie Su

1329

Management of hepatic sarcoidosis - multicentric approach

Poster Presentation

Presenter: Janina Sollors

1360

Plasma proteomics identifies hepatic steatosis and sex differences in 2,147 children and adolescents

Poster Presentation

Presenter: Lili Niu

1388

Pregnancy outcomes in women with Budd Chiari syndrome: a single center experience

Poster Presentation

Presenter: Sagnik Biswas

1415

High-risk Thrombophilia predict early thrombosis recurrence in acute non-cirrhotic portal vein thrombosis related to local factors: LOCAPORT

Oral Presentation

Presenter: Louise Lebedel

1463

New cases of Budd-Chiari syndrome and splanchnic vein thrombosis after COVID-19 vaccination - a vascular liver disease group (VALDIG) initiative

Poster Presentation

Presenter: Rael Maan

1653

Abdominal wall hernia is a frequent complication of polycystic liver disease and associated with hepatomegaly

Poster Presentation

Presenter: Thijs Barten

1658

MR-derived metrics have utility in identifying paediatric patients with stable autoimmune hepatitis

Poster Presentation

Presenter: Piotr Pawliszak

1710

Development and validation of a novel ICP-MS method to quantify different copper species in human plasma from patients with Wilson disease

Poster Presentation

Presenter: Mark Ma

1745

Quantitative magnetic resonance cholangiopancreatography identifies features of ductal disease change in primary sclerosing cholangitis: a prospective observational cohort study

Poster Presentation

Presenter: Palak Trivedi

1806

Quantitative magnetic resonance cholangiopancreatography outperforms Mayo risk score in predicting clinical outcomes in primary sclerosing cholangitis

Oral Presentation

Presenter: Raj Vuppalanchi

1816

Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trial

Oral Presentation

Presenter: Karl Heinz Weiss

1847

Age at diagnosis is associated with mortality in patients with hereditary hemochromatosis

Poster Presentation

Presenter: Clare Foley

1854

Development of Hepatoblastoma organoids as a patient-derived ex-vivo system

Poster Presentation

Presenter: Laura Zanatto

1955

High rates of histological findings compatible with porto-sinusoidal vascular disease in patients with constantly elevated gamma-glutamyl transferase levels undergoing a liver biopsy

Poster Presentation

Presenter: Nicola Pugliese

2019

Plasma metabolomics and machine learning characterizes metabolite signature capable of segregating patients with poor outcome in pediatric cirrhosis

Poster Presentation

Presenter: Babu Mathew

2022

Clinical utility of non-ceruloplasmin copper determined by copper speciation for monitoring Wilson disease therapy: comparative data analysis with 24-hour urinary copper excretion from the CHELATE trial

Oral Presentation

Presenter: C.Omar Kamlin

2063

Experience of cholestatic pruritus emphasized by patients with PBC: results from the PBC Foundation app survey

Poster Presentation

Presenter: Chris Mitchell

2191

Cancer risk in acute hepatic porphyria: a nationwide matched cohort study in 1,245 individuals

Poster Presentation

Presenter: Hannes Hagström

2220

Innovative approach using clinical metagenomics for the diagnosis of non-elucidated liver disease

Poster Presentation

Presenter: Anna Sessa

2237

Accumulation of molybdenum in major organs following chronic oral administration of bis-choline tetrathiomolybdate in Sprague Dawley rats

Poster Presentation

Presenter: Kharmen Billimoria

2254

Bile duct injury in a toxic model of biliary atresia may be reversible

Poster Presentation

Presenter: Orith Waisbourd-Zinman

2255

Liver fibrosis and fat by transient elastography in patients with Alpha-1 antitrypsin deficiency

Poster Presentation

Presenter: Hassaan Yousuf

2283

Novel imaging feature in patients with porto-sinusoidal vascular disorder (PSVD) - radiological evaluation guiding diagnosis

Poster Presentation

Presenter: Georg Semmler

2303

Liver involvement in systemic light chain amyloidosis : is the heart guilty?

Poster Presentation

Presenter: Vincent Leroy

2408

The role of the mechanistic target of rapamycin (mTOR) in Alpha-1 Antitrypsin Deficiency

Poster Presentation

Presenter: Lisa Bewersdorf

2443

Cerebrotendinous xanthomatosis: long-term course in 5 patients and first description of a successful pregnancy management during therapy with chenodesoxycholic acid (CDCA)

Poster Presentation

Presenter: Jan Köhler

2472

A rare genetic variant in the manganese transporter SLC30A10 and elevated liver enzymes in the general population

Poster Presentation

Presenter: Anne-Sofie Seidelin

2960

Patient experience of their Primary Biliary Cholangitis (PBC) management compared to clinical practice guidelines

Poster Presentation



Presenter: Chris Mitchell

3060

Precision-cut liver slices as an ex vivo model to assess impaired hepatic glucose production

Poster Presentation

Presenter: Kishore Alagere Krishnamurthy

3090

The alpha-1 antitrypsin Pi\*Z allele is an independent risk factor for liver transplantation/death in patients with advanced chronic liver disease

Poster Presentation

Presenter: Lorenz Balcar

3158

PNPLA3 rs738409 G allele increases the risk of liver cirrhosis in SERPINA1 MZ heterozygotes

Poster Presentation

Presenter: Sona Frankova

3203

Fontan associated liver disease: a cohort review into the prevalence of portal hypertension

Poster Presentation

Presenter: Hannah Donnelly

3239

Circulating miR-21 parallels the incidence of IBD in PSC patients

Poster Presentation

Presenter: André A. Santos

3268

Defining the boundaries for "stability" in Wilson disease patients on maintenance chelation therapy: lessons from the CHELATE trial

Poster Presentation

Presenter: Michael Schilsky

3320

Reduction of intra-hepatic Z-AAT synthesis by fapirsiran decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency

Oral Presentation

Presenter: Pavel Strnad

3368

A 'melting pot' of genetic variability in Wilson's disease - real world study from London, UK

Poster Presentation

Presenter: James Liu Yin

3396

A small molecule chaperone for alpha-1 antitrypsin deficiency-associated liver disease reduces liver polymer burden in the PiZ mouse model

Poster Presentation

Presenter: Britta Handyside

3397

North american evaluation of 2519 patients with primary sclerosing cholangitis: longitudinal patterns of disease activity identify and validate stable and progressive phenotypes

Oral Presentation

Presenter: Marwa Ismail

3487

Hepatocellular carcinoma in fontan associated liver disease: uncharted territory - are we doing enough?

Poster Presentation

Presenter: Michael Christmas

3527

Evaluation of the clinical impact of the Ceruloplasmin variant p.Thr551Ile in liver cirrhosis

Poster Presentation

Presenter: Marlene Panzer

3528

Are patients with Fontan-associated liver disease (FALD) appropriately screened for oesophageal varices? Queensland quaternary adult congenital heart disease referral centre experience

Poster Presentation

Presenter: Anthony Bergin

3648

Primary liver malignancies in patients with Wilson's disease

Poster Presentation

Presenter: Rodolphe Sobesky

3881

Role of mutant alpha-1-antitrypsin in determining liver cell fate during embryonic development and in HCC origin

Poster Presentation

Presenter: Francesco Annunziata

## Viral Hepatitis A, B, C, D, E: Virology

29

Liver-resident T cell PD-1 correlates with intrahepatic HBV-DNA and is reduced following prolonged antiviral therapy

Oral Presentation

Presenter: Mireia García-López

228

Hepatitis E Virus Capsid Antigen (HEV-Ag): a practical diagnostic biomarker in the HEV outbreak scenerio

Poster Presentation

Presenter: Simon Lytton

241

Bulevirtide is broadly active against all HDV genotypes expressing envelopes from HBV genotypes A-H and a large panel of clinical isolates

Poster Presentation

Presenter: Savrina Manhas

275

Identification of cyclin L1 as a hepatitis B virus host factor regulating viral transcription

Oral Presentation

Presenter: Collins Oduor Owino

291

Novel ultra-potent capsid assembly modulators prevent abnormal accumulation of empty capsids and associated T-cell mediated liver injury in a mouse model of hepatitis B virus infection

Oral Presentation

Presenter: Luca Guidotti

309

A persistent HBV infection features spontaneous cccDNA loss and new rounds of infection

Poster Presentation

Presenter: Yong-Yuan Zhang

369

A genome-wide CRISPR/Cas9 screen identifies Rab5A as host factor of the hepatitis E virus life cycle

Oral Presentation

Presenter: Noémie Oechslin

482

Functionnal and mitochondrial dynamics alterations in patients with chronic hepatitis B and advanced fibrosis

Poster Presentation

Presenter: Dimitri Loureiro

487

Dual antiviral activity of farnesyl transferase inhibitor on hepatitis D virus infection revealed by RT-ddPCR

Poster Presentation

Presenter: Eloi Verrier

710

Characterization of circulating hepatitis B Virus RNAs in vitro and chronic hepatitis B patients

Poster Presentation

Presenter: Doohyun Kim

720

Identification of shuttle protein hnRNPA1 as a modulating factor of circulating hepatitis B Virus RNAs release in chronic hepatitis B patients

Poster Presentation

Presenter: Hyoseon Tak

752

Long-read sequencing of HCC samples reveals complete architecture of HBV integrations and chimeric mRNA isoforms associated with oncogenes

Poster Presentation

Presenter: Cameron Soulette

911

Polymorphic analysis of bulevirtide sequence in PreS1 of large HBsAg across HBV genotypes A-H

Poster Presentation

Presenter: Roberto Mateo

916

RIPK1 plays a survival role in the liver of mice with active HDV replication

Poster Presentation

Presenter: Gracian Camps

941

Limited value of HBV-RNA levels for the prediction of relapse after discontinuation of nucleos(t)ide analogue therapy in HBe antigen negative chronic hepatitis B patients

Poster Presentation

Presenter: Valerie Ohlendorf

1024

A versatile small animal immunocompromised model for chronic hepatitis E

Poster Presentation

Presenter: Siddharth Sridhar

1185

Phospho-proteomic analysis of HBV infection revealed novel mechanisms for the regulation of viral transcription and pro-fibrotic stellate cell activation

Oral Presentation

Presenter: Alessia Virzi

1195

Acquisition of positively charged amino acids in HBsAg C-terminus correlates with HBV-induced liver cancer, hampers HBsAg stability and secretion and promotes cell survival

Poster Presentation

Presenter: Lorenzo Piermatteo

1337

PAGE-B and FIB-4 predict the occurrence of hepatocellular carcinoma in HBV patients: a french nationwide cohort study

Poster Presentation

Presenter: Gautier Boillet

1375

High tolerance of hepatitis E virus towards alcohol-based disinfectants

Poster Presentation

Presenter: Patrick BEHRENDT

1384

Multicentre performance evaluation of the Elecsys HCV Duo immunoassay

Poster Presentation

Presenter: Christian Voitenleitner

1418

Intrahepatic transcriptional profiling demonstrates preclinical models of chronic hepatitis B resemble different stages of natural history in humans

Poster Presentation

Presenter: Ricardo Ramirez

1566

Hepatitis B virus splice variants are associated with reduced likelihood of functional cure and differ across phases of chronic hepatitis B infection

Poster Presentation

Presenter: Peter Revill

1606

Understanding acute HCV infection kinetics in humanized mice via an agent-based modeling approach

Poster Presentation

Presenter: Harel Dahari

1630

Presence of sodium taurocholate co-transporting polypeptide and hepatitis B replication markers on placenta: another home for the virus?

Poster Presentation

Presenter: Ashish Kumar Vyas

1648

Exploring dynamic changes in HBcrAg and HBV RNA in e-Antigen negative HBV/HIV patients on antiretroviral therapy: still evidence of integrated activity after 5 years of treatment

Poster Presentation

Presenter: Ruth Byrne

1651

Next-generation sequencing of Swiss HEV isolates allows for reconstitution of functional clones

Poster Presentation

Presenter: Jérôme Gouttenoire

1696

HEC96719, a novel FXR agonist, inhibits HBV infection in vitro and in vivo

Poster Presentation

Presenter: Pu Wang

1731

Combined effect of Vonafexor and Interferon-alpha on HBV replication in primary human hepatocytes

Poster Presentation

Presenter: David Durantel

1791

Hepatitis Delta virus quasispecies conservation and variability in ribozyme region

Poster Presentation

Presenter: Beatriz Pacín Ruiz

1887

Exosomal cargo as a key player of the immune response after direct-acting antiviral treatment in chronic hepatitis C patients

Poster Presentation

Presenter: Ioannis-Georgios Koskinas

1889

Therapeutic suppression of HBV transcripts promotes reappearance of the SMC5/6 complex and cccDNA silencing in vivo without affecting posttranslational modifications of cccDNA-bound histones

Poster Presentation

Presenter: Lena Allweiss

1930

Updated national prevalence estimates of chronic hepatitis B virus infection in countries within the European (EU) and European Economic Area (EEA): a systematic review

Poster Presentation

Presenter: Sandra Bivegete

1958

Relevance of HEV detection in ejaculate of chronically infected patients

Poster Presentation

Presenter: Mathias Schemmerer

2065

HDV-mediated inhibition of HBV in superinfection mouse model: the role of type I Interferon

Poster Presentation

Presenter: Beatriz Pacín Ruiz

2088

Assessment of Myrcludex or heparin antiviral activity on HBV infection using a 3-dimensional primary human hepatocyte culture system

Poster Presentation

Presenter: Juliette Besombes

2380

Concordance of the Xpert hepatitis B viral load test and conventional quantitative PCR in detecting and quantifying viremia using stored plasma and dried blood spot samples in West Africa

Poster Presentation

Presenter: Gibril Ndow

2409

A high-throughput viral integration sequencing method reveals that mitochondrial DNA is frequently targeted by HBV integration

Poster Presentation

Presenter: Teresa Pollicino

2446

Enhanced T cell responses in patients and mouse model of hepatitis B and comorbid non-alcoholic fatty liver disease

Poster Presentation

Presenter: Nishi Patel

2496

Hepatitis B virus sero-prevalence and genotype distribution among pregnant women in Siem Reap, Cambodia

Poster Presentation

Presenter: Bunthen E

2509

Genotype distribution and mutations associated with hepatocellular carcinoma risk among hepatitis B carriers in Goto Islands, Japan

Poster Presentation

Presenter: Serge Ouoba

2579

Comprehensive analysis of the different phases of chronic hepatitis B virus infection

Poster Presentation

Presenter: Michael Basic

2647

Results from a nationwide hepatitis C serosurvey and progress towards HCV elimination in the country of Georgia

Poster Presentation

Presenter: Amiran Gamkrelidze

2903

Human stem cell-derived hepatic and intestinal culture systems to study HEV transmission along the gut-liver axis

Poster Presentation

Presenter: Sarah PRALLET

3077

CD4 T cell immunity to HEV-infection is characterized by sustained capsid-specific responses that correlate with neutralizing antibodies

Oral Presentation

Presenter: Benedikt Csernalabics



3196

Occult hepatitis C infection detection in people who use drugs with or without direct antiviral agents therapy

Poster Presentation

Presenter: Eliane Silva

3208

Hepatitis B viral load variation between the first and third trimesters of pregnancy

Poster Presentation

Presenter: Stuart Gallacher

3316

Discordant serum HBV DNA and RNA correlation with quantitative HBsAg and high levels of intrahepatic integrated HBV DNA in HBeAg negative chronic hepatitis B

Poster Presentation

Presenter: Daryl Lau

3344

A novel class of glycan-specific human monoclonal antibodies neutralizing the hepatitis E virus

Poster Presentation

Presenter: Katja Dinkelborg

3466

Increased lymphocyte trafficking and myeloid activation in patients with chronic hepatitis delta

Poster Presentation

Presenter: Ester García-Pras

3494

Strong correlation between HBsAg, ALT and HDV-RNA levels in patients with chronic hepatitis D. Results of phase 3 D-LIVR study.

Poster Presentation

Presenter: Maria Buti

3520

Hepatitis B virus-replicating transgenic mice exhibit a functional but restricted responsiveness to exogenous Tlr3 and Rig-I stimuli

Poster Presentation

Presenter: Stefan Schefczyk

3598

Profiling at single hepatocyte level indicates variance in viral replication associated with HBeAg status in chronic hepatitis B patients

Poster Presentation

Presenter: Marianne Tuefferd

3617

Greater sequence diversity during early hepatitis B virus decline on vebicorvir plus entecavir is associated with a lower level of virus rebound following switch to entecavir monotherapy

Poster Presentation

Presenter: Kathryn M Kitrinis

3695

Human stem cell-derived hepatocytes as a model for hepatitis D virus infection

Poster Presentation

Presenter: Huanting Chi

3741

Clinical impact of drug interaction in the use of antipsychotics by HCV patients treated with pangenotypic direct-acting antivirals

Poster Presentation

Presenter: Juan Turnes

## Viral hepatitis A/E: Clinical aspects

308

Detection of highly variable RNA-containing viral particles on CNT-based electrochemical impedimetric DNA-nanosensors

Poster Presentation

Presenter: Victor Hryharovich

469

Hepatitis B Delta: assesment of knowledge and practices of French non academic hepato-gastroenterologists

Poster Presentation

Presenter: Jean-François David Cadranel

1089

Hepatitis E seroprevalence in solid organ transplant recipients in Croatia

Poster Presentation

Presenter: Anna Mrzljak

3582

Microarray analysis of virus-specific IgM and IgG antibodies significantly improves the serological diagnosis of hepatitis E virus infection

Poster Presentation

Presenter: David Springer

## Viral hepatitis B/D: Clinical aspects except therapy

119

Detection of notable hepatitis B virus serologic activity after hepatitis B surface antigen seroclearance

Poster Presentation

Presenter: Danny Ka-Ho Wong

176

Comparison of on-treatment ALT or FIB-4 as an on-treatment biomarker of hepatitis B treatment for liver cirrhosis patients

Poster Presentation

Presenter: JOO HYUN OH

301

Liver fibrosis burden determines risk of hepatocellular carcinoma among patients with hepatitis B surface antigen seroclearance

Poster Presentation

Presenter: Lung Yi Loey Mak

334

Estimating the prevalence of hepatitis delta infection among foreign-born adults with chronic hepatitis B in the United States

Poster Presentation

Presenter: Robert Wong

459

Secular trend of the accuracy of hepatocellular carcinoma risk scores in treated chronic hepatitis B patients in 2005-2020: a territory-wide study of 48,706 subjects

Poster Presentation

Presenter: Terry Cheuk-Fung Yip

510

Risk prediction of hepatocellular carcinoma in chronic hepatitis B patients outside current treatment criteria

Poster Presentation

Presenter: Gi-Ae Kim

534

Suboptimal glycemic control is associated with adverse clinical outcomes in patients with chronic hepatitis B and diabetes mellitus

Poster Presentation

Presenter: Lung Yi Loey Mak

661

Statin use and surface antigen loss in patients with chronic hepatitis B

Poster Presentation

Presenter: Shahed Iqbal

662

The discriminatory power of risk scores for hepatocellular carcinoma in treated chronic hepatitis B patients with and without diabetes: a territory-wide study of 48,706 subjects

Oral Presentation

Presenter: Terry Cheuk-Fung Yip

818

Patient engagement in hepatitis B clinical trials: 'HBV cure' is a motivation for participation in all ethnically diverse patients

Poster Presentation

Presenter: Almuthana Mohamed

827

Anti-HDV reflex testing increases the number of hepatitis D cases diagnosed in both academic and community centers

Poster Presentation

Presenter: Adriana Palom

867

HBVoice: a framework to enhance advocacy for patients and communities affected by hepatitis B virus infection

Poster Presentation

Presenter: Philippa Matthews

982

HBeAg-positive patients with HBsAg<135IU/mL or HBcrAg<3.6logU/mL have more chance to be HBsAg loss after nucleos(t)ide analogue cessation

Poster Presentation

Presenter: Yandi Xie

1037

Serum markers of cccDNA transcriptional activity (HBcrAg and pre-genomic HBV RNA) and large HBsAg (LHBs) protein are predicting response to pegylated interferon in HDV infection

Poster Presentation

Presenter: Ivana Carey

1271

A decision-making model for prediction of a stable disease course in chronic hepatitis B patients

Poster Presentation

Presenter: Imri Ofri

1326

Healthcare resource utilization and costs of hepatitis delta in the United States: an analysis of all-payer claims database

Poster Presentation

Presenter: Joseph Lim

1347

Validation of an internal hepatitis D virus DNA quantitative assay: developing assay suitable for global clinical application and clinical trials assessment

Poster Presentation

Presenter: Natalie Bolton

1370

Early increase in HBcrAg levels after peginterferon withdrawal predicts subsequent ALT flares

Poster Presentation

Presenter: Sylvia Brakenhoff

1371

Hepatitis B pre-genomic RNA differentiates HBeAg-negative disease from infection: time to refine disease stages with new biomarkers?

Poster Presentation

Presenter: Bo Wang

1416

Long term persistence of anti-HBs antibodies after vaccination with a 3-antigen HBV vaccine compared to a single-antigen HBV vaccine

Oral Presentation

Presenter: Timo Vesikari

1423

Fatty liver index as a risk factor for all-cause and liver related mortality in patients under therapy for chronic hepatitis B (ANRS CO22 Hepather cohort study)

Oral Presentation

Presenter: Paul Hermabessiere

1436

Evaluating hepatitis delta virus disease prevalence and patient characteristics among adults in the United States: an analysis of all-payer claims database

Poster Presentation

Presenter: Robert G. Gish

1524

Hepatitis delta in Northern Portugal - a long-term follow-up study

Poster Presentation

Presenter: Isabel Garrido

1540

Impact of hepatitis B virus infection on liver-related death among people tested for HBV in British Columbia: results from a large longitudinal population-based cohort study

Poster Presentation

Presenter: Makuza Jean Damascene

1571

Comparable risk of hepatocellular carcinoma between immune-tolerant and active phase in hepatitis B e antigen-positive patients

Poster Presentation

Presenter: Han Ah Lee

1587

Metabolic dysfunction-associated fatty liver disease subgroups and risk of hepatocellular carcinoma and mortality in patients with chronic viral hepatitis

Oral Presentation

Presenter: Mi Na Kim

1646

Evidence of extensive transcriptionally active HBV integrations involving genetic regions crucial for cell proliferation in the setting of HBeAg positive infection

Poster Presentation

Presenter: Romina Salpini

1700

In the setting of HIV-infection, HBV-reactivation is revealed by highly sensitive assays in a conspicuous fraction of anti-HBc-positive/HBsAg-negative patients switching to Tenofovir-sparing therapy

Poster Presentation

Presenter: Stefano D'Anna

1712

Absence of hepatitis B virus (HBV) in at-risk infants receiving early antiretroviral therapy in a cohort of HIV-transmitting mothers in KwaZulu-Natal, South Africa

Poster Presentation

Presenter: Anna McNaughton

1758

Rising clinical and economic burden among hepatitis D patients who attended Spanish hospitals

Poster Presentation

Presenter: Maria Buti

1769

Analysis from national hospital discharge records database in Spain : increased baseline comorbidity burden including liver severity among HDV coinfection versus HBV mono-infection patients

Poster Presentation

Presenter: Maria Buti

1788

Value of intrahepatic HBV markers in virologically suppressed HBV and HDV infected patients

Poster Presentation

Presenter: Ester García-Pras

1793

Hepatitis Delta virus infection in patients with chronic hepatitis B is associated with greater risk of liver disease progression and liver-related mortality: a systematic review and meta-analysis

Poster Presentation

Presenter: Robert G. Gish

1818

The serum markers of cccDNA transcriptional activity have a role in predicting long-term outcomes in children with perinatally acquired HBV infection

Poster Presentation

Presenter: Christiana Moigboi

1875

Presence of liver inflammation and fibrosis in Asian patients with chronic hepatitis B in the grey zone

Poster Presentation

Presenter: Jiacheng Liu

1879

Characteristics and renal function in patients with chronic hepatitis B virus infection: baseline data from the phase 2b B-Clear study

Poster Presentation

Presenter: Seng Gee Lim

1994

Characterisation of baseline complement values in patients with chronic hepatitis B virus infection in the phase IIb B-clear study

Poster Presentation

Presenter: Jennifer Cremer

2073

Estimations of the global prevalence and clinical burden of occult hepatitis B infection (OBI): a systematic review and meta-analysis

Poster Presentation

Presenter: Yu Ri Im

2110

Time for universal screening for hepatitis D? A study describing screening patterns, characteristics and outcomes of hepatitis D virus infection

Poster Presentation

Presenter: Rohit Nathani

2127

Distribution of patients by guideline-defined disease phase and/or grey zones in B-Clear, an international multicentre clinical trial

Poster Presentation

Presenter: Seng Gee Lim

2185

Benign course of HBV reactivations during DAAs in untreated ENI with HBV-HCV co-infections correlates with different HBsAg kinetics compared to NAs treated CHB patients

Poster Presentation

Presenter: Piero Colombatto

2239

Predictors of advanced liver fibrosis in chronic hepatitis B patients in the daily clinical practice

Poster Presentation

Presenter: Fadi Abu Baker

2257

Metabolic associated fatty liver disease is associated with appendicular lean soft tissue abnormalities in patients with chronic hepatitis B

Poster Presentation

Presenter: Luciana Diniz Silva

2259

The course of COVID-19 infection in patients with chronic hepatitis B and Delta

Poster Presentation



Presenter: Onur Keskin

2301

Serum soluble program cell death-1 is predictive of hepatocellular carcinoma in untreated chronic hepatitis B patients

Poster Presentation

Presenter: Rachel Wen-Juei Jeng

2306

Parameters related to ALT elevation in patients with HBeAg negative chronic infection

Poster Presentation

Presenter: Ulus Akarca

2331

Clinical evidence for unconventional hepatitis delta virus infections in endemic countries

Poster Presentation

Presenter: Mary Rodgers

2402

Rapid point-of-care test for hepatitis B core-related antigen (HBcrAg) to identify HBV-infected patients eligible for antiviral therapy

Poster Presentation

Presenter: Yusuke Shimakawa

2449

Prevalence of HBV infection and receiving antiviral treatment for eligible patients in blood relatives from clustering families of HBV infection with unfavorable prognoses and cascading of care linked to treatment in West China

Poster Presentation

Presenter: yuan yang

2534

Liver inflammation in asian chronic hepatitis B patients with detectable HBV-DNA and normal alanine aminotransferase according to diverse upper limits of normal

Poster Presentation

Presenter: Rui Huang

2546

Diversity of circulating HBV genomes and impact on viral infection

Poster Presentation

Presenter: jules sotty

2612

Chronic hepatitis delta with normal ALT and hepatitis D viremia

Poster Presentation

Presenter: SENA ARICI

2628

Hepatitis B virus antigen reduction effect of RO7049389 plus NUC with/without Peg-IFN in chronic hepatitis B patients

Poster Presentation

Presenter: Jinlin HOU

2708

Changes of enhanced liver fibrosis score predict hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral treatment

Poster Presentation

Presenter: Yan Liang

2710

A systematic literature review and meta-analysis of primary sources reporting health state preference values in chronic hepatitis B, C, and D

Poster Presentation

Presenter: Ankita Kaushik

2872

Trends in decompensated cirrhosis and hepatocellular carcinoma diagnosis among people with a hepatitis B notification in New South Wales: a population-based data linkage study

Poster Presentation

Presenter: Syed Hassan Bin Usman Shah

2887

Presence of HbeAg, HBV DNA in cord blood and down regulation of TLR9 may act as predictive marker for HBV mother to child transmission

Poster Presentation

Presenter: Simanta Kalita

2915

Hepatitis B transmission in early life in very remote Aboriginal communities in northern Australia

Poster Presentation

Presenter: Richard Sullivan

2965

Establishment of a new diagnostic model for significant liver tissue damage in patients with chronic hepatitis B virus infection in the immune tolerance phase

Poster Presentation

Presenter: Airong Hu

3018

Hepatitis B core related antigen, not as good as it seems: a critique and systematic review

Poster Presentation

Presenter: Yong Chuan Tan

3121

Point of care screening tests for hepatitis B and commitment of a dedicated nurse lead to successful linkage to care of ethnic minorities

Poster Presentation

Presenter: Axelle Vanderlinden

3175

Prediction of comprehensive prognosis through computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B

Poster Presentation

Presenter: Heejin Cho

3176

Analysis on the normal threshold of alanine aminotransferase level based on liver pathology in patients with chronic hepatitis B

Poster Presentation

Presenter: Airong Hu

3409

Patients with CHD coinfection have greater comorbidities, higher healthcare resource use and costs than CHB monoinfection - results from a Spanish national hospital database

Poster Presentation

Presenter: Maria Buti

3442

Clinical features predictive of cirrhosis in a large cohort of patients with chronic hepatitis delta infection- Insights from the D-LIVR trial

Poster Presentation

Presenter: Ohad Etzion

3704

Provider factors shaping hepatitis delta screening

Poster Presentation

Presenter: Dewan Giri

3755

Prevalence rates and eligibility for antiviral treatment against hepatitis B in Casamance, Senegal

Poster Presentation

Presenter: Victor Arendt

3770

the changing scenario of HBV chronic related disease in the transplant setting

Poster Presentation

Presenter: sara battistella

3792

Comorbidities, and not viral load, are predictors of cirrhosis in AgHBe-negative chronic infection

Poster Presentation

Presenter: Sara Archer

3798

Utilizing phenotyping algorithms as tools for increasing linkage to guideline-concordant care in patients at risk for hepatitis B

Poster Presentation

Presenter: Brooke Wyatt

3820

T cell epitope mapping of hepatitis B virus in chronic infection

Poster Presentation

Presenter: Marie Viuff

3874

The Comparison of tenofovir alafenamide fumarate with tenofovir disoproxil fumarate in preventing hepatitis B transmission in mothers with high viral load: a retrospective cohort study

Poster Presentation

Presenter: Yunxia Zhu

3880

Hepatitis delta virus reflex testing in patients with hepatitis B improves the HDV screening cascade: 10 years of real-world experience from Avicenne University Hospital, France

Poster Presentation

Presenter: Dominique Roulot

## Viral hepatitis B/D: therapy

220

Safety, tolerability and pharmacokinetics of single ascending doses of ALG-020572, a GalNAc-conjugated antisense oligonucleotide, in healthy subjects

Poster Presentation

Presenter: Edward J Gane

253

Predictors of HBsAg loss after cessation of nucleo(s)tide analogue therapy in asian patients with low HBsAg levels

Poster Presentation

Presenter: Milan Sonneveld

296

Sustained 12 week off treatment antiviral efficacy of ATI-2173, a novel active site polymerase inhibitor nucleotide, combined with tenofovir disoproxil fumarate in chronic hepatitis B patients, a phase 2a clinical trial

Oral Presentation

Presenter: Douglas Mayers

298

Improvement of liver-stiffness after 6 months of therapy: real-life data for HBV/HDV co-infected patients treated with bulevirtide

Poster Presentation

Presenter: Alexander Killer

406

Role of plasmatic and urinary TDF and TAF concentration in a cohort of HBV chronic hepatitis patients

Poster Presentation

Presenter: Giacomo Stroffolini

420

Model to predict on-treatment restoration of functional HBV-specific CD8+ cell response foresees off-treatment HBV control in eAg-negative chronic hepatitis B

Poster Presentation

Presenter: Julia Peña Asensio

424

Antiviral treatment cessation in HBeAg negative chronic hepatitis B: clinical outcome is associated with increase in specific pro-inflammatory cytokines

Poster Presentation

Presenter: Marte Holmberg

435

Tenofovir alafenamide for pregnant chinese women with active chronic hepatitis B: a multicenter, prospective, real-world study

Poster Presentation

Presenter: Qing-Lei Zeng

462

Suboptimal virological response to antiviral therapy in chronic hepatitis B as an independent predictor for occurrence of HCC and development of severe liver events

Poster Presentation

Presenter: Chau-Ting Yeh

509

Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary endpoint results from a phase 3 randomized, multicenter, parallel design study

Oral Presentation

Presenter: Heiner Wedemeyer

557

Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta

Poster Presentation

Presenter: Pietro Lampertico

567

Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta

Poster Presentation

Presenter: Pietro Lampertico

583

Virologic response to bulevirtide is delayed in cirrhotic HDV patients with clinically significant portal hypertension

Poster Presentation

Presenter: Mathias Jachs

587

Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide - Results of a "real world study"

Poster Presentation

Presenter: Mathias Jachs

636

HBV RNA levels are associated with virological response to treatment with pegylated interferon alpha in patients with chronic hepatitis D virus infection

Poster Presentation

Presenter: Lisa Sandmann

639

Management of chronic hepatitis B virus infection within a large integrated health care setting: treatment patterns among kaiser permanente members in southern california, 2008 - 2019

Poster Presentation

Presenter: Deborah Malden

644

Longer treatment duration of monthly VIR-2218 results in deeper and more sustained reductions in hepatitis B surface antigen in participants with chronic hepatitis B infection

Oral Presentation

Presenter: Young-Suk Lim

654

Dose-dependent durability of hepatitis B surface antigen reductions following administration of a single dose of VIR-3434, a novel neutralizing vaccinal monoclonal antibody

Poster Presentation

Presenter: Kosh Agarwal

660

Quantification of HBV hepatocyte burden using novel multiplex immunofluorescence staining and image analysis reveals substantial reduction in HBV liver burden with anti-viral treatment

Poster Presentation

Presenter: Pamela Odorizzi

664

GST-HG141 inhibits de novo HBV cccDNA formation in cultured primary human hepatocytes

Poster Presentation

Presenter: Vadim Bichko

674

Predictive factors of virological response at one year in patients with chronic HBV/HDV co-infected treated with Bulevirtide

Poster Presentation

Presenter: Victor de Lédighen

681

Impact of baseline viral load on hepatocellular carcinoma risk during antiviral treatment in non-cirrhotic patients with HBeAg-positive chronic hepatitis B

Poster Presentation

Presenter: Won-Mook Choi

723

Therapeutic vaccination with CLB-3000 in a mouse model of chronic hepatitis B induces anti-HBs responses associated with functional cure

Poster Presentation

Presenter: Aileen Rubio

775

Therapeutic vaccine JNJ-0535 induces a strong HBV-specific T-cell response in healthy adults and a modest response in chronic HBV-infected patients

Oral Presentation

Presenter: An De Creus

776

Evaluation of the disposition and mass balance recovery of vebicorvir, a first generation hepatitis B core inhibitor, in rats and humans

Poster Presentation

Presenter: Katie Zomorodi

778

Effect of tenofovir disoproxil fumarate treatment on intrahepatic viral burden and liver immune microenvironment in chronic hepatitis B patients with minimally elevated serum alanine aminotransferase

Poster Presentation

Presenter: Abhishek Aggarwal

782

Safety, pharmacokinetics, and antiviral activity of the class II capsid assembly modulator ALG-000184 in subjects with chronic hepatitis B

Poster Presentation

Presenter: Man-Fung Yuen

784

Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naïve patients with HBeAg positive chronic hepatitis B

Poster Presentation

Presenter: Mark S Sulkowski

797

Safety, tolerability, pharmacokinetics, and preliminary antiviral activity of the capsid assembly modulator (CAM) ZM-H1505R after multiple escalating oral doses in patients with chronic hepatitis B virus (CHB) infection

Poster Presentation

Presenter: Jiajia Mai



805

ALT flares were linked to HBsAg reduction, seroclearance and seroconversion: interim results from a phase IIb study in chronic hepatitis B patients with 24-week treatment of subcutaneous PD-L1 Ab ASC22 (Envafolimab) plus nucleos(t)ide analogs

Oral Presentation

Presenter: Guiqiang Wang

832

Evaluation of renal and bone safety at 4 years in post-liver transplant patients with chronic kidney disease receiving Tenofovir Alafenamide for HBV prophylaxis

Poster Presentation

Presenter: Edward J Gane

868

Functional cure based on pegylated interferon alpha therapy in nucleoside analog-suppressed HBeAg negative chronic hepatitis B: a multicenter real-world study (Everest Project in China) - 3.5 years data update

Poster Presentation

Presenter: Chan Xie

888

Efficacy and safety of finite 48-week treatment with the siRNA JNJ-3989 and the capsid assembly modulator (CAM-N) JNJ-6379 in HBeAg negative virologically suppressed (VS) chronic hepatitis B (CHB) patients: results from REEF-2 study

Oral Presentation

Presenter: Kosh Agarwal

891

Understanding the dynamics of HBsAg decline through model-informed drug development (MIDD) of JNJ-3989 and JNJ-6379 for the treatment of chronic hepatitis B virus infection (CHB)

Poster Presentation

Presenter: Huybrecht T'jollyn

902

Serum HBsAg and ddPCR HBV-DNA as predictive parameters of HBsAg loss after nucleo(s)tide analogue (NA) treatment discontinuation in non-cirrhotic patients with chronic hepatitis B

Poster Presentation

Presenter: Anna Francesca Guerra

907

Exploring hepatitis B virus as an immunotherapeutic target for clinical trials of adoptively transferred T cells

Poster Presentation

Presenter: Spyridoula Vasileiou

915

Treatment with Bulevirtide in patients with chronic HBV/HDV co-infection. Safety and efficacy at month 18 in real-world settings

Poster Presentation

Presenter: Victor de Lédighen

917

Two-year safety and efficacy of tenofovir alafenamide in chronic hepatitis B: a Hellenic multicenter ReAl-life CLInical Study (HERACLIS-TAF)

Poster Presentation

Presenter: George Papatheodoridis

930

Treatment of chronic hepatitis B in sub-saharan Africa: 5-year results of a pilot program in Ethiopia

Poster Presentation

Presenter: Asgeir Johannessen

961

Decrease in the burden of integrated hepatitis B virus DNA in chronic hepatitis B patients with minimally elevated alanine aminotransferase on tenofovir disoproxil fumarate as revealed by long-read DNA-sequencing

Poster Presentation

Presenter: David Pan

1091

Serum HBV RNA levels are associated with risk of hepatitis flare after stopping NA therapy in HBeAg-negative patients

Poster Presentation

Presenter: Kathy Jackson

1140

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naive patients with chronic hepatitis B

Poster Presentation

Presenter: Jihye Lim

1196

Bulevirtide 2 mg/day monotherapy in patients with chronic hepatitis delta with or without cirrhosis: a multicenter european cohort real-life study

Poster Presentation

Presenter: Alessandro Loglio

1226

The orally available sodium/taurocholate co-transporting polypeptide inhibitor A2342 blocks hepatitis B and D entry in vitro

Poster Presentation

Presenter: Britta Bonn

1242

Comparative performance analysis between manual and automatic RNA extraction to quantify HDV RNA by RoboGene 2.0 kit in untreated and bulevirtide-treated HDV patients

Poster Presentation

Presenter: Sara Colonia Uceda Renteria

1318

Combination therapy in HBeAg-negative chronic hepatitis B patients with low-level viremia to nucleos(tide) analogues

Poster Presentation

Presenter: Shan Ren

1352

ABI-4334, a novel inhibitor of hepatitis B virus core protein, promotes formation of empty capsids and prevents covalently closed circular DNA formation by disruption of incoming capsids

Poster Presentation

Presenter: Kathryn M Kitrinis

1369

Real-world high adherence to hepatitis B antiviral treatment practice guidelines in Israel

Poster Presentation

Presenter: Yana Davidov

1382

Real life study of bulevirtide in chronic hepatitis delta: preliminary results of the ANRS HD EP01 BuleDelta prospective cohort

Oral Presentation

Presenter: Helene Fontaine

1406

No detectable resistance to bulevirtide in participants with chronic hepatitis D (CHD) through 24 weeks of treatment

Poster Presentation

Presenter: Julius Hollnberger

1410

The HBV siRNA, ALG-125755, demonstrates a favourable nonclinical profile and significant and durable hepatitis B surface antigen reductions in the AAV-HBV mouse efficacy model

Poster Presentation

Presenter: Megan Fitzgerald

1456

Hepatitis delta management in the United States: an analysis of all-payer claims database

Poster Presentation

Presenter: Robert Wong

1461

Evaluation of the drug-drug interaction profile of vebicorvir, a first-generation hepatitis B core inhibitor: findings from phase 1 and phase 2a studies

Poster Presentation

Presenter: Katie Zomorodi

1473

Improving the pharmacokinetic profile of the hepatitis B virus core inhibitor ABI-H3733 following oral administration: results from new formulation activities

Poster Presentation

Presenter: Michael Shen

1491

EDP-514, a novel pangenotypic class II hepatitis B virus core inhibitor: final results of a 28-day phase 1b study in nuc-suppressed chronic hepatitis B patients

Poster Presentation

Presenter: Jordan Feld

1508

Preclinical activity of small-molecule oral PD-L1 checkpoint inhibitors capable of reinvigorating T cell responses from chronic hepatitis B patients

Poster Presentation

Presenter: Emily P. Thi

1509

Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB)

Poster Presentation

Presenter: Edward J Gane

1511

EDP-514, a potent pangenotypic class II hepatitis B virus core inhibitor, demonstrates significant HBV DNA and HBV RNA reductions in a phase 1b study in viremic, chronic hepatitis B patients

Poster Presentation

Presenter: Man-Fung Yuen

1519

Increased HBsAg reduction and relapse outcomes in HBeAg negative patients with chronic hepatitis B after nucleos(t)ide analogue withdrawal: 4.5 year follow up of the Toronto STOP Study

Poster Presentation

Presenter: Arif Sarowar

1530

Pharmacodynamics of durable HBsAg suppression by AB-729 short interfering RNA correlates with pharmacokinetics of RNA-induced silencing complex (RISC) loading within liver

Poster Presentation

Presenter: Emily P. Thi

1537

Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 is associated with increased cytokine signatures in HBV DNA+ chronic hepatitis B patients

Poster Presentation

Presenter: Sharie C Ganchua

1543

Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells

Poster Presentation

Presenter: Emily P. Thi

1555

Characterizing of hepatitis B virus serum RNA kinetics during TDF plus pegylated interferon alfa-2a with and without nucleic acid polymers

Poster Presentation

Presenter: Harel Dahari

1567

Early antiviral efficacy of tenofovir alafenamide fumarate in the initial treatment of chronic hepatitis B patients with normal ALT

Poster Presentation

Presenter: Xin Chi

1615

Viral and ALT kinetics after nucleos(t)ide analogue withdrawal among patients who remain off-therapy: results from a global, multi-ethnic cohort of chronic hepatitis B patients (RETRACT-B study)

Poster Presentation

Presenter: Grishma Hirode

1627

Discovery of oral PDL1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis B

Poster Presentation

Presenter: Francois Gonzalvez

1628

Incorporation of novel ASO chemistries significantly improves the potency and durability of HBV ASOs in the AAV-HBV mouse model

Poster Presentation

Presenter: Jin Hong

1662

Induction of pre-s antibodies in HBeAg negative chronic hepatitis B patients by therapeutic vaccination with the pre-s based vaccine VVX001 - interim analysis

Poster Presentation

Presenter: Petra Munda

1766

HEC121120, a novel allosteric modulator of HBV core protein demonstrates potent antiviral activities in vitro and in vivo

Poster Presentation

Presenter: qingying lai

1850

Evaluation of quantitative HBsAg levels in chronic hepatitis B - a targeted literature review

Poster Presentation

Presenter: Vera Gielen

1904

Lonafarnib combination with peginterferon Lambda diminished triphasic HDV kinetic pattern seen under Lambda monotherapy: the LIFT HDV study

Oral Presentation

Presenter: Harel Dahari

1920

Nucleoside/nucleotide analogues monotherapy is safe and efficient for the prevention of HBV flare-ups after liver transplantation in the long term

Poster Presentation

Presenter: Orly Sneh Arbib

1942

A new method to identify co-variation in hepatitis B virus whole genome sequences identifies networks of polymorphisms associated with drug resistance

Poster Presentation

Presenter: Philippa Matthews

2025

Baseline bile acid levels but not bile acid increases during bulevirtide treatment of hepatitis D are associated with HDV RNA decline

Poster Presentation

Presenter: Katja Deterding

2031

Low levels of qHBsAg and tenofovir therapy are associated with successful treatment withdrawal in HBeAg negative chronic hepatitis B: results from spanish multicentric study

Poster Presentation

Presenter: Anna Pocerull

2043

Preliminary results of the effectiveness and safety of Tenofovir Adefovir Fumarate prophylaxis in HBV-infected individuals, who received chemo/immunosuppressive therapy

Poster Presentation

Presenter: FEYZA GUNDUZ

2069

Real life efficacy, renal and lipid profile data of tenofovir alafenamide in switched chronic hepatitis B patients

Poster Presentation

Presenter: Fehmi Tabak

2072

Mathematical modeling of HDV RNA kinetics suggests high peginterferon Lambda efficacy in blocking viral production: insights from the LIMIT-1 study

Poster Presentation

Presenter: Harel Dahari

2086

Heterologous prime-boost immunotherapy circumvents tolerance and induces broadly neutralizing antibodies that protects against hepatitis B and D co-infection and hepatitis D super-infection

Poster Presentation

Presenter: Lars Frelin

2091

Real-world data on treatment with bulevirtide in patients with chronic hepatitis B and D coinfection

Poster Presentation

Presenter: Toni Herta

2105

Higher rates of virological relapse after nucleos(t)ide analogue withdrawal in HBeAg-negative versus positive chronic hepatitis B patients: results from a global, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B Study)

Poster Presentation

Presenter: Grishma Hirode

2161

Real life efficacy and tolerability of Tenofovir alafenamide fumarate in liver transplant recipients: a multicenter study

Poster Presentation

Presenter: Suna Yapali

2177

Impact of patient-related factors on the pharmacokinetics of Bulevirtide

Poster Presentation

Presenter: Renu Singh

2215

Reduction of liver stiffness in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study

Poster Presentation

Presenter: Heejin Cho

2275

Toll-like receptor 8 agonism activates monocytes and induces antiviral cytokine production by T-cells in HIV and chronic hepatitis B coinfection

Poster Presentation

Presenter: Lydia Tang

2291

Hepatocellular carcinoma incidence is reduced in cirrhotic chronic hepatitis B patients with HBsAg seroclearance comparing to those with viral suppression

Oral Presentation

Presenter: Rachel Wen-Juei Jeng

2524

Comparison of body weight and lipid profiles following tenofovir disoproxil fumarate or entecavir switching to tenofovir alafenamide - an interim analysis



Poster Presentation

Presenter: Pin-Nan Cheng

2581

Real life efficacy and tolerability of Tenofovir Alafenamide Fumarate in patients with hepatitis-B virus-related cirrhosis

Poster Presentation

Presenter: Suna Yapali

2626

Viral nucleic acids suppression activity of RO7049389 plus NUC with/without Peg-IFN in virologically-suppressed and naive chronic hepatitis B patients: 48-week treatment and post-treatment follow up

Poster Presentation

Presenter: Man-Fung Yuen

2746

Generation and functional analysis of spacer modified HBV-specific chimeric antigen receptors that harbor a Fab fragment as binding domain

Poster Presentation

Presenter: Zhe Xie

2759

Safety, pharmacokinetics and antiviral activity of GST-HG141, a hepatitis B virus capsid assembly modulator, in subjects with chronic hepatitis B

Poster Presentation

Presenter: Vadim Bichko

2875

Low level of HBcrAg is beneficial to functional cure obtained with pegylated interferon therapy in inactive HBsAg carriers

Poster Presentation

Presenter: Zhenhuan Cao

2879

Randomised double-blind study of nitazoxanide for virologically suppressed HBeAg negative chronic Hepatitis B

Poster Presentation

Presenter: Yong Chuan Tan

2904

Comparative risk of hepatocellular carcinoma in patients with chronic hepatitis B receiving tenofovir- or entecavir-based regimens: a meta-analysis using individual patient data

Poster Presentation

Presenter: Young-Suk Lim

3009

VIR-2218 plus VIR-3434 combination therapy reduces hepatitis B virus surface antigen levels in vivo

Poster Presentation

Presenter: Julia Noack

3011

Most patients with advanced cirrhosis treated with bulevirtide monotherapy have a non-monophasic HDV RNA decline patterns: an interim kinetic analysis of real-life setting

Poster Presentation

Presenter: Harel Dahari

3044

Bulevirtide avoids future clinical events and related costs compared to pegylated-interferon alpha in chronic hepatitis D in Spain

Poster Presentation

Presenter: Maria Buti

3048

Randomized, double-blind, placebo-controlled trial of Tenofovir Alafenamide in children and adolescents with chronic hepatitis B

Poster Presentation

Presenter: Kathleen Schwarz

3075

Safety, pharmacokinetics, and antiviral activity of the S-antigen Transport Inhibiting Oligonucleotide Polymers (STOPS) drug candidate ALG-010133 in subjects with chronic hepatitis B

Poster Presentation

Presenter: Edward J Gane

3097

Tenofovir alafenamide fumarate increased lipid levels in hepatitis B virus patients

Poster Presentation

Presenter: Wenjuan Zhao

3098

Predictors of sustained response in hepatitis B surface antigen-negative patients after peginterferon therapy: an observational study

Poster Presentation

Presenter: Jun Chen

3117

Quantitative HBsAg(qHBsAg) as an endpoint to stop nucleos(t)ide analogues in chronic hepatitis B: a meta-analysis with meta-regression

Poster Presentation

Presenter: Seng Gee Lim

3167

Improved treatment response and bone density in patients with chronic hepatitis B (CHB) switched to tenofovir alafenamide (TAF) from other nucleos(t)ide analogue: 96-week results from a prospective multinational study

Poster Presentation

Presenter: Eiichi Ogawa

3189

Costimulation of CD40 and type-I interferon immune pathways by a bifunctional molecule in HBV infection models and healthy non-human primates

Poster Presentation

Presenter: Xavier Marniquet

3199

Low-level viremia in patients with chronic hepatitis B receiving entecavir, tenofovir and tenofovir alafenamide

Poster Presentation

Presenter: xiaohao Wang

3237

Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks

Oral Presentation

Presenter: Maria Buti

3278

The discovery of AMS-I-1274, a high potent and orally active capsid-assembly modulator against hepatitis B virus

Poster Presentation

Presenter: Jung-Hee Kim

3328

Phase 1b/2a study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) combined with low-dose nivolumab (LDN) in virally-suppressed patients with CHB on nucleos(t)ide analogues

Poster Presentation

Presenter: Eleanor Barnes

3331

IMC-1109V, a novel T cell receptor (TCR) bispecific (ENVxCD3) designed to eliminate HBV-infected hepatocytes in chronic HBV patients: initial data from a first-in-human study

Poster Presentation

Presenter: Stefan Bourgeois

3332

Bulevirtide monotherapy for 48 weeks in HDV patients with compensated cirrhosis and clinically significant portal hypertension

Poster Presentation

Presenter: Elisabetta Degasperi

3343

Off-therapy cure of hepatitis delta after 3 years of bulevirtide monotherapy in a patient with compensated advanced cirrhosis

Poster Presentation

Presenter: Maria Paola Anolli

3393

Continued suppression of viral markers observed following discontinuation of nucleos(t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729

Poster Presentation

Presenter: Man-Fung Yuen

3414

Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects

Poster Presentation

Presenter: Man-Fung Yuen

3512

Long-term outcomes after cessation of antiviral therapy in HBeAg negative patients

Poster Presentation

Presenter: Rachel Wen-Juei Jeng

3578

Identification of novel antivirals against hepatitis delta virus infection via high throughput screening

Poster Presentation

Presenter: Eirini Tseligka

3590

Combination treatment of a PAPD5/7 inhibitor with an antisense oligonucleotide bepirovirsen with concurrent dosing shows additive HBsAg decreases in the AAV-HBV mouse model

Poster Presentation

Presenter: Martin Leivers

3592

Mechanistic pharmacokinetics/pharmacodynamics modelling of the simultaneous effects of bepirovirsen on hepatitis B surface antigen and alanine transaminase changes in chronic hepatitis B patients: phase 2b analysis to inform phase 3 decision-making

Poster Presentation

Presenter: Ahmed Nader

3595

Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection not on stable nucleos(t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study

Poster Presentation

Presenter: Seng Gee Lim

3611

Effects of the siRNA JNJ-3989 and/or the capsid assembly modulator (CAM-N) JNJ-6379 on viral markers of chronic hepatitis B (CHB): results from the REEF-1 study

Poster Presentation

Presenter: Man-Fung Yuen

3629

Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection on stable nucleos(t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study

Poster Presentation

Presenter: Man-Fung Yuen

3635

Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via Toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study

Poster Presentation

Presenter: Shihyun You

3827

Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience

Poster Presentation

Presenter: Katja Deterding

3832

Challenges with the cascade of HDV care in Mongolia

Poster Presentation

Presenter: Nandintsetseg Tsoggerel

## Viral hepatitis C: Clinical aspects except therapy

252

Active case management to connect hepatitis C notifications to care and treatment in Australia (CONNECT study), a randomised controlled trial

Poster Presentation

Presenter: Tafireyi Marukutira

589

Find out HCV patients: systematic study of 2013-2020 HCV files of a MDT viral hepatitis expert unit on the future of patients has made it possible to find out the lost ones and put them into treatment

Poster Presentation

Presenter: André-Jean Remy

751

Effectiveness of a central monitoring system for the continuum of care of hepatitis C in Brazil during COVID-19 pandemic

Poster Presentation

Presenter: Paulo Bittencourt

753

Retrieval of HCV patients lost to follow-up as a strategy as a strategy for hepatitis C microelimination: results of a brazilian multicentric study

Poster Presentation

Presenter: Paulo Bittencourt

834

Reorganizing and simplifying HCV diagnosis and treatment in special populations during COVID pandemic and beyond

Poster Presentation

Presenter: Paolo Scivetti

860

The health economic outcomes of trial ACTG5360/MINMON

Poster Presentation

Presenter: Benjamin Linas

905

Hepatitis C treatment during the COVID-19 pandemic has similar efficacy with less resource utilization: analysis from the British Columbia HCV network

Poster Presentation

Presenter: Shirley Jiang

928

ELIMINATE - interim results of an Austrian HCV macro-elimination project

Poster Presentation

Presenter: Caroline Schwarz

937

The Korean hepatitis C virus care cascade in a tertiary institution: current status and changes in testing, link to care, and treatment

Poster Presentation

Presenter: Jonggi Choi

966

Macroeconomic assessment of overall and per-patient healthcare costs of Hepatitis C-infected patients in an integrated health system in the era of direct-acting antiviral therapy

Poster Presentation

Presenter: David Kaplan

970

Awareness of chronic hepatitis B and C among men who have sex with men (MSM): epidemiological survey and on-site screening

Poster Presentation

Presenter: Marie Coessens

1063

Predictive factors for lost to follow-up pre and post-hepatitis C treatment: data from the British Columbia hepatitis C virus network

Poster Presentation

Presenter: Alnoor Ramji

1183

HCV screening in a tertiary French hospital : just do it !

Poster Presentation

Presenter: Si Nafa Si Ahmed

1258

Hepatitis C screening rates by age cohort 1945-1965 in a large community health system before, during and after the COVID pandemic

Poster Presentation

Presenter: David Bernstein

1396

Maximizing the potential of Cepheid, GeneXpert PCR rapid testing for hepatitis C through use of finger prick blood samples collected into EDTA capillary tubes

Poster Presentation

Presenter: Anam Choudhry

1446

Healthcare resource utilization in treatment-naïve patients with compensated cirrhosis receiving 8-weeks' glecaprevir/pibrentasvir stratified by drug use and socioeconomic status: a retrospective chart review

Poster Presentation

Presenter: Francisco Jorquera

1649

Progress towards hepatitis C elimination: the feasibility and success of a nurse and harm reduction practitioner led model of care utilising rapid point of care HCV RNA testing at a medically supervised injecting room in Melbourne, Australia

Poster Presentation

Presenter: Michael Maclsaac

1804

Results of a ten year prospective observational study on acute hepatitis C in HCV-mono- and HIV/HCV-coinfected patients

Oral Presentation

Presenter: Christiana Graf

1814

Screening for hepatitis C in Denmark - the effect of a mobile outreach intervention

Poster Presentation

Presenter: Sandra Droese

1967

Screening for HCV infection combined with SARS-CoV-2 vaccination in the Campania region

Poster Presentation

Presenter: Pietro Torre

2120

Treating children with HCV close to home through a virtual national multidisciplinary network

Poster Presentation

Presenter: Deirdre Kelly

2143



Association of sustained virologic response with measures of direct-acting antiviral adherence in patients with Hepatitis C: data from the ASCEND and ANCHOR investigations

Poster Presentation

Presenter: Sarah Kattakuzhy

2159

ATA haplotype of the interleukin-10 gene and low phase angle are associated with liver cirrhosis in chronic hepatitis C

Poster Presentation

Presenter: Nataly Lopes Viana

2184

Use of Glecaprevir/Pibrentasvir (G/P) for the treatment of HCV infection among fentanyl users: an interim analysis of the GRAND PLAN study

Poster Presentation

Presenter: Brian Conway

2242

Indigenous methodologies in practice through community engagement and telehealth outreach increase hepatitis C access to care in Alberta, Canada

Poster Presentation

Presenter: Kate Dunn

2329

Implication of metabolic associated fatty liver disease and sex differences in the risk of developing liver fibrosis in patients with Hepatitis C

Poster Presentation

Presenter: Martín Uriel Vázquez Medina

2358

Micro-eliminating hepatitis C in a network of 47 English Prisons through an industry, prison healthcare and patient organisation partnership

Poster Presentation

Presenter: Andrew Jones

2394

The 'Viennese epidemic' of acute HCV in the era of direct-acting antivirals

Poster Presentation

Presenter: David JM Bauer

2466

Approaches for a hepatitis C-free city: preliminary results

Poster Presentation

Presenter: Manuel Romero Gomez

2552

Success of a peer-led community based model of hepatitis C treatment support for marginalised populations

Poster Presentation

Presenter: Binta Sultan

2611

Impact of hepatitis C virus point-of-care (PoC) viral load assay compared to laboratory-based assays on uptake of testing and treatment, and turnaround times: a systematic review and meta-analysis

Poster Presentation

Presenter: Adam Trickey

2617

Diagnostic accuracy of point-of-care HCV viral load assays for HCV diagnosis: a systematic review and meta-analysis

Poster Presentation

Presenter: Weiming Tang

2622

Hepatitis-C virus viral load reflex testing following an initial positive HCV antibody test: a global systematic review and meta-analysis

Poster Presentation

Presenter: Weiming Tang

2716

HCV-viral load fingerstick assay to simplify screening and linkage to care of people who use drugs attending Italian addiction treatment centres

Poster Presentation

Presenter: Sarah Vecchio

2880

Liver-related mortality among people with hepatitis B and C: a validation study using linked healthcare administrative datasets

Poster Presentation

Presenter: Syed Hassan Bin Usman Shah

3058

From extensive to intensive screening, co-operations model of hepatitis C elimination in out-patients and people who inject drug population in southwest of China

Poster Presentation

Presenter: Qing Lin

3666

A cluster randomized controlled study of secondary distribution of HCV self-test to support micro-elimination in Karachi, Pakistan.

Poster Presentation

Presenter: Saeed Sadiq Hamid

3675

Using time to positivity of hepatitis rapid detection test results to determine active viremia

Poster Presentation

Presenter: Saeed Sadiq Hamid

3689

Identifying risk factors associated with hepatitis C virus infection in participants in the national health and nutrition examination survey using Super Learner

Poster Presentation

Presenter: Laura Telep

3772

Finding cases of hepatitis C for treatment using automated screening in the emergency department is effective, but what is the cost?

Poster Presentation

Presenter: David Prince

3857

Sex effect on key intrahepatic gene networks in hepatitis C virus infection

Poster Presentation

Presenter: Emanuele Marchi

## Viral Hepatitis C: Post SVR and long term follow up

77

Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis

Poster Presentation

Presenter: Ian Lockart

371

Glycomics-based serum marker as reliable tool for assessment of viral response after treatment with direct-acting antiviral drugs in hepatitis C virus infection

Poster Presentation

Presenter: Nicky Somers

397

Post-treatment elevated gamma-glutamyl transferase is the best predictor for future outcomes in HCV patients achieving sustained virological response - data from the German Hepatitis C-Registry (DHC-R)

Poster Presentation

Presenter: Stefan Mauss

506

The impact of liver function improvement after direct-acting antiviral therapy on the outcome in hepatitis C virus patients with decompensated cirrhosis

Poster Presentation

Presenter: Yuki Tahata

702

De-novo occurrence of portal vein thrombosis in patients with HCV-related cirrhosis after sustained virological response: medium to long term observations from the ongoing PITER cohort

Poster Presentation

Presenter: Loreta Kondili

835

Suboptimal follow-up, high re-infection, and drug-related death, among HCV-treated people who inject drugs in Tayside, Scotland

Poster Presentation

Presenter: Christopher Byrne

981

Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study

Poster Presentation

Presenter: Joanne Carson

1061

Five-years follow-up of cured HCV patients with or without cirrhosis under real-world interferon-free therapy

Poster Presentation

Presenter: Robert Flisiak

1074

Clearance of hepatitis C virus infection did not ameliorate the response to hepatitis B vaccine

Poster Presentation

Presenter: Ebada Said

1225

Reverse Inflammaging: biological age is accelerated in chronic HCV patients and decelerates after HCV cure

Poster Presentation

Presenter: Carlos Oltmanns

1283

Overall mortality in patients with chronic hepatitis C: major effects of social vulnerability, tobacco smoking, and history of unhealthy alcohol use (ANRS CO22 HEPATHER cohort)

Poster Presentation

Presenter: Carrieri Patrizia

1312

Is routine Ribavirin mandatory for genotype 3 hepatitis C compensated cirrhosis patients receiving Sofosbuvir/Velpatasvir? A meta-analysis

Poster Presentation

Presenter: Jing Hong Loo

1364

High frequency of hepatitis C virus reinfection following antiviral treatment in the North East of England

Poster Presentation

Presenter: Sumar Askar

1392

Incidence and risk factors of hepatitis C liver morbidity and mortality in the era of direct-acting antiviral therapies: a population-based linkage study

Poster Presentation

Presenter: Maryam Alavi

1674

Direct acting antiviral agents improve survival in patients with hepatitis C virus related hepatocellular carcinoma

Poster Presentation

Presenter: Hyun Young Woo

1853

Lack of Alpha-fetoprotein reduction after successful Hepatitis C treatment in patients with cirrhosis predicts the development of hepatocellular carcinoma during surveillance - a single unit real-world experience

Poster Presentation

Presenter: Aoife Alvain

1860

Patients with chronic HCV and decompensated cirrhosis are at risk for MELD purgatory

Poster Presentation

Presenter: Lisette Krassenburg

1877

The long-term effect of Hepatitis C eradication by direct-acting antivirals on patient's mood and quality of life as determined by the Beck's Depression Inventory and EQ5D Quality of Life questionnaires - a single unit study

Poster Presentation

Presenter: Aoife Alvain

1912

Assessing sustained virological response and reinfection from dried blood spots within an on-site hepatitis C diagnosis and treatment model of care in a harm reduction centre

Poster Presentation

Presenter: Sabela Lens

1963

Hepatitis C virus (HCV)-specific T cell confer resistance to HCV re-infection after sustained virologic response in a non-cytolytic fashion among people who inject drugs: results from ANCHOR study

Poster Presentation

Presenter: Arshi Khanam

2038

Lack of fibrosis remodelling in chronic hepatitis C post SVR, as demonstrated by YKL-40, is predictive of hepatocellular carcinoma occurrence

Poster Presentation

Presenter: Maria Guerra Veloz

2039

HCV reinfection associated with IDU and cocaine use in a cohort of people with OUD: 4 Year follow-up data from the ANCHOR cohort

Poster Presentation

Presenter: Elana Rosenthal

2055

Noninvasive prediction of hepatocellular carcinoma development after oral antiviral therapy in patients with chronic hepatitis C: a multicenter study

Poster Presentation

Presenter: Yu Rim Lee

2136

Sustained low prevalence of HCV viremia among people who inject drugs following the treatment as prevention for hepatitis C (TraP HepC) nationwide elimination program in Iceland

Poster Presentation

Presenter: Magnús Gottfredsson

2209

Direct-acting antiviral treatment in Albanian patients with chronic hepatitis C and advanced liver fibrosis

Poster Presentation

Presenter: Liri Cuko

2214

Improved recurrence-free survival rates in patients with HCV-related hepatocellular carcinoma and sustained virological response to direct-acting antivirals

Poster Presentation

Presenter: Anca Trifan

2245

Long-term outcomes associated with task-shifting of HCV treatment by non-specialist providers: five year follow-up from the ASCEND cohort

Poster Presentation

Presenter: Sarah Kattakuzhy

2305

Risk stratification of hepatocellular carcinoma in cirrhotic patients after hepatitis C virus eradication: russian single - center experience

Poster Presentation

Presenter: Ekaterina Nabatchikova

2321

Distinct hepatocellular carcinoma risks in treated chronic hepatitis C patients with different definitions of advanced chronic liver disease

Poster Presentation

Presenter: Yen-Chun Liu

2323

Hepatocellular carcinoma risks of liver fibrosis changes after viral eradication in chronic hepatitis C patients

Poster Presentation

Presenter: Yen-Chun Liu

2363

Change in fibrosis and clinical progression three years after sustained virological response induced by direct antiviral agents in HIV/HCV subjects

Poster Presentation

Presenter: Maria Carnevali Frias

2517

FOCUS Project: preliminary results toward hepatitis C Virus screening and elimination in Almería, Spain

Poster Presentation

Presenter: Marta Casado

2676

Analysis of liver event-free survival in patients with advanced liver fibrosis or cirrhosis due to hepatitis C virus 5 years after infection cure with direct-acting antivirals

Poster Presentation

Presenter: Miriam Celada-Sendino

2838

Excess mortality risk among hepatitis C patients after being "cured" in the interferon-free era: results from three population-based cohorts

Oral Presentation

Presenter: Victoria Hamill

2929

Usefulness of longitudinal assessment of AFP in DAA cured HCV cirrhotic patients to predict the development of HCC

Poster Presentation

Presenter: Angelo Sangiovanni

3775

A 4 year multi-centre study of persons who inject drugs in Luxembourg, looking at hepatitis C virus seroprevalence, treatment uptake and reinfection rates

Poster Presentation

Presenter: Madiha Sharaf

## Viral hepatitis C: Therapy and resistance

60

Dismal prognosis for cirrhotic HCV patients after initial DAA treatment failure, rescue therapy may be life-saving

Poster Presentation

Presenter: Johan Westin

425

Requests for drug-drug interaction data on direct-acting antivirals and enzyme inducing anti-epileptic agents: an overview of the HEP Interaction checker database of the University of Liverpool



Poster Presentation

Presenter: David Burger

555

Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset

Poster Presentation

Presenter: Alessandra Mangia

809

Sofosbuvir plus velpatisvir for 8 weeks in patients with acute hepatitis C: multicenter, single arm, phase 2 study (The HepNet acute HCV-V study)

Poster Presentation

Presenter: Benjamin Maasoumy

822

Full-length genome characterization of inherently resistant african HCV genotype 1, subtype 1I in patients failing DAA-based therapy

Poster Presentation

Presenter: Slim Fourati

828

Treating HCV in dual diagnosis acute psychiatric inpatients with substance use disorder

Poster Presentation

Presenter: vera dreizin

852

Eight-weeks of glecaprevir/pibrentasvir is well tolerated and yields high sustained virological response in HCV-infected treatment-naive patients with compensated cirrhosis: the CREST study

Poster Presentation

Presenter: Markus Cornberg

925

Glecaprevir/pibrentasvir and sofosbuvir for 16 weeks without ribavirin is safe and highly effective retreatment for patients who have failed an NS5A inhibitor containing antiviral regimen

Oral Presentation

Presenter: Edward J Gane

971

HCV-RNA viral load fingerstick assay as a simplified strategy for screening and linkage to care of people who use drugs attending 3 french addiction centers

Poster Presentation

Presenter: Denis Ouzan

1062

Pangenotypic and genotype-specific antivirals in the treatment of genotype 4 infected patients with HIV coinfection

Poster Presentation

Presenter: Dorota Zarębska-Michaluk

1194

Long-term follow-up of HCV resistance-associated substitutions after DAA treatment failure

Poster Presentation

Presenter: Julia Dietz

1228

Real-life effectiveness and safety of sofosbuvir/velpatasvir in difficult to treat hepatitis C patients

Poster Presentation

Presenter: Hyun Young Woo

1381

Polypharmacy and prevalence of multi drug-drug interactions in hepatitis C patients treated with pangenotypic direct acting antivirals: an analysis from three European countries

Poster Presentation

Presenter: Frank Tacke

1430

Use of comedication in patients with hepatitis C and addiction or drug abuse treated with direct acting antivirals: implication in drug-drug interactions

Poster Presentation

Presenter: Juan Turnes

1440

Five years of progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-October 2021

Poster Presentation

Presenter: Tengiz Tsertsvadze

1551

Simplifying mathematical-based response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients

Poster Presentation

Presenter: Harel Dahari

1565

Epidemiology of hepatitis B virus infection among hepatitis C (HCV) infected patients treated within HCV elimination program in Georgia

Poster Presentation

Presenter: Senad Handanagic

1713

Direct-acting antivirals and the risk of hepatitis B reactivation in hepatitis B and C coinfecting patients: a systematic review and meta-analysis

Poster Presentation

Presenter: JOO HYUN OH

1740

Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents (DAA)

Oral Presentation

Presenter: Christiana Graf

1838

Inhibition of high fitness viruses by different antiviral strategies when the infection has started

Poster Presentation

Presenter: Carlos García-Crespo

1862

Treatment of hepatitis C in primary healthcare in the country of Georgia

Poster Presentation

Presenter: Tengiz Tsertsvadze

1957

Multicenter prospective study for the use of shortened pre-emptive therapy with Glecaprevir/Pibrentasvir (G/P) and Ezetimibe in hepatitis C (HCV) seronegative non-liver solid organ transplant recipients of HCV viremic grafts

Oral Presentation

Presenter: Bashar Aqel

1984

Optimal screening and linkage to care model to achieve hepatitis C elimination targets in Georgia

Poster Presentation

Presenter: Tengiz Tsertsvadze

2174

Establishing a protocol for management and DAA treatment of HCV during pregnancy: adherence to a co-located care protocol

Poster Presentation

Presenter: Tatyana Kushner

2190

Sofosbuvir/Velpatasvir (S/V) for the treatment of HCV infection among vulnerable inner-city residents: extending the results of clinical trial

Poster Presentation

Presenter: Brian Conway

2227

High Intensity Test and Treat (HITT): an overview of the initiative as part of the hepatitis C elimination programme in England

Oral Presentation

Presenter: Beatrice Emmanouil

2539

High efficacy and safety of pan-genotypic direct-acting antiviral regimens in adolescents and children: a global systematic review to inform new World Health Organization recommendations

Poster Presentation

Presenter: Giuseppe Indolfi

2606

Early vs. late treatment for hepatitis C virus discordant solid organ transplantation and direct acting antivirals: a meta-analysis

Poster Presentation

Presenter: Madison Gunn

2722

Effectiveness of pangenotypic retreatment of HCV infection after prior failure of pangenotypic therapies

Poster Presentation

Presenter: Robert Flisiak

2828

Hepatitis C care cascade challenges in the homeless population. A case by case model of delivering care

Poster Presentation

Presenter: Maria Guerra Veloz

2834

Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment naïve patients with compensated cirrhosis: real-world experience from Taiwan HCV registry

Poster Presentation

Presenter: Chao-Hung Hung

2954

Real-world value and innovation of direct-acting antivirals for the treatment of chronic hepatitis C at Kaiser Permanente Southern California

Poster Presentation

Presenter: Ankita Kaushik

2990

Reported safety of HCV direct-acting antivirals with opioids: 2017 to 2021

Poster Presentation

Presenter: Anthony Martinez

3311

Opportunistic treatment of hepatitis C infection: a randomized controlled trial of immediate treatment initiation among hospitalized people who inject drugs (OPPORTUNI-C)

Poster Presentation

Presenter: Håvard Midgard

3432

Infrequent hepatitis C genotypes/subtypes in patients treated with DAA-based regimens: successes and failures

Poster Presentation

Presenter: Isaac Ruiz

3610

Treatment options for hepatitis C in pregnancy: a systematic review of the evidence and future research needs

Poster Presentation

Presenter: Neil Gupta

3677

Preemptive treatment with glecaprevir and pibrentasvir prevents HCV transmission from HCV viraemic donors to solid organ transplant recipients (single centre experience)

Poster Presentation

Presenter: Sona Frankova

3724

Eliminating hepatitis C virus infection in prisons: 7 years of experience

Poster Presentation

Presenter: Frederico Duarte

3727

Impact of the presence of the infectious disease specialist in addiction services (SerDs) as a point-of-care to meet WHO goal of HCV eradication

Poster Presentation

Presenter: Chiara Fanelli

3929

Benefits associated with HCV cure in people with mental disorders

Poster Presentation

Presenter: Stanislas Pol

## Late breaker

3829

Primary data analyses of MAESTRO-NAFLD-1 a 52 week double-blind placebo-controlled phase 3 clinical trial of resmetirom in patients with NAFLD

Oral Presentation

Presenter: Stephen Harrison

3841

Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers

Oral Presentation

Presenter: Laurent Lam

3873

Development and validation of the gender-equity model for liver allocation (GEMA) to prioritize liver transplant candidates

Oral Presentation

Presenter: Manuel Rodríguez-Perálvarez

3887

Nurse-driven post-discharge intervention reduces risk of readmission and non-attendance in patients with decompensated liver cirrhosis: a randomized controlled study

Oral Presentation

Presenter: Malene Barfod O'Connell

# THE INTERNATIONAL LIVER CONGRESS<sup>TM</sup>

22-26  
JUNE  
2022  
LONDON

